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Abbreviations commonly used in this thesis 
BoP =bleeding on probing 
BMU =basic multicellular unit  
CAL =clinical attachment level 
c.p. =commercially-pure (titanium) 
DBBM =deproteinized bovine bone mineral 
EDTA =ethylenediaminetetraacetic acid  
GI =gingival index 
GR =gingival recession 
GTR =guided tissue regeneration  
HAp =hydroxylapatite 
HTX =hematoxylin 
ISQ =implant stability quotient 
L.M. =light microscope 
microCT =micro-computed tomography 
n =number (i.e., number of individuals in sample population) 
n.s. =non significant 
O.M. =original magnification 
OFD =open flap debridement 
PI =plaque index 
PD =pocket depth  
PDL =periodontal ligament  
PTG =porous titanium granules 
PPD =probing pocket depth 
RFA =resonance frequency analysis 
TiO2 =titanium dioxide  
WPTG =white porous titanium granules i.e., PTG heat oxidized at 900 °C. 
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Introduction 
The clinical challenge 
Throughout the adult life, bone is constantly adapting 
to stress by remodeling, and challenged by various 
insults from trauma, infection, pathological processes 
and aging. In the clinic this often present itself as loss 
of mineralized tissue resulting in impaired form and 
function. When a clinical intervention is necessary to 
restore lost bone and re-establish or maintain quality of 
life for the patients the therapy often involves the use of 
bone replacement materials. The clinician is then 
confronted with several clinical challenges, both related 
to the patient per se, as well as regarding the 
mechanical and chemical properties of the biomaterial used. This thesis will focus on titanium 
used as a non-resorbable bone substitute material in peri-implant and periodontal osseous 
defects. 
 
Titanium from a historical perspective 
In 1790, an English cleric, Reverend William Gregor, discovered a new element in a sample 
of sand from Tregonwell Mill in Cornwall, which he decided to call “menaccanite.” Five 
years later a German chemist, Martin Heinrich Klaproth, discovered the exact same element 
but instead named it “titanium”, or “titankalk.” Even if Klaproth recognized that Gregor was 
the first discoverer of the novel element, titanium became the acknowledged name.1 It took 
the scientific community another 155 years to discover that titanium is accepted by biological 
tissues and therefore exceedingly useful in medicine.2, 3 
Some patient related factors: 
1) Systemic and local 
medical conditions  
2) Medications  
3) Social factors (e.g., 
smoking) 
4) Psychosocial factors 
(e.g., stress) 
5) Compliance (e.g., 
infection control) 
Some material related factors: 
1) Biocompatibility 
2) Immunogenicity 
3) Mechanical strength 
4) Availability 
5) Applicability 
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Titanium from a general material perspective 
Titanium is the fourth most frequent metal on planet Earth and is only exceeded by aluminum, 
iron and magnesium.4 Titanium (Ti, atomic nr 22 and atomic weight of 47.9) is a so-called 
transition metal and exists in a number of crystalline forms; it is thus defined as an allotropic 
element.4 In room temperature, titanium exists as a hexagonal close-packed crystal structure 
known as the alpha phase. When heat treated above 883ºC, titanium transforms from the alpha 
phase to a cubic structure called the beta phase.4 The properties of titanium changes 
dramatically when transformed from alpha to beta phase which is interesting from the 
perspective of the medical performance.4 Due to its high affinity for oxygen, titanium exists 
mostly in nature as titanium dioxide (TiO2) in many forms such as rutile (TiO2), ilmenite 
(titanium iron oxide (FeTiO3)), anatase (another form of TiO2), brookite and sphene 
(titanite).5 Rutile is the most attractive and common ore for extracting titanium and contains 
95% TiO2 followed by ilmenite with 50-65% TiO2.4 These minerals consequently have the 
same chemistry (i.e., TiO2) but they are different in structure. Quite soon after titanium was 
discovered it turned out to be difficult to isolate, hence its expensive nature. 99.9% pure 
titanium was first isolated by the chemist Matthew A. Hunter in 1910 with the so-called 
Hunter process.1 In 1936, William J. Kroll invented a more efficient method consequently 
named the Kroll process, which since then has been the “modus operandi” for producing 
commercially-pure (c.p.) titanium.4 The Kroll process can be methodologically described as 
conversion of TiO2 with chlorine to TiCl4 which is then reduced with magnesium to Ti and 
MgCl2. The end result is titanium of 99.3% purity.5 
American Society for Testing and Materials (ASTM) defines titanium as grade 1-31, with 
grade 1-4 being c.p. unalloyed titanium. The four unalloyed c.p. titanium grades (TiCP 1-4 
(Alpha) F67, Grade 1—UNS R50250; Grade 2—UNS R50400; Grade 3—UNS R50550; and 
Grade 4—UNS R50700) are defined based on the amount of impurities (a.k.a. interstitial 
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elements), which affects the tensile and strength properties of the material. The contents of C, 
N and H are similar in all four grades, while the amount of Fe and O increase to some extent 
with the grades.6  
C.p. titanium is as strong as many types of steel but about 45% lighter.7 Titanium is a reactive 
metal which means that in air, water, or as a matter of fact in any electrolyte, an oxide is 
spontaneously formed on its surface.8 Already after 10 nanoseconds a mono-atomic layer of 
oxide is formed on the titanium surface.9 The oxide layer is initially very thin and has been 
described to be only three to six nanometer in thickness.10 It is also shown that the growth of 
the oxide layer can be accelerated by an increase in temperature.9 Importantly this oxide layer 
is one of the most resistant minerals known and is hence protective against chemical attack.8 
The oxide layer also makes titanium passive, which means that it behaves more like a noble 
metal due to the stable, corrosion-resistant oxide layer.11, 12 This also implies a low rate of 
diffusion of metal ions into the surroundings (i.e., the biological tissues.13) The oxide layer 
will spontaneously and instantaneously repair itself if damaged, which for example might 
occur during seating of a titanium implant in bone.12 It has also been speculated that another 
advantage with TiO2 from the perspective of bonding between bone and the implant surface is 
the high dielectric constant,9 which can be defined as relative (i.e., relative to vacuum) electric 
permittivity (i.e., electric resistance) or a measure of how a material is affected (i.e., the ability to 
polarize the electric charges) and affects (i.e., the ability to transmit) an electric field. The reference 
value for vacuum is one. The dielectric constant for anatase is 48, for brookite 78, and for 
rutile 110-117, which all are significantly higher than for any other metal oxides.13 In 
comparison the dielectric constant for iron oxide is 14.2 and for copper oxide 18.2, whereas 
for water the dielectric constant at normal body temperature is approximately 74 and at a 
room temperature of 20 °C it is 80. At the least hypothetically this would result in stronger 
van der Waal´s bonds between the TiO2 surface and water as compared to other oxides.9, 13 
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Thus, the benefit of titanium as an implant material is the combination of a light and 
mechanically strong nucleous (i.e., the bulk metal) and a chemically very attractive thin 
surface coating (i.e., the TiO2 layer).9 These properties, as well as the repeatedly proven fact 
that biological tissues accept it, make titanium interesting as a biomaterial.  
 
Titanium from a biomaterial perspective 
The potential of an element to be implantable, accepted by biological tissues, and remain in 
function as a load bearing device has gained a lot of interest through the history of medicine 
and replacement therapy. Within the field of dentistry, a wide plethora of attempts have been 
made, through the years, to replace lost teeth with crowns retained by various types of 
implanted devices, anchored to the jawbone. Archeological findings from China, Egypt and 
South America show that ancient dental implants were made of stone or ivory.14 An implant 
made of a tooth shaped shell dating back to 600 A.D. was excavated by a Mayan indian 
archeological expedition in Honduras led by Dr. Wilson Popenoe in the 1931. The first metal 
tooth implant probably dates back to late year 100 or early year 200 A.D. and was discovered 
in a scull found in an archeological excavation of a Gallo-Roman population in Chantambre 
in France. This implant, made of iron, had replaced a second upper premolar and notable was 
the close connection between bone and implant, with seemingly no inter-positioned fibrous 
tissue.15 Implants made of gold or ivory were used in the 16th and 17th century, whereas 
allogenic (i.e., from one patient to another) tooth implants were popular in the 17th century 
England, France and North America.14 In the late 19th and early 20th century, a change was 
made towards using metal implants made of e.g., lead, iridium, gold, tantalum, stainless steel, 
silver or cobalt alloy.14, 16 Longevity of these early implants was marginal and usually not 
more than a few years prior to loss.14, 16 In 1913 Dr. E. J. Greenfield gave an oral presentation 
at the monthly meeting of Academy of Stomatology of Philadelphia where he reported on the 
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utilization of hollow and latticed cylinder implants made by iridio-platinum wires soldered 
together with 24 carat gold and placed in trephine sockets filled with bismuth paste. 
Greenfield had developed his novel technique based upon the surgical ligation of bone 
fractures by silver-wire sutures as he had seen performed by orthopedic surgeons. He was 
extremely confident in his reporting and when asked: “How long will this platinum root last?” 
he had stated: “I do not expect to live long enough to answer that question.”17 To the best of 
knowledge no long-term follow-up of Greenfield´s implants was ever published, but it is still 
noteworthy that much of the pioneering techniques, described by Greenfield, are relatively 
similar to techniques used in implant dentistry of today. 
In 1924, Zierold18 conducted an animal experimental study in 63 dogs with the aim to 
evaluate tissue reactions from a wide range of metals surgically implanted in vital bone. The 
metals were gold, zinc, copper, nickel, aluminum bronze, aluminum, magnesium, silver, high 
and low carbon steel, iron lead and stellite. The dogs were euthanized at 2 or 6 weeks after 
implantation, and sections with bone and the metallic implants were analyzed by histology. 
Zierold´s analyses showed that none of the implanted metals had fused with bone, but there 
was a marked difference in tissue reactions to the different metals. Gold, aluminum and 
stellite seemed to be best tolerated and were all, quote: “surrounded by a dense zone of 
connective tissue of three or four layers, closely approximated by new bone.” He also stated 
that silver and lead provoked more connective tissue response which he suggested to be an 
effect of their corrosiveness. Zink, nickel and magnesium seemed to interfere with bone 
growth. Copper provoked pronounced bone growth but also seemed to be toxic when in close 
contact with bone. Steel, but also iron, inhibited bone growth, and steel was by Zierold judged 
to be quote: ”least suitable of all for bone prosthesis.” Noteworthy is the fact that Zierold 
considered the corrosive properties of a metal to be of crucial importance for its inert nature. 
Experimental studies by Venable, Stuck and Beach19 further elucidated on Zierold´s findings 
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with regard to corrosiveness and inertness and performed experiments in dogs where pegs of 
various metals were implanted and the “electrolytic action” (i.e., difference in electrochemical 
potential) and bone reactions were examined by performing biochemical analyses of the 
tissues adjacent or adhering to the implanted pegs to study if ions of one metal had been 
carried to the other. They suggested that the minimal electrolytic activity, and thus low rate of 
corrosion of the alloy Vitallium (i.e., an alloy of 60% cobalt, 20% chromium and 5% 
molybdenum and some additional substances), was the reason for the total absence of tissue 
reactions or bone changes around these pegs. This made Vitallium a potential candidate for 
use as a surgical implant. 
In a report from 1939 Strock20 presented findings both from treating patients with Vitallium 
implants as well as from an animal experimental study in dogs. Based on the findings by 
Venable, Stuck and Beach19, Strock implanted screws of Vitallium in human extraction sites 
and reported that in two of three cases the screw was stable, and in one of the cases bone had 
filled the extraction alveoli in close connection with the implant when evaluated eight months 
after implantation. As reported by Shulman and Driskel14 who later followed up on Struck´s 
patients, at least one implant remained stable and asymptomatic for 16 years i.e., until 1955 
when the patient passed away. This probably makes it the very first implant with long term 
documented success.14 Bone fill and stable implants after six months of follow-up were also 
seen in two dogs treated with Vitallium implants as reported by Strock.20 
In 1940, Bothe, Beaton and Davenport3 performed an animal experimental study in cats with 
the aim to compare tissue reactions of various metallic implants. The authors state that: 
“titanium was fully as well tolerated as Vitallium and stainless steel, perhaps better in that the 
bone had a tendency to grow into contact with it.” Opposite to Veneable, Stuck and Beach19 
they reported that bone reactions were not correlated to the electric potential (i.e., electro 
negativity) of a given metal. In retrospect one may comment this finding is not surprising 
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since titanium is pacified by the surface oxide layer and thus do not corrode. In 1951, 
Leventhal21 performed animal experimental studies in rabbits and rats to study soft tissue and 
bone reactions to titanium. The author reported no signs of soft tissue reactions to titanium 
bars subcutaneously placed at the dorsal aspect of rabbits and that screws inserted in rat 
femurs were progressively more difficult to remove at six, 12 and 16 weeks. Furthermore, 
microscopic examination of the bone at the implanted sites revealed no reactions to the 
titanium screws. Animal experimental studies by Laing, Fergusson and Hodge22 compared 
tissue reactions from different metals implanted for six months in muscle of 430 rabbits. 1500 
muscle specimens with implanted material were analyzed by histology. The authors report 
that ”the tissue reaction to titanium and titanium-alloy implants was remarkable for its 
consistency and its thinness.” Noteworthy in this report is also that zirconium implants were 
reported to show pronounced tissue reactions and quote: “very unsatisfactory results.” The 
authors state that “the results of this suggest that titanium and its alloys present enough 
evidence of their suitability for the manufacture of surgical implants to warrant their 
continued use in human subjects.”  
In 1959 Beder and Ploger23 presented findings from intraoral usage of titanium bolt and nut-
retained plates for stabilization of ostectomized mandibles in dogs, as well as for permanent 
closure of an oro-antral defect surgically created in the palate. The authors report that in one 
of the three dogs which had no exposure of the titanium devices during the healing period, 
complete acceptance of the material was found. This was the first published scientific report 
documenting intraoral implantation of titanium devices. 
In 1969 Brånemark and Breine24 presented some findings on the performance of titanium after 
studies in animal experimental models. A microscopic chamber technique had been used to 
study the function of nutritive capillaries in bone marrow of rabbits and dogs. The chambers, 
made of titanium, were inserted through the covering tissues and penetrated through bone and 
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then left in place for up to 150 days. It was reported that the appliances had caused quote: “no 
undesired side effects on the soft tissue” and that “it was possible to secure a firm anchorage 
of the titanium appliance in the bone.” These early findings led this group to further explore 
titanium as a material for surgical implants. In 1969 the Brånemark research group25 
presented findings from an animal experimental study on screw-shaped titanium implants for 
permanent bone tissue anchorage of dental prostheses. 67 screw-shaped implants had been 
inserted in dog jaw bone and left for submerged healing for 6-8 weeks. Thereafter second 
stage surgery was performed, and two weeks later prostheses were manufactured and 
anchored to the implants. All implants were subjected to a torque resistance test, and a 
number of the implants were subjected to tensile strength test. Implants were removed en bloc 
and histological sections prepared. It was suggested that screw-shaped implants made of 
titanium, if placed with minimized operative trauma, if allowed to heal without 
communication to the oral cavity and if kept free from gingivitis, become stable, well 
integrated in bone and with surrounding connective tissues absent of inflammation.  
In this context it may be interesting to mention that the first orthopedic hip stem prostheses 
were developed in the early 1960s by Charnley.26 Noteworthy is the fact that still today the 
absolute majority of such orthopedic hip stem implants are manufactured in stainless steel and 
not titanium. Presumably this relates to the complexity of manufacturing such prostheses in 
titanium, since the method of turning the material to appropriate shape cannot be used, but 
instead they have to be casted, which is a much more costly technique. The scope of this 
thesis is however titanium when used as implant material in the jaws and further discussion on 
orthopedic implants will thus be left aside.  
 
In 1976 Schroeder, Pohler and Sutter27 reported findings from an animal experimental study 
in monkeys on the performance of different types of titanium hollow cylinder implants 
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sprayed with powdered titanium. These authors also reported that the titanium implant had a 
quote: “solid incorporation” in bone as seen on radiographs and “an immediate growing in of 
the bone into the rough implant surface” as seen by both light microscopy and electron 
microscopy. Schroeder used the expression “functional ankylosis” to describe the solid 
fixation and incorporation of an implant to mineralized bone. 
A great number of other dental implant designs have been suggested and manufactured 
throughout the years. Examples include the endosseous Linkow blade-vent implant,28 
subperiosteal implants29 and transosseous implants, such as the mandibular staple bone plate 
as described by Small.30 Noteworthy, the first subperiosteal implant was placed and patented 
by Dr. G Dahl in Sweden in 194131, 32 later followed by Goldberg and Gershkoff in 194932, 33 
in the Unites States who reported on clinical cases with mandibular subperiosteal implants. It 
is however beyond the scope of this thesis introduction to discuss such implant designs, but 
instead to discuss implantology from the perspective of titanium as a biomaterial. 
In 1977 Brånemark and co-workers34 published data from up to 10 year follow-up of 211 
completely edentulous patients consecutively treated with screw-shaped implant fixtures 
made of titanium. The fixtures had healed immobilized and quote: “for a long period of time 
(minimum three months) separated from the oral cavity by the mucoperiosteum.” The fixtures 
were made of quote: “the purest kind of titanium available” which was ATi 24; 99.6% 
Titanium (Fe 0.20, 02 0.10, N2 0.04 C 0.05 H20.012 manufactured by Avesta Jernverk. 
Sweden). The fixtures (XENODENT®) were machined (“turned”) to standardized dimensions. 
A comprehensive report of the clinical and radiographic, 10 year follow-up data, was 
presented. Furthermore biopsies from 60 patients had been analyzed by histology. Some 
previous histological reports on various metals implanted in bone had described a border zone 
of connective tissue characterized as a “pseudoperidontium.” This was the first clinical study 
presenting human histological evidence for true “osseointegration”, which was carefully 
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described in the report. The patients had observation times between nine months and 10 years, 
and it was reported that: “94% of the upper jaws and 100% of the lower jaws had a stable 
bridge on osseointegrated implants.” 
In 1981 Adell et al.35 reported retrospective data on 1997 titanium dental implants placed in 
284 consecutive patients between the years 1965 and 1980.The report was divided into both 
the development phase and later routine phases of fixture installation and anchorage of 
prostheses according to the “Brånemark method.” After three years of follow-up, persisting 
fixtures were reported to be between 53% and 91% depending on jaw and routine or 
development phase of treatment. With regards to bone loss it was also shown that more bone 
was lost during the first year after installation of the implants (0.8-1.5 mm) and thereafter less 
pronounced (0.1 mm/ yearly) for the first five to nine years of follow-up. The early findings 
by Brånemark and co-workers initiated an era with a great number of scientific reports on the 
clinical use of so-called endo-osseous screw-shaped titanium dental implants.  
 
Biocompatibility 
Biocompatibility by principle means “harmonious with life”36 and is pivotal when implanting 
a medical device in living tissue with the objective of acceptable long term function. It defines 
the ability of a specific material to “function in a specific application in the presence of an 
appropriate host response.”37 The definition also implies that the specific material must be 
free of any safety concerns for the recipient patient.37 In 1987, Williams38 proposed the 
following definition of biocompatibility: “the ability of a material to perform with an 
appropriate host response in a specific situation.” The major thought behind this definition 
was that a biocompatible biomaterial has to perform some kind of function i.e., at the least be 
compatible with the function but preferably actively support the function. 39 It is, though, 
obvious that even if the biomaterial supposedly shall perform a function, it shall still not harm 
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the patient.  More recently this led Williams39 to propose a new definition of biocompatibility 
as follows: “Biocompatibility refers to the ability of a biomaterial to perform its desired 
function with respect to a medical therapy, without eliciting any undesirable local or systemic 
effects in the recipient or beneficiary of that therapy, but generating the most appropriate 
beneficial cellular or tissue response in that specific situation, and optimizing the clinically 
relevant performance of that therapy.” A noteworthy fact is that, over some time, no 
implantable biomaterial has so far been shown to be completely free of adverse reactions in 
humans or animals.4  Whether this relates to the biomaterial, per se, or instead to host related 
factors is an issue for discussion. 
To evaluate the biological behavior and potential biocompatibility of a novel biomaterial, it 
will be fundamental to test it from many different perspectives such as cytotoxicity, 
histocomptibility, mutagenicity and microbiological effects.37 Such tests are complex and 
when considering a potential novel application for a specific biomaterial it is of great value 
that the material has already been successfully used for biological applications. This is 
obviously one of the crucial advantages with titanium when utilized within the field of 
osseous reconstructive therapies. 
Bone characteristics  
Bone is a mineralized connective tissue with specialized functions and consists of 33% 
organic matrix i.e., 28% type I collagen, and 5% non collagenous proteins. The non- 
collagenous proteins include osteonectin, osteocalcin, bone morphogenetic proteins, bone 
proteoglycan and bone sialoprotein. The remaining 67% of bone is inorganic and consists of 
calciumphosfate in the form of hydroxyapatite (Ca10(PO4)6(OH)2; HAp) crystals.  
Microscopically, four types of bone tissue can be defined: woven, composite, lamellar and 
bundle. Woven bone is soft, unorganized immature bone which forms early during healing 
and later is replaced with the more mature and organized lamellar bone. The bone tissue seen 
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in the transitional phase between woven and lamellar bone is known as composite bone. 
Bundle bone lines the bone adjoining joints and ligaments and is highly perforated (a.k.a. the 
cribriform plate) since it transmits nerves and vessels and provides anchorage for the fibers of 
the periodontal ligament (PDL). The bone approximating the PDL and thus lining the socket 
walls is called the alveolar bone proper.  
Formation of bone is primarily defined as either: endochondral i.e., through ossification of 
cartilage with mesenchymal cells from blood vessels migrating into the cartilage and thus 
differentiating into bone-forming osteoblasts; or intramembraneous bone formation, which is 
when bone develops directly within the mesenchymal soft connective tissue once osteoblasts 
differentiate and start producing bone matrix. A third bone formation pattern is sutural bone 
growth which play an important role in the growth of the face and cranium for 
accommodating the growing organs of the head. Endochondral ossification occurs at the end 
of bones i.e., long bones, vertebrae and ribs, at the head of the mandible and base of the skull 
primarily at fetal development and growth in length, but also when bone fractures heal. On the 
other hand intramembraneous bone formation occurs at multiple sites within each bone during 
both fetal development and at healing of bony fractures or defects.63 Importantly the human 
mandible is by definition formed almost entirely through intramembraneous ossification even 
if the center of bone formation is the cartilage of the first embryonic arch (a.k.a. Meckel´s 
cartilage). Similarly in the maxilla the center of ossification is the cartilages of the nasal 
capsule and the zygomatic process, which have little involvement in the bone formation 
process. The ossification of the human maxilla is also by definition intramembraneous.64 
The mandible and the maxilla consist of two separate entities of bone: basal bone and alveolar 
bone which have different origins. The basal bone of the jaws has no connection to the teeth 
whereas the portion of the maxilla and mandible that supports the teeth is known as the 
alveolar process. Importantly it forms when the tooth erupts and has it origin in the dental 
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follicle.65 It also gradually resorbs when a tooth is lost. Whether or not this bone can be 
restored or maintained after a tooth has been lost is issue for scientific dispute and has 
obvious and important implications with respect to reconstruction of the alveolar bone.  
Bone undergoes constant remodeling all through life. The basic multicellular unit (BMU) 
consisting of osteoclasts and osteoblasts is responsible for the bone remodeling event,57, 66, 67 
which also is the response to trauma such as fractures, healing of bone defects and placement 
of implants. 
Osseointegration 
Brånemark coined the term “osseointegration” which describes a condition where a 
biomaterial (e.g., titanium) is in intimate contact with surrounding vital bone as viewed 
microscopically (Fig. 1) and bears up with functional loading. It consequently implies that 
there is no inter-positioned, non-mineralized connective or fibrous tissue between the bone 
and the implant. Furthermore, successful osseointegration necessitates that the bone 
surrounding an implant, that carries the load from a prosthesis, does not “react to the presence 
of the non-biologic component by initiating rejection phenomena.”40 
Brånemark´s original definition of osseointegration reads: “The direct structural and 
functional connection between ordered living bone and a load carrying implant.”41, 42 
Osseointegration is hence mainly a histological definition and can only in part be assessed by 
clinical and subclinical criteria.43 Thus one may suspect that an implant is osseointegrated by 
means of clinical or radiographic evaluation such as immobility and absence of inflammation, 
but histological evaluation is necessary to verify true osseointegration.  
 
 
16 
 
 
Figure 1. Photomicrograph showing histological evidence for osseointegration (a.k.a. functional ankylosis) of a 
treaded titanium implant. HTX-Eosin. Light microscope 25X original magnification and on the right hand side 
schematic illustration of TEM analyses of bone implant interface as cited in the text. *20-40 nm collagen free 
proteoglycan zone, †100-500 nm randomly arranged collagen filaments with mineral content gradient, ‡100-400 
nm amorphous substance zone without collagen or mineral content, § about 50 nm lamina limitans like electron 
dense line. Schematic illustration in part derived from Albrektsson, Johansson and Sennerby (1994).44 
 
Albrektsson et al.45 examined 33 retrieved titanium implants and reported that implants 
clinically judged as integrated corresponded to 60% or more of bony contact and 70% or more 
of bone filling of individual threads. 
When analyzing the implant and bone interface at the transmission electron microscopic level 
(TEM) it has however been suggested that mineralized bone is not in absolute contact with the 
implant surface. Albrektsson et al.46 analyzed integration of polycarbonate plugs coated with 
titanium or gold inserted in the proximal tibial metaphysis of rabbits and harvested at three 
months. Titanium-coated, as well as the gold-coated, plugs were all surrounded with living 
bone. The bone appeared to be in “continuum with the titanium interface” whereas a 
“discontinuous layer of cells separated the gold-coated plugs from the bone.” When analyzing 
the sections with TEM it was however seen that the last 20-40 nm of tissue away from the 
titanium surface lacked collagen filaments and mainly consisted of partly calcified amorphous 
ground substance. 
Linder et al.47 also performed an animal experimental study in rabbits to analyze the interface 
between titanium implants and mineralized bone. Polycarbonate plugs, coated with a layer of 
pure titanium, were implanted in the tibial metaphysis and left healing for 12 weeks prior to 
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harvest. The implants were not put in function. At the light microscopic level, implants 
appeared to be in close contact with bone, but when analyzing sections with TEM at up to 
67000X original magnification, a thin (collagen free) gap between the collagen filaments of 
bone and the titanium surface of approximately 20-50 nm (200-500Å) was seen. The zone 
stained as normal ground substance containing proteoglycans and with hyaluronic acid and 
chondroitin sulfate closest to the titanium surface. Using a similar methodology also with 
polycarbonate plugs, Johansson et al.48 further explored this zone and showed a significantly 
wider zone (500-1000 Å) when implants made of titanium alloy were instead used as 
compared to the zone (200-400Å) when c.p. titanium implants were used. In continuation of 
these experiments Linder et al.49, 50 used solid metal c.p. titanium implants inserted in rabbit 
tibia and reported that a collagen free gap of approximately 50 nm, but also as wide as 1000 
nm, was found. Interestingly these authors also included implants of Tivanium® (Ti-6Al-4V 
alloy, Zimmer Inc., Indiana, USA), Vitallium and stainless steel in the analysis, and it was 
reported that these metals had similar results with respect to the metal-bone interface as the 
titanium implants. 
Later Sennerby et al.51 examined ultra thin sections of seven osseointegrated titanium 
implants that had been in function in humans between one and 16 years. At the light 
microcopic level, all seven implants were judged to be osseointegrated with mineralized bone 
tissue in close contact with the titanium surface but at the TEM level an amorphous layer of 
100-400 nm in width was seen between the mineralized bone and the titanium surface. It was 
also reported that in areas with lower mineralization an electron dense zone of about 50 nm 
was bordering the bone; the authors described this as a “lamina limitans like” line.  
It is interesting that the amorphous zone in the human histological samples analyzed by 
Sennerby et al.51 was close to ten times wider than what had been reported in previous animal 
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experiments. One may possibly attribute this either to differences related to type of species 
(i.e, human vs. animals) or the fact that the implants studied by Sennerby had been in function.  
One may furthermore argue that the gap was an artifact either from trauma when removing 
the bloc sections from the surrounding tissues or from shrinkage of tissue and removal of 
water by the use of alcohol when embedding the histological sections. Though, this argument 
is probably complicated by the presence of proteglycans in the amorphous zone. 
It is repeatedly demonstrated that titanium is biocompatible but the biological properties of 
titanium are less elucidated on. Except if produced under vacuum, the surface of a titanium 
dental implant is always covered with an oxide layer with a thickness of at least one to six 
nano meter. The layer of TiO2 also increases in thickness with time, and it has been reported 
that the titanium oxide layer of a dental implant placed in human bone triples from 50 to 150 
Å during the first three months after implantation and increases to 2000 Å after about six 
years in function.52, 53 However, other authors have presented contradictory findings, showing 
no increase in thickness over time but instead support a TiO2  layer, with a constant thickness 
of five to 10 nm.54, 55 The crux is that bone and surrounding tissues are not in direct contact 
with pure titanium but instead with an amorphous layer of TiO2.41  
 
Comments on healing of titanium implanted in bone 
The establishment and maintenance of osseointegration represents a dynamic process both 
with respect to the interaction between the bone walls in the prepared osteoectomy and the 
newly-installed titanium implant and during the phase of loading with continuous bone 
remodeling and functional adaptation.56 Roberts et al.57 analyzed patterns of bone healing 
after implantation of spring loaded titanium fixtures in a rabbit animal experimental study. 
Unloaded implants were compared with implants that were exposed after six, eight or 12 
weeks and thus loaded for four, six or eight weeks with stainless steel coil springs with the 
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aim of comparing bone healing around unloaded and loaded implants. The implants 
penetrated through the cortical bone into the marrow space. Tetracycline labeling revealed 
that new woven bone had formed within three days after implantation. During the early weeks 
of healing, primarily woven unstructured bone was seen. Six weeks after implantation mature 
lamellar bone with primary osteons had started to replace the woven-bone lattice. From six to 
16 weeks remodeling from woven bone to lamellar bone with well-organized and mature 
secondary osteons were consistently observed. Complete osseous encapsulation was only 
observed in implants subjected to load. This study consequently suggests that the rate of bone 
turnover of immature to mature weight-bearing bone (i.e., the remodeling cycle a.k.a. sigma) 
adjacent to implants in rabbits is about six weeks. Parallel to this the corresponding 
remodeling cycle in man has been reported to be three to four months.58  
To address the healing response of c.p. titanium implants inserted in bone, Sennerby, 
Thomsen and Ericson59 performed an animal experimental study in rabbits. The implants were 
penetrating through periosteum and cortical bone, but with the major portion of the implant 
protruding into the marrow space. Tissue specimens were studied from three to 180 days after 
implant insertion. After three days very limited bone to metal contact was seen at the cortical 
section, whereas at the marrow section red blood cells formed a continuous layer along the 
entire implant surface. After seven days woven bone formation was seen at the part of the 
implant associated with the endosteal surface of the cortex (i.e., at the junction between the 
cortical bone and bone marrow). The bone approached the implant, but was never in close 
contact with the implant; according to the authors, this would indicate that this bone formation 
did not start at the implant surface. Bone formation at the periosteal surface was first seen 
after 14 days when remodeling of the old bone with fibrous tissue in contact with the implant 
surface at the cortical part were also seen. At 28 days the cortical part of the implant was, to a 
large extent, in contact with dense woven bone. Remodeling was still observed after 42 days. 
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Remodeling to lamellar bone was completed six weeks to three months after implant insertion 
which is in agreement with the findings by Roberts et al.57 At day 90 the bone close to the 
implant in the cortical regions appeared as mature as the original bone.  
From the perspective of osseous formation, bone marrow is an interesting tissue. Bone 
marrow contains mesenchymal progenitor cells that can differentiate to osteoblasts and is also 
rich in vasculature with circulating mononuclear precursors that may differentiate into 
osteoclasts and endothelial cells needed for neo-angiogenesis.60 In the study by Roberts et 
al.57 the part of the implant protruding into the marrow space often had a fibrous capsule. 
Bone always grew towards the implant surface, hence never it originated from the implant 
surface. Roberts et al.57 reported: “a complete endosteal encapsulation of the implants” which 
was also depicted by figures in the publication whereas Sennerby et al.59 reported that the 
section of the implant protruding into the marrow space had a fibrous capsule. These findings 
are interesting with respect to the origin of the bone in contact with the implant. The bone at 
the marrow part of the defects may thus either originate from cortex and grow down along the 
surfaces of the implant into the marrow compartment (appositional bone formation a.k.a. 
distance osteogenesis61) or start to form on the surface of the implant i.e., bone apposition 
directly onto the implant surface a.k.a. contact osteogenesis.61, 62  
Both Roberts et al.57 and Sennerby et al.59 studied peri-implant bone healing in rabbit tibia 
using a cortical bone model. One may thus argue that this is not representative of the clinical 
situation with intraoral implants since implants in these rabbit models were placed in cortical 
bone; this was in contrast to the combined cortical and cancelous bone morphology 
representative of the jaw. Berglundh et al.56 studied bone healing around c.p. titanium 
implants placed in dog mandibles. These authors also reported presence of newly formed 
woven bone one week after implants insertion. Importantly, at two weeks the new bone 
extended only from the cut bone surface (“parent bone”) towards the implant surface, whereas 
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after four weeks, bone formation extended both from the cut bone surface towards the implant 
surface (appositional bone formation) and also projected directly along the implant surface 
“remote of the parent bone.” The authors suggested that this may be bone formed by contact 
osteogenesis. This finding is in contrast to the findings by Sennerby et al.,59 who observed no 
direct bone formation at the implant surfaces. This discrepancy may though obviously be 
related to the different animal models used in these studies, i.e., the rabbit tibia defect model 
involving both the cortical bone and marrow space versus the dog alveolar bone defect model.  
 
Reconstitution of osseous defects 
In 1969 Amler68 studied healing of normal healthy extraction sockets in human histological 
specimens taken at different time intervals post extraction (Table 1). 
 
Table 1. Summary of time sequence of normal human tissue regeneration of alveoli after tooth extraction  
described by Amler (1969). Copyright © 1969, Elsevier 
 
Seven days after tooth extraction osteoid was seen at the base of the socket which corresponds 
with the healing pattern described for implant osteoectomies.56 It may thus be stated that c.p. 
titanium implants at the least do not obstruct normal bone reformation in humans. Whether or 
not titanium improves osseous healing by e.g., osteoconduction is still unclear and an issue for 
discussion. 
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The mechanisms of bone healing are quite similar to embryonic osteogenesis and growth, and 
since bone has a unique spontaneous healing pattern the optimal regenerative methodology 
would be to harness the internal regenerative capacity of bone.69 So far it has not been 
possible to develop strategies that completely mimic these complex biological events, and 
bone reconstructive strategies have for the most part instead been directed towards 
substituting bone with various types of biomaterials. Over the years a vast number of osseous 
reconstructive strategies have been suggested.  
 
Autogenous and allogeneic bone 
The most obvious strategy and still the gold standard for osseous defect reconstruction, is 
using a graft constituting of bone harvested from a donor site within the same patient, a.k.a. 
autogenous bone graft. Within the field of periodontology the use of an autogenous bone graft 
was first described by Hegedüs in 1923,70 who used bone blocks from the tibia to reconstruct 
bone lost due to “advanced pyorrhea” (i.e., advanced periodontitis). Hegedüs reported some 
evidence for increase in alveolar bone height as well as decrease in mobility. In 1964 
Hirakawa and Uji71 presented the first cases with autogenous bone harvested intraoraly and 
used for grafting of defects caused by cysts, root resection, filling of sockets after extraction 
and mandibular fractures. In 1965 Nabers and O´Leary72 presented a classic paper detailing 
the successful use of autogenous particulate bone for grafting periodontal osseous defects. 
The graft material was harvested intraorally, from the same surgical area as where the 
recipient defects were localized. The limitation of using autogenous bone lies in the restricted 
bone volume at intraoral donor sites, which sometimes may not be sufficient for complete fill 
of the recipient site. Harvesting donor bone also involves an extent of patient morbidity, in 
that quite often a second surgical site is needed. Adverse events such as nerve damage,73 
mucosal defects at the donor site or damage to neighboring structures, such as apices of teeth, 
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are also risks involved in the harvesting of autogenous bone. Using extraoral donor sites such 
as iliac bone is extraordinarily involving and has also been reported to be associated with an 
increased risk of root resorption.74 The utilization of bone transplants harvested from another 
individual of the same species (homogenous bone, allogenic bone) gained a lot of momentum 
during the 1970s.  In 1958 Green75 published a case series of six patients with intraoral 
defects reconstructed with particulate grafts, either autogenous bone or fresh frozen 
homogenous bone and were optimistic regarding the clinical and radiographic results. In 1970 
Hiatt and Schallhorn76 published a study on usage of human bone allografts for treating 
periodontal defects. In contrast to previous attempts with allogenic bone grafting, these 
authors had blood group- and human lymphocyte antigen (HLA) typed the patients and thus 
cross-matched the donor and the recipient patients. Since immune rejection is an obvious 
problem when using allogenic bone grafts, developing methods for altering the antigenicity of 
allogenic bone became an important focus in science. An animal experimental study in dogs 
by Kreuz et al.77 evaluated grafting of osseous defects with freeze-dried allogenic bone. The 
freeze-dried bone grafts were reported to incorporate well with surrounding bone tissue. Due 
to the freeze-drying process, it was possible to make allogenic bone storable in room 
temperature in bone-tissue banks. In an animal experimental study in rabbits and later in a 
human study, Friedlander, Strong and Sell78, 79 furthermore demonstrated that the antigenicity 
of bone was markedly reduced by the freeze drying process, which had been suggested to 
distort the three-dimensional presentation of HLA.80  
Freeze-dried bone allografts (FDBA) are considered to be osteoconductive.80 It has also been 
suggested that hydrochloric acid demineralization of FDBA (i.e., to DFDBA) would project 
factors stimulating bone growth, such as bone morphogentic proteins, and thus make the 
allograft osteoinductive.81-83 This has also been demonstrated by means of histology,84, 85 
albeit opposing results have later been presented.86 The presence of bone morphogenetic 
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proteins (BMP)87 and the osteoinductive potential of DFDBA has been debated and at the 
least seem to be dependent on factors such as preparation88 and donor age.89 The major 
concern, although for the most part considered solely as a hypothetical risk,90, 91 is disease 
transmission. For such reasons, developing and testing non-human bone substitutes have 
gained a lot of focus throughout the years.  
 
Xenogenic bone 
Biological tissue transferred between different species is known as xenogenic. Since bone 
structure is similar in most mammals, it was an early focus towards experimenting with the 
use of xenogenic bone for reconstitution of bone defects in humans. Already in 1934 Beube 
and Silvers92 had performed an animal experimental study in dogs where surgically-created 
defects were filled with boiled cow bone and a more rapid healing in the cow bone filled 
defects was reported.93, 94 In a subsequent series of case reports, the successful reparative 
treatment of osseous defects in humans with boiled cow bone was presented.94 A number of 
later investigations developed and examined techniques other than boiling for extracting the 
organic matrix of cow bone, such as ethylene diamine and alcohol,95 96 with the aim to solely 
implant the inorganic component of the xenogenic bone and thus avoid provoking an 
immunologic reaction. In an animal experimental study in rhesus monkeys, Losee and 
Boyne95 reported that ethylene diamine-treated inorganic cow bone grafts were well accepted 
by the host bone. Melcher97 later presented contradictory findings from a clinical study 
showing that even if the implanted cow bone was well accepted by the host tissues, much of 
the material persisted non-resorbed, and sequestration of the material was seen for more than 
three years after implantation. It was also reported, quote, that: “the presence of the material 
tends to hinder rather than assist the healing of bone.” Later methods of deproteinizing bovine 
bone suggest more positive results. Deproteinized bovine bone mineral (DBBM) is as of today, 
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a commonly-used bone substitute and the osteoconductive properties and potential as a bone 
replacement graft have been demonstrated repeatedly98-100 whereas other authors present more 
negative findings.101, 102 A second example of a xenograft is hydrothermally and chemically 
derived HAp from the exoskeleton of sea coral. By architecture the exoskeleton of corals 
resembles natural bone and thus potentially could be used to mimic natural bone structure and 
work as an osteoconductive bone substitute. Positive outcomes have been demonstrated both 
in animal experimental103 as well as in clinical studies.104-107  
 
Synthetic bone substitutes 
A synthetically derived material is available in ample amounts without having to perform a 
harvest procedure as compared to autogenous bone. Furthermore there is no disease 
transmission risks with a synthetically derived biomaterial as compared to the potential 
concerns with allografts and xenografts.109 Synthetically derived bone substitutes includes 
alloplasts, such as a wide range of ceramics but also polymers and metals.  
 
Alloplastic bone substitutes 
Alloplasts are inorganic synthetically derived bone substitutes fabricated with the aim to 
mimic the chemical and/or the morphological composition of the mineral phase of bone for 
usage as an osteoconductive bone replacement biomaterial.108 Alloplasts may be used either 
alone as a bone void filler or as an extender of an autogenous bone graft.108 A range of 
alloplasts have been presented throughout the years. Examples of alloplasts are ceramics such 
as calcium sulfate (CaSO4) a.k.a. “gypsum”),110 calcium phosphate (Ca10(PO4)6OH2) e.g., 
triple calcium phosphate as presented in an animal experimental study by Albee and 
Morrison111, synthetically derived HAp and tricalcium phosphate.108 Other examples of 
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ceramic alloplasts are bioglasses (i.e., SiO2, Na2O, CaO and P2O5), and polymers such as 
polymethyl-methacrylate and hydroxy-methylmethacrylate.112  
 
Titanium from the perspective of osseous defect reconstitution 
It is interesting to speculate on the biological properties of titanium from the perspective of 
osseous reconstruction. Little is known about the biological performance of a titanium body 
when implanted into vital living tissue with the aim to reconstruct bone. 
In studies on bone and blood cell reactions to titanium, it has been shown that the surface 
structure and surface properties of an implant, such as oxide thickness, chemical composition 
and roughness, has an impact on bone response to an implant surface,113-122 thus affecting the 
release of growth factors and cytokines that are of importance for bone healing.60, 123  
A study by Hong and co-workers124 used an in vitro whole blood chamber model to study 
platelet adhesion and platelet activation of titanium and titanium-nitride with various surface 
roughness as compared with PVC and steel. Only the titanium surfaces induced clotting by 
activation of the complement system as seen by the generation of thrombin-anti-thrombin 
(TAT). When analyzing effects of surface roughness it was shown that the rougher surfaces 
induced more generation of TAT than the smooth surfaces. Moreover it was also shown that 
blood contact with titanium lead to a more pronounced surface binding of platelets and 
increased platelet activation, as reflected by higher levels of β-thromboglobulin and platelet 
derived growth factor (PDGF) as compared to the other tested materials.124 It has previously 
been shown that PDGF and other platelet α-granule proteins such as transforming growth 
factor-β (TGF-β), are substantial promotors of bone growth.125 126 Based on these 
observations it was suggested by these investigators that the osteointegrating properties of 
titanium may to the least in part be the result of the potent activation of the coagulation 
system. One may thus speculate that increasing the total titanium surface exposed to blood, 
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e.g., by using porous particles may further enhance platelet activation. Adapting these 
observations to the field of regenerative surgery, one may consider using a strategy with a 
bone substitute made of titanium with a surface as large as possible to promote new bone 
formation in osseous defects. Porous titanium granules (PTG, Natix®, Tigran Technologies 
AB, Malmö, Sweden) represent one such titanium biomaterial which may potentially have 
properties corresponding with the above discussion (Fig. 2).  
 
Figure 2. A) PTG and blood. B) PTG and blood. Note the blood clotting. C) Heat oxidized PTG (WPTG)  
and blood. 
 
A porous titanium granule is 700-1000 μm in diameter but the total titanium surface of one 
granule is approximately two cm2, which accordingly leads to a significant area for blood-to-
titanium contact. 
There has been anecdotal evidence supporting the theory that PTG can integrate in human 
bone and potentially induce osseous healing. However, the scientific rationale for utilization 
of porous titanium granules for reconstructive treatment of osseous defects has been scarce 
and limited to case reports127 128 as well as one animal experimental study.129 The material 
was first used by orthopedic surgeons in conjunction with fixation of titanium hip stem 
prostheses. 
Alffram et al.128 reported on findings from a series of five cases with titanium hip stem 
prostheses fixated with PTG instead of regular acrylic cement. Both clinical and radiographic 
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analyses revealed stable prostheses after nine to 15 years follow-up. One post mortem autopsy 
was also retrieved. The histological analysis from this patient as well as computerized 
tomography of the treated area from three patients supported the clinical and radiographic 
findings and revealed that PTG became incorporated in bone (Fig. 3). 
 
 
Turner et al.129 performed an animal experimental study in 10 dogs with the aim to perform a 
histological evaluation of PTG when utilized for cementless fixation of a hip replacement 
femoral stem. At termination, six-months after surgery, nine out of ten dogs had healed 
uneventfully and the histological analysis showed PTG incorporated in bone. In a clinical 
pilot study, Jónsson and Mjöberg130 used PTG with the aim to achieve a non-resorbable 
reduction of depression fractures of the lateral tibial plateau. Four cases were followed for up 
to six months, and it was reported that the radiographic results indicated no loss of plateau 
height (Fig. 4) after treatment. The clinical stability was also reported to be excellent. For the 
orthopedic applications the size of the granules has been one to two millimeters.   
Figure 3. Derived from Alffram et al.128 A) 10 year follow-up radiograph of a subject with a hip 
stem implanted in a bed of PTG B) Backscattered electron micrograph showing the interface 
between the titanium hip stem, PTG and the surrounding trabecular bone. Copyright © 2007 
TAYLOR & FRANCIS  
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Figure 5. Tatum type sinuslift performed 
with PTG. Five years control radiograph. 
Compliments of Dr. Hans Bystedt. 
 
 
 
 
 
PTG of the size 0.7 to one millimeter have been 
used within the field of oral and maxillofacial 
surgery. In a case report by Bystedt and 
Rasmusson,127 results after follow-up of Tatum type 
sinuslifts131 with PTG performed in 16 patients were 
presented (Fig. 5). In total 23 implants were 
installed. Four of the patients had their implants 
installed in a second surgical procedure. After a 
follow-up period of 12 to 36 months, three implants were lost which gives a survival rate at 
the implant level of 87%. Noteworthy were two failures in the two-stage group which 
consequently may be important from the perspective of preparation of an osteotomy by 
drilling into PTG potentially incorporated in bone. It is important to further elucidate on this, 
prior to clinical usage of the material for augmenting or preserving implant sites. Holmberg et 
Figure 4. Preoperative radiograph and six months control radiograph after 
treatment with PTG of a depression fracture of the lateral tibial plateau From 
Jónsson and Mjöberg130 Copyright © Upsala Medical Society. 
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al.132 reported on one case where PTG were used in conjunction with a split crest technique 
for horizontal expansion of a severely resorbed maxillary dento-alveolar ridge. At the 12 year 
radiographic follow-up, an average of less than two mm marginal bone loss was found and the 
implants were stable. Sabetrasekh et al.133 performed an in vitro analysis of the biological and 
morphological properties of PTG versus three other bone replacement biomaterials. It was 
shown that PTG performed significantly better with respect to cell proliferation rate compared 
to DBBM. When characterizing the architecture of the PTG particles it was also shown that 
the majority of the pores were larger than 100 μm and with a mean pore size of 241.6 μm as 
compared with 129.9 μm for DBBM. Pore size seems to be important from the perspective of 
bone growing in to the bone substitute particles and a study by Klawitter and Hulbert shows 
that a size of interconnecting pores above 100 μm is required for mineralized bone growth 
into a biomaterial whereas osteoid was demonstrated in pore sizes down to 40 μm.134 The 
biomaterial used in this study was a ceramic made of calcium aluminate. Later studies, instead 
testing outcome of pore size in perforated titanium plates with pores down to the size of 50 
μm, have failed to verify the above threshold values for mineralized bone ingrowth.135 One 
may thus speculate that the in-growth of mineralized bone also may depend on the type of 
biomaterial used. 
By convention a bone substitute should resorb and be replaced by new bone. It is however 
interesting to reflect on the potential advantages of using a non-resorbable bone substitute. 
Since osseous growth and maturation is a long-term process it may well be that a biomaterial 
acting as a permanent growth substrate may be an advantage as compared with resorbable 
biomaterials. It is noteworthy that the scientific data on resorption time and resorption pattern 
of bone substitutes are conflicting. Hallman, Lundgren and Sennerby100 compared human 
histological results from biopsies taken six months and three years after a sinus augmentation 
with DBBM (Bio-Oss®, Geistlich Pharmaceutical, Wollhausen, Switzerland) mixed with 20% 
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autogenous bone and demonstrated no resorption of the DBBM particles neither after six 
months nor after three years. Interestingly the new bone to DBBM surface contact had 
increased from 28.8% at six months to 54.5% at the three year biopsies. When analyzing the 
biopsies taken after six months, the bone was predominantly immature and woven, whereas it 
was mainly mature and lamellar at three years. In a sequel to the Hallman, Lundgren and 
Sennerby study, Mordenfeld et al.136 retrieved biopsies from the same patients, 11.5 years 
after the augmentative surgical procedures and reported 17.3% remaining non-resorbed 
DBBM particles. Furthermore, no significant differences with respect to surface length and 
area of the DBBM particles were seen at the 11.5 years biopsies, as compared with the 
biopsies retrieved after six months and after three years, or as compared to virgin particles. 
Similarly, Iezzi et al.137 reported that remaining anorganic bovine bone (Osteograf, Ceramed, 
Lakewood, USA) particles were demonstrated in a biopsy from a patient who had been treated 
with a sinus lift augmentation 14 years earlier.  
 
Intraoral osseous defects being potential candidates for reconstructive therapy 
Within the field of dento-alveolar surgery a number of osseous defect types are potential 
candidates for reconstructive therapy. The bone of the alveolar process is formed by the 
development and the eruption of teeth and later dependent on teeth. The consequence of tooth 
loss is accordingly and by principle physiological loss of alveolar bone. With regard to 
pathological intraoral bone loss, periodontal disease is the most common cause. Advanced 
periodontitis affects approximately 10-15% of the population.138-140 A number of cross-
sectional studies report that the relative contribution of advanced periodontitis as the reason 
for extractions of teeth is between 18-36%.141-146 Osseous defects as a consequence of tooth 
loss may be detrimental to the individual patient, for example with respect to the plausibility 
of replacing lost teeth with dental implants.  
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Peri-implantitis and peri-implant osseous defects 
Notwithstanding the high success rate reported for dental implants147-149 evidently a relatively 
high number of implants develop loss of attachment over time. Peri-implantitis has been 
defined as bone loss of dental implants induced by infection and was described by Mombelli 
in 1987.150 Throughout the years a numbers of diagnostic criteria for this disease entity have 
been suggested. It is probably important to distinguish between early bone loss, which may be 
due to osseous remodeling after implant placement, and which takes place early after implant 
seating. This early bone loss, which usually has been described to take place within the first 
year after seating of the implants, has been considered to be physiologic in nature. 
Albrektsson et al.43 stated that one criteria for dental implant success, should be less than 0.2 
mm annual vertical bone loss, following the implant´s first year of service. With respect to 
loss of peri-implant attachment, this success-criterion implies that: (1) implants may or may 
not lose bone the first year of function due to physiological conditions not possible to 
withstand, (2) that 0.2 mm of yearly bone loss is within physiological limits and should be 
considered acceptable. A yearly bone loss of 0.2 mm over e.g., 25 years would by such 
criteria connote five mm of lost peri-implant attachment and potentially an additional one mm 
under the circumstance that one mm of bone also was lost during the first year of function. In 
this context it is interesting to relate to animal experimental studies on ligature-induced peri-
implantitis showing that after a lesion has been established it continues to progress in most 
cases (i.e., after ligature removal)151 even if it has been suggested that the extent of the 
continued bone loss varies depending on the implant surface type.152-154 Whether such 
findings also relates to the clinical situation, have not been completely examined and further 
studies on this theme will be of major importance, since this may relate to the necessity to 
intervene against established peri-implant lesions. 
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The definition of peri-implantitis has changed throughout the years. Lately Zitzmann and 
Berglundh155 proposed that the joint term for inflammatory reactions in the tissues 
surrounding an implant should be peri-implant diseases, while peri-implant mucositis was 
defined as quote: “inflammation in the mucosa at an implant with no signs of loss of 
supporting bone.” Peri-implantitis was defined as inflammation in the mucosa with loss of 
supporting bone. 
It is also important to distinguish between peri-implantitis, which describes the disease entity 
according to the above definitions, while a “peri-implant osseous defect” is the bony defect 
potentially in need for reconstructive therapy after finished causative therapy. The osseous 
defect, rather than peri-implantitis, as a disease entity is reconstructed, while the disease per 
se is treated causatively. It is important though to know that so far no non-surgical treatment 
method has been shown to be effective in hindering defect progression, and the lesions caused 
by peri-implantitis are usually in need of surgical intervention for achieving a sufficient result. 
So far there is scarce evidence based research data to endorse a specific treatment strategy for 
peri-implantitis. The dental scientific community consequently needs to evolve within this 
field (Appendix II). 
 
The concept of re-osseointegration 
The ultimate outcome when treating peri-implant bone loss is re-osseointegration. Renvert et 
al.156 defined re-osseointegration as: “formation of new bone onto a previously biofilm- 
contaminated implant surface.” This definition implies that histology, or plausibly other high 
resolution methods for analyzing the bone to implant interface, is needed when evaluating if a 
specific treatment regime promotes re-osseointegration. Several animal experimental studies 
suggest that it is possible to accomplish this treatment goal after various treatments of 
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experimentally induced peri-implant osseous defects157-166 but there has been no human 
histological evidence for re-osseointegration presented in the literature.  
 
Periodontal furcation defects 
Classification of furcation involvement is based on the degree of horizontal loss of osseous 
support in the inter-radicular area, with degree I being up to one third of the width of the tooth, 
degree II more than one third but not encompassing the total width of the tooth and degree III 
being a through-and-through destruction of the periodontal support.167  
A great number of studies have investigated different treatment protocols for reconstructing 
lost periodontal support in furcation defects (Appendix I and III). Clinical studies by Schroer 
et al.168 and Kalkwarf et al.169 compared closed versus open flap debridement (OFD) and 
showed no beneficial effects of non regenerative surgical therapy as compared to scaling and 
root planning alone. Noteworthy, the study by Kalkwarf et al.169 demonstrated that neither 
non-surgical nor non-regenerative surgical techniques were able to hinder progression of 
horizontal bone loss as demonstrated after two years of periodontal supportive therapy.  
Guided tissue regeneration (GTR) is the regenerative approach for degree II furcation defects 
with most scientific documentation. A systematic review by Murphy and Gunsolley170 report 
that GTR procedures for regenerative treatment of degree II furcation defects resulted in a 
greater gain in clinical attachment level (CAL), as well as a greater reduction in pocket depth 
(PD) as compared to OFD alone. The included studies had a follow-up of six months or more. 
The mean gain in CAL for the studies finally included was 1.9 mm with 3.1 mm of reduction 
in PD.  
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General hypothesis of the thesis 
The general null hypothesis (H0) of the thesis was that: Reconstitution of osseous defects with 
porous titanium granules will not significantly improve the defect resolution as compared to 
control defects left empty. The alternate hypothesis (HA) of the thesis was that: Reconstitution 
of osseous defects with porous titanium granules will significantly improve the defect 
resolution as compared to control defects left empty. 
 
General objective of the thesis 
The general objective of the thesis was to investigate the potential of PTG when used as a 
bone substitute material in peri-implant and periodontal osseous defects. 
 
Specific aims of the thesis 
The specific aims of the studies included in this thesis were:  
A) To compare the osteoconductive properties of PTG with controls left empty in osseous 
defects adjacent to c.p. titanium implant surfaces. (Paper I) 
 
B) To analyze the biological performance (bone formation, resorption and inflammation) 
of PTG in osseous defects adjacent to c.p. titanium implant surfaces. (Paper I) 
 
C) To compare the potential of PTG with sham and DBBM in the reconstructive 
treatment of surgically created buccal, degree II furcation defects. (Paper II) 
 
D) To evaluate periodontal ligament regeneration and the presence of root resorption 
lacunae, when PTG is placed in surgically created, buccal, degree II furcation defects. 
(Paper II) 
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E) To analyze the osseous reconstitutive properties and potential to support re-
osseointegration of PTG when used as a bone substitute in the reconstitution of a 
human peri-implant osseous defects. (Paper III) 
 
F) To compare clinical and radiographic results from PTG implanted peri-implant 
osseous defects with non-implanted controls. (Paper IV) 
 
G) To evaluate clinical and radiographic performance of PTG when used as a bone 
substitute in the treatment of mandibular degree II furcation defects. (Paper V) 
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Materials and methods 
This thesis consists of a series of studies analyzing the performance of PTG using animal 
experimental and clinical research models. In paper I, calibrated osseous defects were 
prepared in the tibias of 24 New Zealand rabbits, which were grafted with either metallic or 
oxidized porous titanium granules (PTG or WPTG respectively), whereas control defects 
were left empty (sham). The defects were closed with a submerged coin shaped titanium 
implant and left for healing for four weeks. After healing, the implants were removed and the 
tissue formed onto the implant surface was analyzed using RT-PCR. Wound fluid was 
sampled at time of harvest with 6.25 mm circular filter papers. Samples were analyzed at the 
same day by spectrophotometry. Histological and micro-computed tomography (microCT) 
analyses were also conducted to study osseointegration of titanium granules, as well as 
osseous reformation in defects.  
In paper II buccal degree II furcation defects were surgically created in maxillary premolar 
teeth in adult, female, mini pigs and filled with PTG or DBBM, or left empty (sham) (Fig. 6). 
After six weeks of healing, pigs were euthanized. Teeth with defects were excised en bloc and 
analyzed by microCT and histology.   
 
 
Figure 6. Furcation defect model used in paper II. A) A muco-periosteal flap was raised and buccal degree II 
furcation defects were surgically created in premolar teeth P2, P3 and P4, The periodontal ligament and root 
cementum were removed using curettes and surgical diamonds. Notches were made at the most apical part of the 
defects. B) Defects were randomized to either grafting with DBBM, PTG or left empty (sham). C) The surgical 
sites were closed with Vicryl® 4.0 resorbable sutures. 
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Paper III is a human histological analysis of an implant that 12 months earlier underwent PTG 
reconstructive treatment of a peri-implant osseous defect. Analyses of the biopsy were 
performed by means of microCT and histology. Presence of phosphorous and calcium in the 
newly formed bone were validated by scanning electron microscopy using an energy 
dispersive x-ray analyzer (EDAX). 
 
Paper IV is a prospective, randomized, case-control, clinical study of 12-months duration (Fig. 
7) comparing open-flap debridement and surface decontamination with titanium curettes and 
24% EDTA gel or additional insertion of PTG. Implants were submerged and allowed to heal 
for six months. Probing pocket depth (PPD), bleeding on probing, implant stability using 
resonance frequency analysis (RFA), and radiographic evaluation were performed at baseline 
and at 12 months. 
 
In paper V surgical intervention with PTG used as a bone graft substitute was performed in 10 
patients with 10 mandibular degree II buccal furcation defects. Clinical parameters (probing 
depth (PD), CAL, gingival recession (GR), gingival index (GI), bleeding on probing (BoP), 
horizontal and vertical bone sounding) and radiographic measurements of vertical furcation 
height were compared between baseline (pre-surgery) and six and 12 months (post-surgery). 
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Figure 7. Consolidated Standards of Reporting Trials (CONSORT)171, 172 flow diagram outlining the  
study presented in paper IV. Flow diagram format: Copyright © 2010, British Medical Journal Publishing  
Group 
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Summary of results  
Paper I 
Significantly more new bone formed in PTG and WPTG treated defects compared to sham. 
The new bone grew both through the porosity of the granules and onto the implant surface. 
The WPTG group showed significantly less expression of key inflammation markers, but with 
no significant difference in a marker for necrosis. The WPTG group also showed a significant 
increase in collagen-I mRNA expression as compared to PTG. 
Paper II 
The histological analysis showed significantly more vertical bone formation in both PTG and 
sham groups compared with DBBM treated defects (P <0.01). MicroCT analysis showed 
significantly more bucco-palatal bone formation in furcations implanted with PTG compared 
with the DBBM and sham (P <0.05). Bucco-palatal cylindrical microCT cores demonstrated a 
mean defect fill of 95.2% for PTG-implanted defects, which was significantly greater than 
sham (62.3%) and DBBM (66.5%) (P <0.001) treatments. Significantly more regenerated 
PDL was seen for sham than DBBM treated defects (P <0.05) (Fig. 8).  
 
 
 
 
 
Figure 8. Photomicrograph of histological sections from a furcation treated with PTG in study II 
A) Polarized light 25X. B) Polarized light 100X. C) L.M. 100X. N =Notch, NB =New Bone, PDL 
=periodontal ligament fibers, PTG =porous titanium granules. 
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Figure 9. Human biopsy from patient reported 
in paper III. Microradiograph showing bone in 
close contact with PTG particles, bone between 
PTG and the dental implant surface and in close 
contact with the treated implant. L.M. 25X 
Root resorption lacunae were small and infrequent and did not differ between groups. 
 
Paper III 
No signs of objective side-effects such as exfoliation of graft material or overt inflammatory 
reaction were seen at any time-point during the follow-up. No subjective side-effects such as 
pain or discomfort exceeding similar type surgical procedures were reported. The implant was 
partly covered with mucosa at time of excising the biopsy and PPD measurements could thus 
not be performed. Only very minor signs of mucositis, and no signs of suppuration of pus, 
were observed at the time of implant removal. 
The baseline radiographic mesial and distal defect heights were 9.24 mm and 5.70 mm 
respectively, while the corresponding radiographic defect heights at the 12 months terminal 
evaluation were 0.97 and 0.74 mm respectively. Horizontal microCT sections demonstrated 
PTG embedded in new bone and areas of re-osseointegration of the implant, i.e., new bone 
formed between the granules and the implant, and new bone in contact with the treated 
implant surface (Fig. 9). 
The SEM analysis demonstrated areas where 
the implant was re-osseointegrated with new 
bone growing onto the implant surface, onto 
the PTG and into the porosities of the granules. 
The SEM-EDAX element analysis 
demonstrated calcium and phosphorus in the 
tissue embedding the PTG and implant giving 
further support for presence of calcified tissue in  
the spaces between the PTG and between PTG  
 
42 
 
 
and the dental implant.  
The histological analysis demonstrated PTG well integrated in zones of woven and lamellar 
bone. Clear presence of lamellar bone between the granules and the implant surface and areas 
of contact between the new bone and the implant surface were furthermore demonstrated i.e., 
re-osseointegration. Instances of narrow zones of fibrous tissue were however also observed 
between the new bone and the implant surface. 
 
Paper IV 
Change in radiographic defect height and percent fill of the peri-implant osseous defect 
significantly favored patients treated with PTG (P <0.001). Both treatment modalities 
demonstrated significant improvements in PPD (P <0.001), but no significant differences 
between groups were observed. The PTG treated implants showed an increase in RFA of 1.6 
implant stability quotient (ISQ) units compared with a decrease of 0.7 ISQ for the control 
group (n.s.). No adverse effects were associated with PTG treatment. 
 
Paper V 
With respect to vertical and horizontal bone sounding measurements, CAL and GR, no 
significant improvements between baseline and the 12 month examination were seen. Both 
PD and radiographic vertical furcation height were significantly reduced between baseline and 
12 months. When comparing the baseline and 12 months data, a significantly lower GI score 
was seen but the BoP score was unchanged for the same time interval.  
None of the treated teeth showed radiographic signs of root resorption. 
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Discussion 
Methodological considerations  
Research models 
Two different animal experimental models and two clinical models were used to elucidate on 
the specific aims of this thesis. In paper I, a New Zealand White rabbit (Oryctolagus cuniculus) 
tibia defect model were used whereas a mini pig (Sus Scrofa) furcation defect model where 
used in paper II. Animal models are primarily hypothesis generating and clinical studies are 
always necessary to further explore or verify the experimental findings in humans. In paper III 
and IV the use of PTG as a bone substitute in the surgical treatment of peri-implant osseous 
defects was investigated. In paper V, the utilization of PTG as a reconstructive biomaterial for 
periodontal furcation defects in mandibular molars, was investigated. 
The animal model in paper I was only performed to get an initial idea of the performance of 
the novel biomaterial prior to the execution of preclinical investigations (paper II) and clinical 
testing (paper III-IV). In paper I the material was tested in a closed implant defect model 
without any load from neither teeth, nor implants, whereas the dental furcation defect model 
in study II both involved load from occlusion forces as well as potential inflict on the healing 
from the oral environment.  
One of the major advantages with performing animal experimental studies is standardization 
of the experimental system. The choice of animal model is obviously related to the objective 
of the study. When aiming at evaluating osteoconductivity and biocompatibility of a 
material, bone defects large enough to avoid spontaneous healing (a.k.a. critical size defect173) 
and small enough that also minor relative improvements can be detected.174 Two methods 
exist for creating critical size defects: 
(1) To create a defect and thus prevent healing by for example insertion of a foreign body 
such as a ligature or dental impression material.  
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(2) To create a defect large enough that spontaneous healing does not occur.  
Only the second method creates a true critical size defect and is thus often considered to be 
the best method of choice since the first method involves too many uncontrollable variables 
(e.g., infection, nutritional and metabolic abnormalities) while the second model optimizes the 
bodies physiologic response.173 The less the number of uncontrollable variables involved in a 
model the easier it is to create calibrated defects. This saves number of animals involved in 
the study but also makes the testing system more rigid. The uniform, radial geometry of the 
cylindrical defects used in paper I, makes them highly defined. By using a closed system it is 
also possible to avoid variation in external encroachment affecting the healing pattern. In 
paper I, defects three millimeters in diameter and five millimeters in height were created in 
the tibia of rabbits. Two defects were created in each leg. The defects were covered with a 
titanium disc to study healing in close proximity with a titanium implant surface (Fig. 10). 
The variation between defects is minimal. The rabbits may plausibly have been somewhat 
young since they were only eight months, while rabbits has been reported to be skeletally 
mature at 10-11 months,174 albeit other authors have reported that female New Zealand white 
rabbit is skeletally mature already after six to seven months.175, 176 It is in this context 
important to note that all animals were of the same age which probably canceled out for this 
hypothetical consideration. In paper I an animal experimental model was used to assess the 
performance of PTG in proximity to a titanium surface and for analyzing bone growth in PTG 
treated defects. The major crux with this study was to assess osteoconductivity and 
biocompatibility of PTG and the findings from this closed defect model in rabbit tibia bone 
should thus not be directly derived to the related intra oral clinical situation with a dental 
implant with an infected osseous defect communicating with the oral cavity. 
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Rabbits have a much faster bone healing rate than humans,177 and the bone forming rate has 
been reported to be approximately three times as fast in rabbits as in humans.57 Roberts et al. 
report that the BMU in rabbits femur is 1300 μm and moves at a speed of 220 μm per weeks 
time and hence a total bone forming period (a.k.a. sigma66) of six weeks. The average BMU 
in human cortical femur bone has been demonstrated to be 3700 μm.178 Sigma in humans (rib 
bone) is four to five months.57 One may still argue that the study was short in length. Again it 
is important to note that the major task was to compare three different treatment modalities to 
get a basis for testing in more advanced animal experimental models which to a greater extent 
mimic the clinical situation (paper II).  
In paper II the aim was to perform a preclinical test of PTG as a reconstructive material and a 
mini pig (Sus Scrofa) furcation defect model was used. One of the secondary objectives was 
Figure 10. Tibia defect model used in study I: A) Intra-surgical pictures of test-
device (PTG) versus control defects left empty. B) Defects are covered with coin-
shaped titanium implants, covered by a teflon cap and stabilized by a pre-shaped 
titanium plate fixed by titanium screws. C) Indexes used for the 
histomorphometrical analyses *Index A. Horizontal dimension of regenerated peri-
implant cortical bone. †Index B. New bone in the marrow space compartment. 
‡Index C. Vertical dimension of new peri-implant cortical bone. Image in part 
derived from Wohlfahrt et al. 2010 with Copyright © 2010 John Wiley & Sons Inc 
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to perform a safety assessment and test if PTG in close narrowness to root surfaces may cause 
root resorptions. A challenge was to distinguish between root damage caused by excessive 
preparation of the root surfaces in conjunction with creating the furcation defects and true 
resorption lacunae. It is important to stress that the model used in paper II only in part mimic 
the clinical situation of furcation defects caused by periodontal disease. The furcation defects 
created were significantly larger than what is typically seen in humans. The aim with this was 
to extend the defects to critical size.173 Moreover the model used does not involve infection 
with representative periodontal pathogens nor does it comprise a state of chronic 
inflammation. When performing analyses of different treatment modalities in an animal 
experimental setting, it is of importance to use a model with a high sensitivity and by this: (1) 
limiting the number of animals but also reaching sufficient statistical power and (2) limiting 
the study time to keep away from unnecessary morbidity for the animals. Under such 
circumstances, calibrated defects, homogenous in defect size will be important.179 It has 
though previously been argued that neither furcation defects which are caused by ligature 
induced infection, nor naturally occurring furcations will be sufficiently homogenous for 
optimal comparison between test and control groups.180, 181 Creating surgical defects and 
performing experimental treatment in the same surgical session is also less stressing for the 
animals than other models with experimentally induced defects that has previously been 
described in the literature (Appendix I).  
In paper III the performance of PTG when used for reconstruction of a peri-implant osseous 
defect was evaluated by means of histology. The major crux was to explore if a dental implant 
affected by peri-implantitis can re-osseointegrate. By definition osseointegration implies that 
the implant is in function. One may thus argue that since the implant was never put in 
function after the defect had been reconstructed with PTG the complete definition of re-
osseointegration has not been fulfilled. It is though argued that the definition re-
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osseointegration has previously been used for animal experimental studies exploring the 
principle of re-osseointegration and in these studies the implants were never put in function 
after treatment and prior to harvest.166, 182, 183  
Few randomized clinical trials have been performed on the treatment of peri-implantitis and 
on reconstructive surgery of peri-implant defects (Appendix I). One concern with clinical 
studies on peri-implant defects is to ascertain balance between test and control groups. The 
reason for this is multi-plethoral (for a comprehensive review see Esposito et al. 1998.184):  
(1) It is often difficult to securely determine the etiology of a peri-implant defect. To do so 
it will be necessary to compare radiographs taken at the one year control with 
radiographs taken at time of screening for the study. By experience such radiographs 
are not often attainable. So called “physiological” loss of bone due to bone remodeling 
during the first year of function is not the same entity as bone loss caused by peri-
implantitis and may not even need treatment if no progression is demonstrated over 
time.  
(2) The author´s experience is that the peri-implant defect morphology varies to a much 
greater extent than what is generally understood. The optimal situation would certainly 
be a split mouth clinical study. Out of 66 potential subjects screened for study IV only 
one had a matched pair of peri-implant osseous defects.  
(3)  Technical contributing factors must be completely elucidated on and potentially 
resolved prior to inclusion. Poorly performed prosthetics may potentially contribute to 
peri-implant attachment loss by e.g., obstructed measures of oral hygiene. Traumatic 
occlusion as a contributing factor needs further research. Animal experimental 
findings show that traumatic occlusal overload aggravate bone loss at implants with 
ligature induced infection.185, 186 Since it is not clearly demonstrated that traumatic 
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occlusion does not contribute to peri-implant bone loss, occlusal correction should be 
performed prior to final inclusion. 
(4) The implant site may have been grafted prior to implant placement. This must be 
elucidated on prior to treatment of a peri-implant defect since the biological situation 
may be totally different if there are remaining old graft particles in the surrounding 
bone.  
(5) Angulations of the implants and potentially partial placement outside of the skeletal 
envelope may be detrimental to reconstructive treatment. This needs to be explored 
prior to therapy. 
(6) Reason for tooth loss may vary from patient to patient. It is not resolved if patients 
with a history of periodontitis respond as well to treatment of peri-implantitis as 
compared to periodontaly healthy patients. The same issue may have an impact on the 
outcome of regenerative or reconstructive measures. It is also sometimes not known if 
the patient has a history of chronic or aggressive periodontitis and if these two disease 
entities affect the outcome of peri-implantits therapy.  
(7) As of today there is a great range of implant systems on the market. There have been 
major changes of all implants systems throughout the years. Implant development take 
place both at the macroscopic as well as the microscopic level, i.e., with both new 
prosthetic connections, implant body design, such as thread types, as well as surface 
characteristics down to the nano level. Before including an implant such factors should 
probably be defined and potentially later balanced between the test and control group. 
By experience it may sometimes be extremely difficult to track what exact implant the 
referred patient has. Even if a specific surgical approach works for one type of implant 
it may well be that a different implant may respond less favorable.  
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(8) Implants with a one stage installation protocol may be difficult to re-submerge in 
conjunction with surgical therapy of peri-implant osseous defects. Early penetration of 
the implant through the mucosa may potentially affect the outcome of the therapy. 
(9) Presence or absence of keratinized mucosa may potentially affect the outcome of a 
therapeutic approach. In study IV a weak positive correlation with r =0.371 between 
presence of keratinized mucosa and no progression of bone loss was found.  
 
Only subjects with removable and preferably screw retained supraconstructions were included 
in the study presented in paper IV. The reasons for this were:  
(1) The possibility to remove the supraconstruction and thus perform more accurate 
clinical measurements. 
(2) To gain access for the surgery. 
(3) Since a submerged protocol was used, removal of the supraconstruction was obviously 
mandatory. 
(4) To check potential prosthetic complications such as loose abutment screws potentially 
contributing to the etiology. A complete prosthetic assessment is only possible after 
removal of the supraconstruction. One example of this is fractured bridge screws or 
fractured implant walls hidden under a full implant retained bridge.  
(5) Resonance frequency analysis (RFA) can only be performed at the implant level.  
(6) To exclude loose implants hidden under full implant retained bridges it is also 
mandatory to remove the supraconstructions.  
(7) To avoid excess dental cement as a contributing factor to the peri-implantitis lesion.187  
 
In paper IV the patients were given a combination regime of antibiotics i.e., Amoxicillin and 
Metronidazole. There is no scientific evidence for the adjunctive use of antibiotics when 
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performing surgical corrective treatment of peri-implant osseous defects, but anecdotal 
evidence seems to support its use. Opposed to periodontal treatment where the antibiotic 
when used, is usually an adjunct to the causative treatment phase, it has been a convention to 
instead use antibiotics in conjunction with surgery when treating peri-implantitis. The reason 
is probably that it has been considered impossible to perform sufficiently good closed implant 
surface debridement and disruption of the biofilm since access is often difficult. Leonhard et 
al.188 reported that the typical periodontal pathogens Porphyromonas gingivalis, Prevotella 
intermedia and Aggregatibacter actinomycetemcomitans were recovered from the peri-
implant sulci in 60% of patients which may support the adjunctive use of Amoxicillin and 
Metronidazole.189-191 It is however important to point out that the microbiological diversity is 
much higher in the peri-implantitis lesions and atypical oral microorganism, such as 
Staphylococcus Epidermidis188 are more frequently found in peri-implantitis lesions than in 
periodontitis lesions. The general understanding is though that the peri-implantitis subgingival 
microbiota is a mixed anaerobic infection dominated by gram negative bacteria i.e., a flora 
similar to chronic periodontitis.192 A standardized antibiotic regime was used for all patients 
in an attempt to avoid having to control for differences in antibiotics used when analyzing the 
results. One alternative may potentially have been to perform microbiological testing and try 
to level out the microbiota prior to surgical intervention but there is no support for such a 
regime in the literature. 
After mechanical debridement of the implants a chemical surface cleansing with 24% 
ethylenediaminetetraacetic acid (EDTA) -gel was performed. There is limited scientific 
evidence in the literature for usage of chemical agents for decontamination of dental implants. 
The choice to use 24% EDTA-gel was done on arbitrary means and it has never been shown 
that it has any positive clinical effects in conjunction with treatment of peri-implantitis, nor in 
conjunction with surgical treatment of periodontal defects.193, 194 EDTA is a pH neutral 
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calcium chelator which has been reported to dissolve the smear layer of organic and 
mineralized debris, consisting of bacterial plaque and contaminated cementum and dental 
calculus left after root surface debridement.195 Importantly and in contrast to many other 
chemical decontaminants, EDTA-gel has been shown to have no necrotizing effect on the 
surrounding tissues.196 It was judged to be of significant importance to maintain as much as 
possible of the vitality of the surrounding tissues, primarily due to the potential for bleeding to 
the defects hence rapidly achieving a stable blood coagulum. The major biological concept 
behind utilizing titanium as a biomaterial for reconstructive therapy lies in the thrombogenic 
effects and from this perspective it was decided to use EDTA-gel as a chemical 
“decontaminant.” Later in vitro results from our department have demonstrated that EDTA 
has no significant effect on the biofilm of a titanium surface and with this more recent 
knowledge in mind it may have been preferable to choose a chemical decontaminant with 
better biofilm distruptive potential such as e.g., citric acid or H2O2.197  
No selection was made based on the defect morphology. With respect to defect width and 
defect angle a clinical judgement was done after surgical exploration of the defect and 
potential for accomplishing graft stability. It was later shown that the groups were balanced 
with respect to number of defect walls and defect angle. A recent study report that the defect 
angle has a significant effect on the potential to achieve regeneration of a peri-implant 
osseous defect198 and the results may well have been different if the study was purified to 
narrower or only 3 wall defects leading to improved stability of the inserted PTG particles. In 
this context one must though keep in mind that many peri-implant defects are rather wide. 
 
The clinical study presented in paper V was executed to get an initial evaluation of the 
performance of PTG when used in degree II furcation defects and to achieve pilot data and 
gain experience with the methodology prior to initition of a full randomized clinical trial. All 
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patients included clearly had a history of chronic periodontitis and had undergone a causative 
periodontal treatment phase. It may though well be that some of the teeth had undisclosed 
contributing etiological factors such as root fractures, partial pulpal necrosis with lateral 
canals invading in to the furcation or such, but the fact that the results were relatively 
homogenous probably opposes this. The teeth were all vital and the defects were limited to 
the furcations. The proximal bone height was above the level of the furcation entrance in four 
of the included teeth while six of the included teeth had the proximal bone height at the level 
of the furcation entrance.  
A number of factors seem to influence the outcome of the surgical reconstructive therapy of 
furcation defects such as:  
(1) Vitality of the involved tooth.  
(2) Traumatic occlusion.  
(3) Height of the root trunk.  
(4) Furcation defect morphology with e.g., respect to presence or absence of a buccal 
bony wall.  
(5) Divergence between roots.  
(6) Morphology of the root cones with sometimes deep concavities on the distal surface of 
the mesial root hindering proper instrumentation prior to grafting.  
(7) Height of the buccal keratinized gingiva affecting the risk of recession of the gingival 
margins and exposure of the grafted furcation.  
(8) Patient related factors such as smoking.199  
The study presented in paper V did not involve sufficient number of patients to control for 
such variables and it may be that the outcome of the study would have been different under 
other and potentially more optimal conditions.  
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Inclusion criteria however left many teeth or subjects out from participation based on the 
above described variables. Attempts were also made to optimize the potential for a successful 
outcome in all treated defects both with respect to tooth related factors such as removal of 
enamel pearls and aiming at the best possible surgical technique. 
 
Analytical methods 
The study presented in paper II was designed to evaluate new bone formation along the root 
surfaces and histological sections were intended to be cut out at the bucco-palatal midline of 
the teeth. It was though established that mini pig teeth have some characteristics that makes it 
difficult to evaluate all aspects of bone growth in furcations:  
(1) Concerns were raised with respect to remaining bone due to incomplete 
instrumentation of the pronounced mesial and distal radicular grooves. This made it 
difficult to clearly determine if bone along the root surfaces above the notch was 
newly formed or remaining old bone which had been overlooked while creating the 
defects. Due to this it was decided to solely analyze vertical bone formation at the 
mesio-distal center of the furcations. It is also important to point out that this concern 
also may be related to other animal models that have been used for studies on 
regeneration of furcation defects. It has previously been reported that osseous 
regeneration in furcations first occur adjacent to the root surfaces followed by fill of 
the more central portion of the inter-radicular area.200 Such a verdict may obviously be 
related to the here mentioned root morphological findings. It is also important to point 
out that the presence of radicular grooves differs to a large extent between species. 
Further evaluation of animal model related issues is important and microCT is a 
valuable tool to perform such investigations. One may also consider to use methods 
for labeling new bone such as injection with fluorochromes during healing.  
54 
 
(2) The root dentin of the mini pigs has a low degree of mineralization and is sometimes 
difficult to clinically differentiate from bone. This makes preparation of the defects 
relatively complicated and perforation in to the pulpal space excludes a tooth from 
analysis.  
(3) The premolar roots of the mini pigs are rather slender and curved. MicroCT images 
were utilized to direct the histological sectioning, but it was still sometimes difficult to 
embrace the complete surfaces of both the mesial and the distal roots in the same 
histological section.  
The bone regeneration rate in mini pigs has been reported to be relatively similar as for 
humans.177, 201 The bone regeneration rate in pigs has been reported to be 1.2 to 1.5 mm/day as 
compared with humans which is one to 1.5 mm/day.202 One may with this in mind argue that a 
longer period of healing would have given a different outcome of study II. The literature on 
growth rate in the jaws of mini pigs is however scarce and unclear and I feel that further 
studies would be motivated to resolve this issue. The experience from our lab is that in 
alveolar bone of mini pigs growth is significantly faster than in humans and has in our 
previous experimental studies been judged to be approximately twice as fast. The exact 
growth rate needs though to be addressed in a separate animal investigation which specifically 
is designed to look at growth kinetics of bone defects. From this perspective it may potentially 
be interesting to instead use a circular critical size defect model in alveolar bone.174  
 
The statistical comparisons both in study I and II were performed on a defect level. The New 
Zealand white rabbits are, as are laboratory animals in general, systemically inbreeds, which 
means that the genetic variation between animals is highly reduced. In addition to this the 
uniformity and consistency of the environmental setting and animal housing makes 
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Figure 11. Paper I: MicroCT analyzes of bone within a 
volume of 4.13 mm3 in the cortical compartment of the 
defects A, C) PTG, B, D) Sham  
comparisons at a defect level feasible. This consideration also relates to the mini pigs in paper 
II.  
In paper I and II the new bone was analyzed both by microCT and histology. The advantage 
with the microCT analysis as compared to histology is the three dimensional mode of analysis 
which is accomplished by non destructive microCT technique. The marrow compartment of 
the tibia defects obviously lacked osseous boundaries and the spread of the granules thus 
varied between the defects. Analyzing new bone within a distinct volume of interest (VOI) 
was hence not possible to accomplish for the marrow compartment section of the defects, i.e., 
to define comparable volumes in both tests and control groups was not doable. Therefore, it 
was decided to analyze bone within a VOI solely in the cortical compartment of the defects 
(Fig. 11).  
A cylindrical VOI, 2.8 mm in 
diameter and 46 slices in height (i.e., 
0.67 mm) i.e., a total volume of 4.13 
mm3), in the center of the critical-size 
defect and excluding the walls 
consisting of old bone was created. 
The microCT analysis software was 
then used to distinguish between air 
filled spaces, titanium and bone, 
setting the upper grey threshold value 
to 110 and setting the lower grey 
threshold value to 60.  
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Figure 12. Tibia defect model used in study I: 
Clinical picture after removal of titanium 
implants and collection of wound fluid. Wound 
fluid was sampled with 6.25 mm circular filter 
papers. RNA was also isolated from the tissue 
that attached to the implant covering the defects 
and analyzed through real-time (RT)-PCR. 
The new bone volume within the VOI was compared between test and control defects. One 
may argue that the solely cortical VOI limits the value of the microCT analysis which in part 
is why a more extensive histological analysis was performed.  
It is important to point out that the grey threshold values for bone were derived from the 
cortical old bone. More immature woven bone may thus have been omitted from the analysis. 
Importantly, precise quantitative measurements of the bone volume are difficult because of 
scatter effects from the metal particles which makes the interface between the biomaterial and 
new bone imprecise. Attempts were made to perform a virtual eradication of the granules but 
due to their irregular architecture this was at the time of the analysis not possible.  
A general consideration for all non digital analyses performed is the problem with blinding 
the examiner due to the metallic, non-resorbable properties of PTG. This consideration is 
reflected both in the histological analyses and microCT analyses in study I and II as well as in 
the radiographic analyses of the clinical studies. With respect to the clinical analyses in paper 
II, IV and V it was not possible to clinically distinguish between subjects based on presence 
of PTG due to the mucosa coverage of the bone substitute. The digital analysis using the 
microCT software to some extent resolves this 
potential bias consideration. 
Wound fluid was sampled in conjunction with 
harvest at 4 weeks (Fig. 12).  
The wound fluid samples were taken after 
removal of the titanium coins i.e., at the interface 
between the titanium coin and bone substitutes 
and new bone.  
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The capability to perform gene expression analyses in small samples of tissue is important for 
assessing the biological performance of new biomaterials in the field of regenerative surgery.  
Importantly the RT-PCR results are solely indicators for several biomarkers related to bone 
formation, resorption and inflammation, and should thus be interpreted accordingly. While the 
gene expression rate is presented as numbers of PCR cycles, corrected for the total amount of 
RNA and normalized for the relative values of several housekeeping genes, the significance 
of the results is sometimes difficult to interpret. The results show the trends in gene 
expression within the isolated tissues and this molecular data should be interpreted only 
together with the results from the histological and microCT analyses. One may thus argue that 
the results should not be related to the microCT and histological findings since sampling was 
made at a much more superficial level and that the titanium coin obviously also affects the 
outcome hence the wound fluid results is the joint outcome of effects from both PTG and the 
titanium coin surface. A more invasive method to sample wound fluid or tissue would 
however have destroyed the samples, and disqualified them from histological and microCT 
analyses. 
The clinical measurement of the pigs at time of harvest was performed right after euthanasia. 
This may consequently have made the BoP recordings obscure. However, since all animals 
were treated in the same fashion, i.e., with probing directly after euthanasia, the significance 
of this is probably not a major concern. It would have been more stressful for the animals to 
undergo one additional sedation for performing the clinical measurements and since the value 
of the clinical results in this study still was considered to be limited this procedure was chosen 
for animal ethical reasons.  
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In paper III sections from the base of the defect to the top of the implant were analyzed both 
by microCT and histology. The implant was not notched at the base of the defect and the 
sectioning was done in a fashion perpendicular to the implant (i.e., horizontal sectioning, Fig. 
13). Bone growth was demonstrated between the implant and the PTG particles to at least half 
way from the base to the top of the defect, where obviously no old bone was present (Fig. 13). 
The microCT and histological sections were compared with both clinical pictures as well as 
with intrasurgical registrations of the defect morphology.  
 
 
 
 
The aim with sectioning the implant in a horizontal fashion was to study ingrowth of PTG 
into bone. This was done both within the intraosseous component of the defect as well as 
facially of the fenestrated implant section, where the PTG particles were placed without the 
stability of bony walls. One may argue that arbitrary microCT threshold values for bone may 
have skewed the results in a positive fashion. Opposing to this is the fact that the threshold 
Figure 13. a) 3D reconstruction of microCT images of en bloc excised trephine biopsy containing 
implant, bone and PTG particles. b) Horizontal section at the vertical midpoint of the defect. c) 
Magnification of b with new bone embedding PTG particles as well as new bone in close contact 
with the implant surface implying re-osseointegration. 
59 
 
value for bone was set with lower and upper values corresponding with the bone tissue at the 
base of the implant which hence was clearly defined as old bone. This may instead have led to 
a less positive outcome, since immature woven bone, with less degree of mineralization, as a 
consequence may have been omitted. 
Attempts were made to analyze CAL in the study presented in paper IV. Many of the implants 
had been placed deep with a thick and bulky mucosa coronal of the implant and with manifest 
bleeding and inflammation at baseline. It was thus difficult to justify CAL or bone sounding 
measurements, since localization of a rigid reference point with high reproducibility was 
difficult to ascertain. Moreover, 12 of the 33 patients received new supraconstructions, which 
made baseline reference points for CAL or bone sounding measurements obscure at the later 
examination points. In hindsight, relating on a reference point at the coronal margin of the 
implant body was not an optimal approach for CAL measurements. Using the margin of a 
healing abutment or even fabricating a stent type device with vertical canals, for accurate and 
reproducible measurement at the different examination time points may have made CAL 
measurements possible with acceptable accuracy. One may also argue that CAL 
measurements under all circumstances are of less value, due to the non-resorbable nature of 
PTG.  
No significant difference in PPD between the test and control groups was demonstrated. 
Probing of the peri-implant mucosal crevice to disclose clinical signs of inflammation and 
loss of bone are important for diagnosing peri-implantitis, but PPD as a surrogate marker for 
assessing the outcome of reconstructive peri-implant therapy, call for discussion. It has been 
reported that factors such as mucositis, applied probing force and accessibility to the pocket 
have an impact on the penetration of the periodontal probe.203-207  
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Lang and co-workers206 compared probe penetration, as seen on histological sections, with 
true attachment level in healthy and inflamed peri-implant tissues. An error of up to 1.6 mm at 
implants with peri-implantitis was reported. The error was smaller at healthy sites or at sites 
with only mucositis and instead only varied between -0.35 and +0.3 mm. To compensate for 
such errors a “click-on” probe with a defined probing force (20 g) was used in study IV (Fig. 
14).  
A recently published systemic review discussed endpoints, which have been used in studies 
on peri-implantitis treatment.208 These authors argued that the most valid clinical outcome in 
such studies would be implant loss. PPD and CAL are non validated surrogate markers for 
disease progression and it has never really been shown that a demonstrated change in CAL or 
PPD will capture the risk for future loss of an implant. The patient group in study IV will be 
followed carefully over time to reveal implant loss in the case or control group. 
From the perspective of reconstructive outcomes, bone fill is the only component of the 
potentially regenerated peri-implant tissues in a treated peri-implant defect that can be rigidly 
assessed clinically. With the implant in situ, true validation of bone fill can only be done by 
re-entry surgery.209 In view of patient morbidity, re-entry surgery is often impractical to 
execute. As a consequence to this, radiographic assessments, as well as clinical variables, 
such as CAL and bone sounding, have been implemented as surrogate markers to bone fill. 
BoP and PLI was scored dichotomously in the study presented in paper IV. No difference 
between groups was found. It may have been preferable to use a graded index such as the 
modified bleeding index (mBI).150 The obvious crux with BoP was to use it as a surrogate 
marker for presence or absence of active disease. It is from this perspective, thus argued that a 
dichotomous scoring is more rigid. 
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Figure 14. 0.20 N (20 g) defined force “click-on” 
periodontal probe (University of North Carolina, DB 
764 R, AESCULAP®, B Braun, Tuttlingen, 
Germany) 
Figure 15. Resonance frequency analysis using the 
Osstell mentor® (Osstell AB, Gothenburg, Sweden) 
with the SmartPeg™ inserted into the implant and 
directing the Osstell® probe against the peg at four 
different directions to achieve the lowest ISQ value 
which then was recorded. 
In hindsight an intra-examiner calibration prior to initiation of the study should have been 
performed. On the other hand a proper calibration should if so have been performed in peri-
implantitis sites with at least a 5 days interval between probings.210 This would have meant 
that the supraconstruction should have been removed a second time, which would be difficult 
to ethically justify. Furthermore, a defined force “click-on” periodontal probe was used and 
probing was performed at six sites around each implant (Fig. 14).  
 
When initiating the study, it was to the best 
of our knowledge the first time a non-
resorbable bone substitute was used in a 
case-control clinical study setting for 
reconstructive treatment of peri-implant 
osseous defects. It was consequently not 
possible to derive data on power from 
another study to determine the number of 
patients needed. With the aim to develop 
this novel surgical methodology and to 
calculate power, a small pilot study was 
performed prior to study start. Resonance 
Frequency analysis (RFA) (Fig. 15) was at 
the time of the present study initiation 
considered to be an objective way to 
quantify implant stability211 and judged to 
be a potential surrogate marker for 
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osseointegration.212  
 
The manufacturer of the RFA claims that one millimeter of peri-implant marginal bone loss, 
correspond with a loss of three ISQ. Based on this, one millimeter of re-osseointegration 
would reasonably correspond with a gain of three ISQ. Zarb and Albrektsson212 suggested a 
clinically applicable (i.e., non-destructive) definition of osseointegration instead based on 
implant stability: “a process whereby clinically asymptomatic rigid fixation of alloplastic 
materials is achieved and maintained in bone during functional loading.” In this context RFA 
may be a potential candidate for a non-invasive objective method to assess implant stability 
and bone to implant contact.211 Measuring RFA was consequently decided to be done in an 
attempt to determine change in implant stability between baseline and the 12 months follow-
up. Later studies have though questioned the rigidity of RFA and a recently published animal 
experimental study report no correlation between histological assessment of osseointegration 
measured as bone to implant contact (BIC) and RFA values.213 The rigidity of RFA to be used 
as an instrument for the analysis of defect fill of peri-implant osseous defects and potentially 
re-osseointegration remains however to be determined.  
It is of significant interest to find objective non-destructive parameters for osseointegration. 
The results from this study do not provide any clear evidence in either direction and further 
studies will be needed. 
 
Clearly the fact that titanium is metallic is a hindrance from the perspective of radiographic 
evaluation of bone fill and the non-resorbable nature of PTG made discrimination between 
true re-osseointegration or true bone fill of the defects and integrated PTG particles 
impossible. It may thus be argued that the results from this study have limited value. On the 
contrary to this, it is argued that this study has clinical relevance since: (1) Importantly both 
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treatment modalities lead to significant reductions in both pocket depths and radiographic 
defect height at 12 months as compared with the baseline measurements. This may indicate 
that either one of these two methods may have some potential in the treatment of peri-implant 
osseous defects. Very few randomized case control clinical studies have so far been published 
evaluating regenerative treatment of peri-implant osseous defects, thus such findings are 
valuable from a clinical perspective. There was a tendency towards less defect progression 
and improvement in RFA in the test group but longer observation times will be necessary 
(Table 2). The patients in paper IV are being followed and comparisons between groups at 3 
and 5 years will be performed. No adverse events were seen for the PTG treated defects which 
is important to know when planning for further studies on this novel biomaterial. 
 
 
 
PPD Radiographic defect height 
Case Control Case Control 
mm change n % n % n % n % 
1.5- 0 0 2 12.5 0 0 3 18.75 
>0 - 1.5 0 0 1 6.25 2 12.5 4 25 
0 5 31.25 2 12.5 0 0 0 0 
<0- -1.5 0 0 2 12.5 4 25 7 43.75 
-1.5 - 11 68.75 9 56.25 10 62.5 2 12.5 
Total 16 100 16 100 16 100 16 100 
 
 
 
In paper V the main endpoint for validating the performance of the material was change in 
vertical and horizontal bone sounding, which would indicate defect fill, albeit it do not 
provide true evidence for integrated PTG particles, in-growth of bone or regeneration of 
Table 2.  Study IV: Frequency distribution. Change in PPD (p =0.17) and radiographic defect height 
(p <0.01) selecting on the mesial or distal defect with the deepest infrabony component as recorded 
during surgery. X2-test. 
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periodontal attachment. Invasive evaluation methods would be necessary to fulfill such aims 
with the study. The non-resorbable metallic thus radiopaque nature of PTG makes the 
radiographic endpoint obscure for showing true defect fill. One would also tend to expect that 
the non-resorbable nature of PTG would tend to hinder probe penetration and thus by all 
means lead to reduction of clinical measurements of defect width and height. The outcome in 
paper V was on the contrary opposite to this, which hypothetically implies that the biomaterial 
was embedded in loose connective tissue which makes it possible to penetrate the periodontal 
probe between the PTG particles. To further elucidate on this a re-entry surgery will be 
necessary. There were even examples of defect progression but, since no control group were 
included it was not possible to determine if this finding was caused by the material per se or 
from bone remodeling due to the surgical trauma.  
 
Statistical considerations 
The study presented in paper I included a total of 15 separate tests and the outcome of the 
analysis should be considered explorative rather than giving a definite answer to one specific 
hypothesis. It should thus be noted that a number of the positive findings in study I were as a 
matter of fact rejected when Bonferroni correction where applied. In lieu of this one may 
argue that each analysis of the different biological markers may be considered as a separate 
experiment, which accordingly make Bonferroni corrections unnecessary, i.e., to avoid false 
rejection of the alternate hypothesis.214, 215 
Since data in paper II was pooled from three sets of surgery series, it was decided to further 
elucidate on potential differences between the three experimental surgical time points. The 
sham results were compared between the three series of surgeries. A Kruskal-Wallis test 
demonstrated no statistically significant differences between outcome of sham treatment in 
the three animal experimental surgeries (p >0.05). Statistical comparisons were performed at 
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the tooth site level. When comparing the distribution of teeth P2, P3 and P4 between groups 
in paper II, no significant difference was seen (p =0.64). Furthermore a Pearson product-
moment correlation coefficient was calculated in the study presented in paper II, comparing 
two separate histo-morphometrical readings by the same examiner (SPL) with an interval of 
two months. A positive correlation between the two separate histological readings by the 
same examiner (blinded from results of the first reading) with r =0.567 was demonstrated. In 
the clinical study presented in paper IV it was not possible to blind the examiner when 
performing the radiographic measurement. The radiographs were however randomized with 
respect to time-point, i.e., the examiner was blinded to at which examination time-point the 
specific radiograph was taken. Radiographs from the first 19 subjects were analyzed twice 
with an interval of two weeks. Pearson correlation coefficient was calculated comparing the 
two separate radiographic readings, demonstrating a strong positive correlation between two 
separate readings, with r =0.996. The clinical study presented in study IV compare a case and 
control group of patients, whereas no control group was included in the study presented in 
paper V. This is an obvious limitation with paper V. Baseline data compared with 12 months 
data is instead presented. 
 
Discussion of results 
This series of studies evaluate titanium when used as non-resorbable bone substitute and its 
efficacy for reconstructing some types of osseous defects. The initial animal experimental 
studies were encouraging and led to the execution of two clinical studies. The choices of 
clinical surgical indications were peri-implant osseous defects and degree II mandibular 
furcation defects. Both these indications are complex and numerous suggestions have been 
made throughout the years to find potential treatment methods. As of today there are no 
predictable evidence based methods for treating neither peri-implant osseous defects nor 
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furcation defects. It is thus considered to be of significant interest to evolve on these 
indications. 
In paper I it was by histological means observed that mineralized tissue form directly onto the 
titanium granules. Mineralized tissue was also filling the voids between the titanium particles. 
This observation verify that porous titanium granules are osteoconductive, which correspond 
with previous findings as reported by Turner et al.129 It is interesting that new bone had 
formed on PTG particles residing deep in the marrow compartment and without obvious 
connection to the old cortical bone. Since the tibial bone in rabbits does not exhibit trabecular 
bone structures in the bone marrow space the histological observation of trabecular bone 
growth within the marrow compartment would thus potentially suggest that the titanium 
granules act as an osteoconductive scaffold also when placed in the bone marrow. This newly 
formed bone may: 
(1) origin from the old cortical bone and grow along the surfaces of the titanium granules 
into the subjacent marrow compartment.  
(2) be formed by bone apposition directly onto the implant surface a.k.a. contact 
osteogenesis.62  
If the latter bone forming mechanism is factual, it is a crucial observation in study I. However 
further verification in experiments, specifically focusing on the growth kinetics of the 
involved tissues, will be necessary. This bone formation is also interesting, since one might 
suspect that the granules within the marrow space were not completely immobile during the 
healing phase.Still bone has formed in close connection with the particles. It may furthermore 
be interesting to elucidate on the porosities of the granules which from this perspective is a 
protected environment which potentially may favor osseous growth. 
A suggested cause for orthopedic hip replacement femoral stem, implant loosening, is the 
biological reaction to wear particles from the actual implant. It has been demonstrated that 
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such wear particles induces a granulomatous reaction, with subsequent release of cytokines, 
which potentially may induce bone resorption.216-218 It has also been shown that tissues 
proximal to failed prosthetic implants, demonstrate copious macrophages and foreign-body 
giant cells as well as profuse particulate wear debris.217, 219, 220 An in vitro experimental study 
demonstrated that exposure to titanium-vanadium-aluminum particles can induce increased 
release of lactate dehydrogenase (LDH), which is a sensitive marker for tissue necrosis.221 
Small metal particles have been demonstrated within the cytoplasm of macrophages while 
larger metal particles seem to be encapsulated by connective tissue with a mild or no signs of 
an inflammatory infiltrate. The particle diameter of PTG is 700-1000 µm, whereas the 
experiments referred to above, studied particles less than one micrometer in diameter. Since 
the heat oxidized PTG (i.e., WPTG) is brittle, the risk of fragmentation must though be kept 
in mind from the perspective of a foreign body reaction, which obviously may have fatal 
consequences when the material is used for augmentation purposes. It was thus decided to 
further elucidate on this and in study I it was decided to evaluate a range of markers 
potentially indicative of necrosis, inflammation and bone resorption. No significant difference 
in LDH activity between test and control defects was found, which supposedly would indicate 
that the PTG and WPTG particles do not induce tissue necrosis. To further study this potential 
issue, smaller fragments of the PTG and WPTG particles should be employed in similar test 
systems. 
An in vitro study compared leukocyte activation on titanium surfaces with different surface 
properties such as oxide layer thickness. It was reported that after four hours of incubation in 
blood, implants with a thick oxide layer had fewer monocytes residing on the surface than 
implants with a thin oxide layer.116 Such findings shall not be put in direct comparison with 
the findings from paper I but defects treated with the heat oxidized WPTG particles showed 
significantly less total protein when compared to PTG and sham, but significantly higher 
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collagen-I mRNA levels. Based on the findings in paper I, one may hypothesize that the 
degree of oxidization may have an impact on inflammatory mechanisms, albeit one would 
then tend to expect significant differences between WPTG, PTG and the control group for the 
IL-6 and IL-10 mRNA levels. It is not realistic to conclude on these early observations but to 
further elucidate on potential anti-inflammatory mechanisms of TiO2 is of significant interest. 
Paper II suggested that implantation of experimental degree II furcation defects with PTG led 
to significantly better osseous defect resolution as compared with DBBM implanted sites. The 
comparisons between PTG and sham were though incoherent as two out of four of the 
microCT analyzes as well as the histomorphometrical comparisons did not show significant 
differences between groups. A vast number of previous animal experimental studies have 
been performed with the aim to study various methods for grafting furcation defects. 
Murakami et al.222 performed animal experimental studies in monkeys and beagle dogs to test 
the regenerative potential of basic fibroblast growth factor in a gelatinous carrier. Furcation 
defects 4 mm in height and 3 mm in width, i.e., significantly smaller than in paper II, were 
created and filled with either the test material, the carrier alone or left empty. The healing 
time was 6 weeks for dogs and 8 weeks for monkeys. Significantly better healing was seen for 
the test group as compared to the control group with respect to mean percent of the area with 
newly formed bone. For the test group, 79.6 % new bone was demonstrated in the dogs and 
71.3% new bone was demonstrated in the monkeys. It is not possible to make a direct 
comparison with the results from study II, but a mean vertical osseous formation of 62.9% on 
the mean was seen for PTG treated sites as demonstrated with histology and 84.4% with 
microCT. In an animal experimental study in monkeys, executed by Ripamonti et al.,223 
significantly better bone height regeneration was seen for defects treated with BMP-2 alone as 
compared to recombinant human osteogenic protein (OP-1) with or without BMP-2. Insoluble 
collagenous bone matrix was used as a carrier in all groups. The healing time was 60 days. A 
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mean regenerated vertical bone height of 48.3 % was seen for the BMP-2 alone group. 
Takayama et al.224 evaluated regenerative treatment of degree II furcations with recombinant 
basic fibroblast growth factor (FGF) using a primate model. The healing time was eight weeks. 
71.3% new vertical bone height was seen for the FGF treated defects. 
The 62.9% mean regenerated bone height in paper II corresponds well with historical results 
(Appendix I) but it is also important to keep in mind that PTG is a non-resorbable material. 
Albeit bone was analyzed as new bone between PTG particles it is still not completely 
comparable to a situation where the biomaterial is completely resorbed as the PTG particles 
may act as a permament growth scaffold for the bone and potentially hinder resorption. 
Moreover also the sham defects demonstrated good results with a mean new vertical bone 
height of 61.5%, which was not significantly different than the PTG treated defect. It is also 
important to point out that many of the historical controls employed smaller defects and with 
a longer healing time. Such factors may have an impact on the results and direct comparisons 
between studies should thus be avoided.  
In the human histological analysis presented in paper III it was shown that PTG integrate well 
in human alveolar bone and this study supports the principle that re-ossseointegration of a 
dental implant is feasible. To the best of my knowledge this is the first published human 
histological data showing re-osseointegration of an ailing dental implant. The histological 
findings concur with findings by Alfram et al.,128 but these authors evaluated the performance 
of PTG when used for stabilizing a titanium hip stem implant in conjunction with the primary 
surgery. From the perspective of infection of the surgical site the intraoral situation is also 
much more intricate as compared to the closed environment of a hip implant.  
In a prospective randomized clinical trial, Deppe et al.225 performed treatment of 73 peri-
implant defects in 32 patients. Four different surgical methods including airpowder abrasive 
and CO2 laser for decontamination of implants, and a combination of an alloplast bone 
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substitute, consisting of β-tricalcium phosfate mixed with autogenous bone and GTR, were 
studied. Patients were followed between five and 59 months. For the grafted sites, without 
GTR, a reduction in PD of 2.3 mm was shown. This corresponds relatively well with the 
findings in paper IV. A prospective randomized parallel arm clinical study by Khoury and 
Bouchman226 evaluated grafting of peri-implant defects with autogenous bone with or without 
GTR. 41 implants in 25 patients were included. Implants were submerged after the surgical 
therapy. A reduction in PD at the three years follow-up of 5.1 mm for the defects treated with 
the graft alone was seen. The radiographic defect height for the defect treated with the bone 
substitute alone was reduced with 2.4 mm on the mean. In a case control clinical study of 12 
months duration Roos-Jansåker et al.105 analyzed reconstructive treatment of peri-implant 
osseous defects with a coralline xenograft with or without GTR. No significant differences 
between groups were shown and a reduction in PD of 3.4 mm for the defects treated solely 
with the bone substitute i.e., without GTR was found at the 12 months evaluation. With 
respect to radiographic defect fill a gain of 1.4 mm was seen for the defects filled with the 
bone substitute alone. These implants were left non-submerged after the surgical treatment 
whereas the implants treated in paper IV were left submerged for a period of 6 months. This 
may to the least hypothetically be the reason for the difference in the PD reduction between 
the Roos-Jansåker study as compared with paper IV in the sense that the submersion may 
have lead to a coronal positioning of the flap margin. A prospective, randomized, parallel arm, 
clinical study by Schwarz et al.227 compared grafting of peri-implant defects with either 
nanocrystaline HAp or DBBM. A resorbable collagen membrane was also used in the DBBM 
group. Implants were left non-submerged after surgical intervention. A reduction in PD for 
the implants sites treated with nanocrystaline HAp of 1.5 mm was shown at the two year 
follow-up whereas the DBBM and GTR treated sites demonstrated a reduction of 2.4 mm. 
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Recently, the four year follow-up data from the same study was presented with stable PD 
reductions.228  
The demonstrated radiographic defect fill in PTG treated sites correspond relatively well with 
the findings in the studies by Khoury and Buchmann226 and Roos-Jansåker et al.105 It is 
noteworthy that both these independent investigations report that the additional utilization of 
GTR did not lead to significant additional improvement in neither clinical nor radiographic 
parameters in comparison with grafting alone. In the current study, PTG was used without 
GTR. At some occasions dislodged PTG particles were seen, especially in wider defects. A 
combination of PTG and a titanium reinforced GTR or a titanium mesh may from this 
perspective be interesting to investigate in future studies.  
With respect to fill of osseous peri-implant defects PTG may have a potential, but to evaluate 
true endpoints such as progression of bone loss, longer follow-up time is necessary. It is 
essential to follow this patient group over time to evaluate the long-term outcome of grafting 
with PTG as compared with the control group.  
In paper V the performance of PTG when used as bone substitute in the surgical treatment 
mandibular degree II furcations was analyzed. In a systematic review by Reynolds and co-
workers229 on the usage of bone replacement grafts in the treatment of periodontal osseous 
defects it was stated that with regard to degree II furcations, clinical results after the 
application of bone grafts or bone graft substitutes were superior to open flap debridement 
alone. Aimetti et al.230 analyzed a combination of enamel matrix derivative (EMD) and 
autogenous bone grafts in the treatment of mandibular degree II furcation defects. After 24 
months of follow-up the mean vertical attachment level at bone sounding was reduced with 
3.6 mm and the horizontal attachment level at bone sounding was reduced with 3.4 mm. It has 
also been reported that the combination of a bone replacement graft with GTR may be 
beneficial. A recent study by Santana and collaborators231 investigated the combination of 
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HAp mixed with tetracycline and GTR for treatment of mandibular degree II furcations. After 
12 months the mean improvement of the vertical clinical attachment level was 3.1 mm 
whereas the horizontal attachment level gain was 3.5 mm on the mean. (Appendix III) 
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General conclusion 
Both the animal experimental and human histological results suggested that PTG is 
biocompatible and can promote healing of osseous defects and re-osseointegration of dental 
implants. The clinical results were intriguing, but inconclusive. The general null hypothesis 
was only in part rejected. Further studies, combining PTG with other reconstructive therapies 
such as GTR, or potentially used as a carrier for bone growth promoting molecules, is 
encouraged. 
 
Conclusions related to specific aims 
Within the limitations of this thesis, it was demonstrated that:  
A) Both PTG and WPTG are osteoconductive graft materials suitable for regenerative 
treatment of osseous defects. (Paper I)  
B) PTG integrate well in newly formed bone and can also be used safely adjacent to 
titanium implants and without inducing bone resorption or inflammation. However to 
address the efficacy of PTG and WPTG when utilized as graft material in osseous 
regenerative surgery adjacent to functionally loaded titanium implants, clinical trials 
will be needed. (Paper1) 
C) Based on the findings in paper II it is suggested that PTG may integrate well in 
alveolar bone and supports osseous re-growth in degree II furcation defects. PTG led 
to significantly better defect resolution than treatment with DBBM or sham. The 
comparisons between PTG and sham were, however, inconsistent as two of the four 
microCT analyses, as well as the histomorphometrical comparisons, did not 
demonstrate significant differences. (Paper II) 
D) The findings presented in paper II support that PTG is safe to use in close proximity to 
root surfaces. Some signs of regenerated PDL were demonstrated. Regarding presence 
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of root resorption lacunae no significant difference between groups were found. 
(Paper II) 
E) The human histological analysis presented in paper III suggests that PTG integrate 
well and promote re-osseointegration of dental implants placed in human jaw bone. 
(Paper III) 
F) The findings presented in paper IV show that reconstruction with PTG lead to 
significantly better radiographic peri-implant defect fill compared with controls. These 
results do not necessarily imply re-osseointegration or osseointegrated PTG particles. 
Improvements in clinical parameters were observed in both the case and control group, 
however no significant differences between the groups were demonstrated. (Paper IV) 
G) It is suggested that PTG is safe to use in close proximity to root surfaces of mandibular 
molar furcations but no significant improvements in clinical endpoints of defect 
resolution were observed in this case series. (Paper V) 
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Future perspectives  
The ultimate outcome of osseous reconstructive therapy is complete regeneration of bone and 
the gold standard is the utilization of autogenous bone grafts. Degradation of the graft 
material and substitution with new bone is considered to be the optimal outcome after a 
grafting procedure, but the importance of this is not completely clear. It may well be that a 
bone substitute, that do not resorb, is favorable for some indications, since osseous healing 
and maturation is a biological process extensive in time.  
As more implants are used to replace missing teeth an escalating number of individuals will 
potentially be affected by peri-implantitis. Avoiding progression of bone loss is an important 
goal for peri-implantitis treatment but reconstruction of lost peri-implant bone is of significant 
interest in the aesthetic zone and in other areas where osseous resective surgical techniques 
are judged inappropriate (Fig. 16) from a technical perspective, such as proximity to 
neighboring teeth or implants. By this it is indisputable that new surgical strategies for 
treating peri-implant osseous defects are important to develop. Even if it has been suggested 
that the problem with peri-implant osseous defects can be surgically resolved with an apically 
positioned flap type surgery, the main predicament with such an approach is again a peri-
implant osseous defect approximating a neighboring tooth. To make it possible to apically 
position the flap, it will in such cases be necessary to remove alveolar bone and attachment on 
the tooth (Fig. 16). The dilemma with such an approach is obvious. Again with respect to 
implants in the esthetic zone with peri-implant defects, it may be difficult to motivate the 
patient to denude the implant body to gain access for oral hygiene measures. 
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Figure 16. Clinical pictures and radiograph of implant regio 11 (FDA) with a peri-implant osseous defect. 
Note the close proximity of the osseous defect walls to the neighboring teeth excluding the possibility of 
treatment with an apically positioned flap with osseous resection. Removal of the implant would create a 
major osseous defect making esthetic reconstruction challenging. The value of further evolving within the 
field of regenerative therapy is obvious 
While more and more researchers present data on the prevalence of peri-implantitis, dental 
implant scientists has in recent years, changed from being purely focused on developing the 
implants per se, towards instead finding methods to preserve ailing implants. The importance 
of this, both from the perspective of the affected patients, as well as for the therapists is 
obvious. One must though not forget that much of the complications with resulting extensive 
and costly treatments, potentially might have been avoided, if the teeth had been saved in the 
first place. From this perspective doing science on osseous reconstructive biomaterials is of 
utmost importance. 
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Errata 
On page 40 row 9-11 should be changed to: “Bucco-palatal cylindrical microCT cores 
demonstrated a median defect fill of 96.8% for PTG-implanted defects, which was 
significantly greater than sham (72.2%) and DBBM (62.0%) (P <0.001) treatments.”  
On page 52 row 10 after the word “defects” three references has fallen out:  
Roussa E. Anatomic characteristics of the furcation and root surfaces of molar teeth and their 
significance in the clinical management of marginal periodontitis. Clin Anat 1998;11:177-186  
and Novaes AB, Jr., Palioto DB, de Andrade PF, Marchesan JT. Regeneration of class II 
furcation defects: determinants of increased success. Braz Dent J 2005;16:87-97 
and reference number 199. 
Reference 62 (Hanser) is mistakenly inserted and shall be omitted and replaced by reference 
number 61 (Davies JE, 1998) 
Paper I:  Abstract: reactuion should be changed to reaction 
Paper I page 172: Column one last sentence now reads “These findings can clearly not be put 
in direct comparison with our data, but is interesting to note that the defects treated with 
WPTG demonstrate significantly less total protein when compared to PTG and WPTG” and 
should be changed to: “These findings can clearly not be put in direct comparison with our 
data, but is interesting to note that the defects treated with WPTG demonstrate significantly 
less total protein when compared to PTG and sham.” 
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m
al
ga
m
 a
nd
 z
in
k 
ox
yp
ho
sf
at
e 
ce
m
en
t s
ite
s 
 
C
af
fe
ss
e 
et
 a
l. 
19
90
 
6 
be
ag
le
 d
og
s, 
N
at
ur
al
ly
 
oc
cu
rr
in
g 
pe
rio
do
nt
iti
s. 
SR
P 
+ 
1 
m
on
th
 la
te
r i
nt
er
ve
nt
io
n 
+ 
m
em
br
an
e 
re
m
ov
al
 a
t 4
 w
ee
ks
 +
 
ha
rv
es
t a
t 3
 m
on
th
s. 
R
an
do
m
iz
at
io
n 
 
1.
Te
st
 =
 O
FD
 +
 G
TR
 
(e
PT
FE
, G
or
e 
Te
x)
   
2.
 C
on
tro
l =
 O
FD
 a
lo
ne
 
 n
 =
6 
do
g 
w
ith
 8
 te
et
h 
pe
r 
do
g 
St
at
is
tic
al
 u
ni
t =
an
im
al
 
Si
gn
ifi
ca
nt
ly
 b
et
te
r r
eg
en
er
at
io
n 
of
 c
on
ne
ct
iv
e 
tis
su
e 
at
ta
ch
m
en
t a
nd
 b
on
e 
in
 G
TR
 g
ro
up
. 
C
af
fe
ss
e 
et
 a
l. 
(1
99
3)
 
 
4 
be
ag
le
 d
og
s, 
N
at
ur
al
ly
 
oc
cu
rr
in
g 
pe
rio
do
nt
iti
s. 
SR
P 
+ 
1 
m
on
th
s l
at
er
 in
te
rv
en
tio
n 
+ 
m
em
br
an
e 
re
m
ov
al
 a
t 6
 w
ee
ks
 +
 
ha
rv
es
t a
t 5
.5
 m
on
th
s 
R
an
do
m
iz
ed
 to
: 
1.
 D
em
in
er
al
iz
ed
, f
re
ez
e-
dr
ie
d 
hu
m
an
 c
or
tic
al
 b
on
e 
gr
af
ts
 (D
FD
C
B
) +
 G
TR
 
(e
PT
FE
) 
2.
 G
TR
 (e
PT
FE
) a
lo
ne
 
4 
do
gs
 w
ith
 4
 +
 4
 te
et
h 
(m
an
di
bu
la
r P
2,
 P
2,
 P
4 
an
d 
M
1)
 A
na
ly
si
s a
t t
oo
th
 le
ve
l 
w
ith
in
 d
og
 
H
is
to
lo
gy
 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 b
on
e,
 c
em
en
tu
m
 o
r 
co
nn
ec
tiv
e 
tis
su
e 
be
tw
ee
n 
gr
ou
ps
. 
M
ea
n 
ne
w
 b
on
e 
D
FD
C
B
 +
 G
TR
: 3
5.
1%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
G
TR
 a
lo
ne
: 3
5.
2%
 (a
re
a)
. 
 
Pl
ot
zk
e 
et
 a
l. 
(1
99
3)
 
4 
be
ag
le
 d
og
s, 
Su
rg
ic
al
ly
 c
re
at
ed
 
de
fe
ct
s +
 im
m
ed
ia
te
 in
te
rv
en
tio
n 
+ 
ha
rv
es
t a
t 4
 m
on
th
s 
R
an
do
m
iz
at
io
n 
 
1.
 N
on
-r
es
or
ba
bl
e 
ca
lc
iu
m
-
la
ye
re
d 
po
ly
m
er
 o
f 
po
ly
m
et
hy
l-m
et
ha
cr
yl
at
e 
an
d 
hy
dr
ox
ye
th
yl
-
m
et
ha
cr
yl
at
e 
(H
TR
) 
2.
 S
ha
m
 
H
is
to
lo
gy
, S
ta
tis
tic
al
 u
ni
t =
 
an
im
al
 
N
 =
6 
te
et
h 
ea
ch
 d
og
, 5
 d
og
s 
=3
0 
de
fe
ct
s 
H
TR
 w
as
 w
el
l t
ol
er
at
ed
 a
nd
 a
ct
ed
 a
s a
 b
io
co
m
pa
tib
le
 
“f
ill
er
.”
 R
eg
en
er
at
io
n 
of
 b
on
e 
w
as
 si
gn
ifi
ca
nt
ly
 b
et
te
r i
n 
co
nt
ro
l d
ef
ec
ts
. 
H
TR
 3
0.
8%
 n
ew
 b
on
e 
(a
re
a)
 
C
on
tro
l 7
2.
1%
 n
ew
 b
on
e 
(a
re
a)
 
 2 
 
Le
ko
vi
c 
et
 a
l. 
19
93
 
6 
m
on
gr
el
 d
og
s. 
N
at
ur
al
ly
 
oc
cu
rr
in
g 
pe
rio
do
nt
iti
s. 
SR
P 
+ 
1 
m
on
th
 h
yg
ie
ne
 p
ha
se
+ 
in
te
rv
en
tio
n 
+ 
G
TR
 re
m
ov
ed
 a
t 
4 
m
on
th
s +
 h
ar
ve
st
 a
t 6
 m
on
th
s. 
  
R
an
do
m
iz
at
io
n 
Po
ro
us
 c
al
ci
um
 p
ho
sp
ha
te
 
gr
an
ul
es
 in
 a
ll 
te
st
 d
ef
ec
ts
+ 
1.
 G
TR
: P
ol
yc
ar
bo
na
te
 
fil
te
r (
M
ill
ip
or
e)
 
2.
 G
TR
: S
ili
co
ne
 ru
bb
er
 
3.
 G
TR
: E
xp
an
de
d 
po
ly
te
tra
flu
or
et
hy
le
ne
 
(e
PT
FE
, G
or
e-
Te
x)
 
4.
 G
TR
: P
ol
yc
ap
ro
la
ct
on
e 
5.
 S
ha
m
 
n 
 =
5 
fu
rc
at
io
ns
 in
 e
ac
h 
do
g 
  
A
ll 
te
st
 g
ro
up
s s
ig
ni
fic
an
tly
 b
et
te
r t
ha
n 
co
nt
ro
l a
nd
 n
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
4 
te
st
s.
 
N
ew
 b
on
e:
Te
st
 g
ro
up
s:
 1
.7
4-
2.
02
 m
m
, C
on
tro
l. 
0.
34
 m
m
 
A
ll 
te
st
 g
ro
up
s s
ig
ni
fic
an
tly
 b
et
te
r t
ha
n 
co
nt
ro
l a
nd
 n
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
4 
te
st
s.
 
Po
ly
ca
pr
ol
ac
to
ne
 a
nd
 P
ol
yc
ar
bo
na
te
 h
ad
 m
or
e 
in
fla
m
m
at
io
n 
th
an
 c
on
tro
l. 
N
o 
ro
ot
 re
so
rb
tio
n 
or
 a
nk
yl
os
is
. 
D
ye
r e
t a
l. 
(1
99
3)
 
8 
be
ag
le
 d
og
s, 
N
at
ur
al
ly
 
oc
cu
rr
in
g 
pe
rio
do
nt
iti
s. 
SR
P 
+ 
1 
m
on
th
s l
at
er
 in
te
rv
en
tio
n+
 
m
em
br
an
e 
re
m
ov
al
 a
t 6
 w
ee
ks
 +
 
ha
rv
es
t a
t 4
 m
on
th
s 
R
an
do
m
iz
ed
 to
: 
1.
Te
tra
cy
cl
in
e 
H
C
l+
 G
TR
 
Ex
pa
nd
ed
 
po
ly
te
tra
flu
or
et
hy
le
ne
 
(e
PT
FE
) 
2.
 C
itr
ic
 a
ci
d 
+ 
G
TR
 
(e
PT
FE
) 
3.
 G
TR
 (e
PT
FE
) a
lo
ne
 
 
H
is
to
lo
gy
 
n 
 =
12
 q
ua
dr
an
ts
, 4
8 
te
et
h 
 
R
eg
en
er
at
io
n 
of
 c
em
en
tu
m
, P
D
L 
an
d 
bo
ne
 in
 a
ll 
gr
ou
ps
. 
 N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
gr
ou
ps
 
C
af
fe
ss
e 
et
 a
l. 
(1
99
4)
 
N
in
e 
fo
x 
ho
un
d 
do
gs
 
(p
er
io
do
nt
al
ly
 h
ea
lth
y)
 
SR
P 
+ 
pl
aq
ue
 c
on
tro
l +
 a
fte
r 2
 
w
ee
ks
 S
ur
gi
ca
lly
 c
re
at
ed
 
de
fe
ct
s+
In
te
rv
en
tio
n 
+ 
H
ar
ve
st
 
at
 1
 m
on
th
s, 
3 
m
on
th
s a
nd
 6
 
m
on
th
s 
D
es
ig
na
te
d 
to
 e
PT
FE
 
(G
or
eT
ex
) v
s. 
2 
bi
oa
bs
or
ba
bl
e 
m
em
br
an
es
 
m
ad
e 
fr
om
 a
 sy
nt
he
tic
 
co
po
ly
m
er
 o
f g
ly
co
lid
e 
an
d 
la
ct
id
e 
(R
es
ol
ut
) 
n 
=9
 d
og
s w
ith
  4
 d
ef
ec
ts
 
pe
r d
og
 b
ut
 3
 ti
m
ep
oi
nt
s 
i.e
., 
12
 d
ef
ec
ts
 p
er
 ti
m
e 
po
in
t a
nd
 3
 tr
ea
tm
en
t 
gr
ou
ps
 (i
.e
., 
n 
=3
 +
 3
 +
 3
 
pe
r t
im
e 
po
in
t) 
H
is
to
lo
gy
 M
ea
n 
pe
r t
oo
th
  
w
ith
in
 a
ni
m
al
s 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 c
on
ne
ct
iv
e 
tis
su
e 
at
ta
ch
m
en
t, 
ce
m
en
tu
m
, b
on
e 
or
 e
pi
th
el
ia
l d
ow
ng
ro
w
th
 
be
tw
ee
n 
gr
ou
ps
 a
t a
ny
 ti
m
e 
po
in
t. 
6 
m
on
th
s d
at
a:
 
eP
TF
E 
m
ea
n 
%
 n
ew
 b
on
e 
he
ig
ht
: 5
9.
6 
R
es
ol
ut
 ty
pe
 1
 m
ea
n 
%
 n
ew
 b
on
e 
he
ig
ht
: 6
6.
3 
R
es
ol
ut
 ty
pe
 2
 m
ea
n 
%
 n
ew
 b
on
e 
he
ig
ht
: 7
6.
6 
R
ip
am
on
ti 
et
 
al
. (
19
94
) 
 3
 b
ab
oo
ns
- S
R
P+
 p
la
qu
e 
co
nt
ro
l 
pr
og
ra
m
 u
nt
il 
cl
in
ic
al
ly
 fr
ee
 o
f 
gi
ng
iv
iti
s-
 S
ur
gi
ca
lly
 c
re
at
ed
 
de
fe
ct
s +
 in
te
rv
en
tio
n 
+ 
5 
m
on
th
s h
ea
lin
g 
+ 
ha
rv
es
t 
D
es
ig
na
te
d 
to
 
1.
B
ov
in
e 
B
M
P 
+ 
B
M
P3
 in
 
in
so
so
lu
bl
e 
co
lla
ge
no
us
 
bo
ne
 m
at
rix
 (B
M
P-
IC
B
M
) 
2.
 IC
B
M
 a
lo
ne
 
H
is
to
lo
gy
 
n 
=6
 +
 6
 te
et
h 
Si
gn
ifi
ca
nt
ly
 b
et
te
r r
eg
en
er
at
io
n 
of
 b
on
e 
an
d 
pe
rio
do
nt
al
 
at
ta
ch
m
en
t i
n 
B
M
Ps
-I
C
B
M
 g
ro
up
 a
s c
om
pa
re
d 
to
 IC
B
M
 
al
on
e.
 A
pp
ro
xi
m
at
el
y 
51
%
 n
ew
 b
on
e 
he
ig
ht
 in
 g
ro
up
 
B
M
Ps
+ 
IC
B
M
 a
s c
om
pa
re
d 
to
 2
4%
 fo
r I
C
B
M
 a
lo
ne
. 
 
 3 
 
V
er
ni
no
 e
t a
l. 
19
95
 
R
aj
na
y 
et
 a
l. 
(1
99
7)
 
B
ut
le
r e
t 
al
.(1
99
8)
 
 
6 
ba
bo
on
s, 
Su
rg
ic
al
ly
 c
re
at
ed
 
de
fe
ct
s +
 T
w
is
te
d 
w
ire
 w
ith
 
ga
us
e 
3 
w
ee
ks
 +
 1
0 
w
ee
ks
 
un
di
st
ur
be
d 
he
al
in
g 
+ 
su
rg
ic
al
 
in
te
rv
en
tio
n-
  h
ar
ve
st
 o
ne
 a
ni
m
al
 
at
 6
 w
ee
ks
 a
nd
 5
 a
ni
m
al
s a
t 1
3 
w
ee
ks
 
R
an
do
m
iz
ed
 to
: 
1.
O
pe
n 
fla
p 
de
br
id
em
en
t 
(O
FD
) +
 G
TR
 (e
PT
FE
, 
G
or
e-
Te
x)
 (n
 =
15
) 
2.
 O
FD
+G
TR
 (p
ol
yl
ac
tic
 
ac
id
, E
pi
-G
ui
de
) (
n 
=1
4)
 
3.
O
FD
  a
lo
ne
 (n
 =
5)
 
4.
 S
ur
ge
ry
 a
lo
ne
 i.
e.
, S
R
P 
(n
 =
5)
  
  
St
at
is
tic
al
 u
ni
t: 
Fu
rc
at
io
ns
 
n 
=3
9 
C
om
m
en
t: 
Pe
rf
or
m
ed
 a
 
Pe
ar
so
ns
 c
or
re
la
tio
n 
co
ef
fic
ie
nt
 a
na
ly
si
s t
o 
ch
ec
k 
w
ith
in
 a
ni
m
al
 
re
sp
on
se
. 
(1
 a
ni
m
al
 w
ith
 o
nl
y 
te
st
 
5 
an
im
al
s w
ith
 te
st
 a
nd
 
co
nt
ro
l) 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
gr
ou
ps
. O
FD
 a
lo
ne
 
ha
d 
th
e 
m
os
t o
ve
ra
ll 
de
fe
ct
 fi
ll.
  
Po
ls
on
 e
t a
l. 
(1
99
5)
 
6 
be
ag
le
 d
og
s, 
su
rg
ic
al
ly
 c
re
at
ed
 
an
d 
na
tu
ra
lly
 o
cc
ur
rin
g 
de
fe
ct
s. 
Im
m
ed
ia
te
 in
te
rv
en
tio
n-
  
R
ee
nt
ry
 a
t 4
-5
 m
on
th
s, 
ha
rv
es
t a
t 
9-
12
 m
on
th
s  
M
ec
ha
ni
ca
l a
nd
 c
he
m
ic
al
 o
ra
l 
hy
gi
en
e 
du
rin
g 
he
al
in
g 
ph
as
e 
D
es
ig
na
te
d 
to
 
1.
G
TR
 (P
ol
ym
er
 o
f l
ac
tic
 
ac
id
 (P
LA
) d
is
so
lv
ed
 in
 N
-
m
et
hy
l-2
-p
yr
ro
lid
in
e 
(N
M
P)
, A
tri
so
rb
) 
 N
o 
co
nt
ro
l  
H
is
to
lo
gy
 
11
 su
rg
ic
al
ly
 in
du
ce
d 
de
fe
ct
s a
nd
 4
 n
at
ur
al
ly
 
oc
cu
rr
in
g 
de
fe
ct
s. 
U
nc
le
ar
 
if 
on
ly
 fu
rc
at
io
n 
de
fe
ct
s 
w
er
e 
in
cl
ud
ed
. 
R
ee
nt
ry
: 
Su
rg
ic
al
ly
 in
du
ce
d 
de
fe
ct
s:
 1
00
 %
 n
ew
 b
on
e 
in
 
fu
rc
at
io
ns
 
N
at
ur
al
ly
 o
cc
ur
rin
g 
de
fe
ct
s:
 1
00
%
 n
ew
 b
on
e 
in
 
fu
rc
at
io
ns
  
 Su
rg
ic
al
ly
 in
du
ce
d 
de
fe
ct
s:
 
72
%
 o
f  
ro
ot
 su
rf
ac
e 
ha
d 
ne
w
 c
on
ne
ct
iv
e 
tis
su
e 
at
ta
ch
m
en
t 
 N
at
ur
al
ly
 o
cc
ur
rin
g 
de
fe
ct
s:
 7
7%
 o
f  
ro
ot
 su
rf
ac
e 
ha
d 
ne
w
 c
on
ne
ct
iv
e 
tis
su
e 
at
ta
ch
m
en
t 
R
ip
am
on
ti 
et
 
al
. (
19
96
) 
3 
ba
bo
on
s M
od
el
 a
cc
or
di
ng
 to
 
R
ip
am
on
ti 
et
 a
l. 
19
94
 
bu
t o
nl
y 
60
 d
ay
s o
f h
ea
lin
g 
D
es
ig
na
te
d 
to
 
1.
R
ec
om
bi
na
na
t h
um
an
 
os
te
og
en
ic
 p
ro
te
in
-1
,1
00
 
μg
 (h
O
P-
1)
 in
 b
ov
in
e 
in
so
so
lu
bl
e 
co
lla
ge
no
us
 
bo
ne
 m
at
rix
 (b
IC
B
M
)  
(n
 =
4)
 
2.
 R
ec
om
bi
na
na
t h
um
an
 
os
te
og
en
ic
 p
ro
te
in
-1
, 5
00
 
μg
 1
00
 (h
O
P-
1)
 in
 b
IC
B
M
  
(n
 =
6)
 
3.
 b
IC
B
M
 a
lo
ne
 (n
 =
2)
 
St
at
is
tic
al
 u
ni
t: 
D
ef
ec
ts
   
n 
=1
2 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
tw
o 
di
ffe
re
nt
 
co
nc
en
tra
tio
ns
 o
f  
hO
P-
1 
bu
t b
ot
h 
hO
P-
1 
gr
ou
ps
 
si
gn
ifi
ca
nt
ly
 b
et
te
r t
ha
n 
co
nt
ro
l (
bI
C
B
M
-a
lo
ne
) 
.   
 4 
 
G
ia
nn
ob
ile
 e
t 
al
. (
19
96
)  
10
 C
yn
om
ol
gu
s m
on
ke
ys
, 
Li
ga
tu
re
 (3
.0
 si
lk
) i
nd
uc
ed
 
pe
rio
do
nt
iti
s-
W
he
n 
es
ta
bl
is
he
d 
le
si
on
s a
fte
r 1
2 
– 
16
 w
ee
ks
: 
SR
P-
 o
ra
l h
yg
ie
ne
 3
 w
ee
ks
- 
Su
rg
er
y 
1(
3 
m
on
th
s s
pe
ci
m
en
) –
 
at
 2
 m
on
th
s s
ur
ge
ry
 2
 (1
 m
on
th
s 
sp
ec
im
en
)-
 h
ar
ve
st
 3
 m
on
st
ha
 
af
te
r s
ur
ge
ry
 1
 
R
an
do
m
iz
ed
 to
: 
1.
In
su
lin
 li
ke
 g
ro
w
th
 
fa
ct
or
-1
 (I
G
F-
1)
, 1
0 
μg
 
2.
 P
la
te
le
t d
er
iv
ed
 g
ro
w
th
 
fa
ct
or
 (P
D
G
F)
, 1
0 
μg
 
3.
 P
D
G
F/
 IG
F 
4.
 C
on
tro
l: 
m
et
hy
l-
ce
llu
lo
se
 v
eh
ic
le
 a
lo
ne
 
St
at
is
tic
al
 u
ni
t: 
qu
ad
ra
nt
s 
n:
 O
ne
 a
ni
m
al
 e
xc
lu
de
d,
 2
 
qu
ad
ra
nt
s e
ac
h 
an
im
al
 
de
si
gn
at
ed
 a
s c
on
tro
l  
27
 q
ua
dr
an
ts
 te
st
 i.
e.
, 9
 
qu
ad
ra
nt
s e
ac
h 
gr
ou
p.
 
 
IG
F-
1 
vs
 c
on
tro
l: 
no
 d
iff
er
en
ce
 
PD
G
F 
si
gn
ifi
ca
nt
ly
 b
et
te
r t
ha
n 
co
nt
ro
l 
PD
G
F+
 IG
F-
1 
si
gn
ifi
ca
nt
ly
 b
et
te
r t
ha
t P
D
G
F 
al
on
e 
D
en
es
h-
M
ey
er
 
et
 a
l  
(1
99
7)
 
11
 sh
ee
p,
 S
ur
gi
ca
lly
 c
re
at
ed
 
de
fe
ct
s +
 im
m
ed
ia
te
 
in
te
rv
en
tio
n+
 h
ar
ve
st
 a
t 7
 w
ee
ks
 
D
es
ig
na
te
d 
to
 
1.
G
TR
 G
or
eT
ex
 
pe
rio
do
nt
al
 m
at
er
ia
l  
 
2.
G
TR
 S
of
t T
is
su
e 
pa
ck
  
3.
Sh
am
 
H
is
to
lo
gy
 
Si
gn
ifi
ca
nt
ly
 b
et
te
r r
eg
en
er
at
io
n 
of
 b
on
e,
 c
em
en
tu
m
 a
nd
 
co
nn
ec
tiv
e 
tis
su
e 
at
ta
ch
m
en
t i
n 
G
TR
 g
ro
up
s 
N
o 
di
ffe
re
nc
e 
be
tw
ee
n 
G
TR
 g
ro
up
s 
H
ur
ze
le
r e
t a
l 
19
97
 
O
rth
od
on
tic
 e
la
st
ic
s i
nd
uc
ed
 
de
fe
ct
s (
C
at
on
 &
 Z
an
de
r 1
97
5)
- 
5 
m
on
th
s-
St
ai
nl
es
s s
te
el
 w
ire
 
ex
te
nd
in
g 
in
to
 th
e 
bu
cc
al
 
fu
rc
at
io
ns
+ 
pl
aq
ue
 a
cc
um
ul
at
io
n 
fo
r 3
 m
on
th
s-
 w
ire
s p
us
he
d 
fu
rth
er
 in
to
 fu
rc
at
io
ns
 e
ve
ry
 
ot
he
r d
ay
-th
er
ea
fte
r S
R
P 
+ 
pl
aq
ue
 c
on
tro
l r
eg
im
en
 fo
r 3
 
w
ee
ks
-th
en
 su
rg
ic
al
 
in
te
rv
en
tio
n-
 5
 m
on
th
s h
ea
lin
g 
tim
e-
ha
rv
es
t 
 
D
es
ig
na
te
d 
to
: 
1.
G
TR
 B
io
re
so
rb
ab
le
 
co
po
ly
m
er
 o
f g
ly
co
lid
e 
an
d 
la
ct
id
e,
 M
ill
ip
or
e)
 2
.S
ha
m
 
H
is
to
lo
gy
 
Si
gn
ifi
ca
nt
ly
 b
et
te
r r
eg
en
er
at
io
n 
of
 b
on
e,
 c
em
en
tu
m
 a
nd
 
co
nn
ec
tiv
e 
tis
su
e 
at
ta
ch
m
en
t i
n 
G
TR
 g
ro
up
s 
 
B
og
le
 e
t a
l. 
(1
99
7)
 
6 
be
ag
le
 d
og
s, 
N
at
ur
al
ly
 
oc
cu
rr
in
g 
pe
rio
do
nt
iti
s, 
Sp
lit
 
m
ou
th
, I
nt
er
ve
nt
io
n 
+ 
or
al
 
hy
gi
en
e 
+ 
ha
rv
es
t a
t 6
 m
on
th
s. 
   
   
D
es
ig
na
te
d 
to
: 
1.
 T
es
t: 
A
tri
so
rb
 (n
 =
8)
 
2.
 C
on
tro
l: 
Sh
am
 (n
 =
8)
 
 
St
at
is
tic
al
 u
ni
t: 
an
im
al
s n
 
=6
 
Si
gn
ifi
ca
nt
ly
 m
or
e 
bo
ne
 a
nd
 c
em
en
tu
m
 b
ut
 n
ot
 
co
nn
ec
tiv
e 
tis
su
e 
at
ta
ch
m
en
t i
n 
te
st
 si
te
s 
 5 
 
C
ire
lli
 e
t a
l. 
(1
99
7)
 
4 
m
on
gr
el
 d
og
s, 
Su
rg
ic
al
ly
 
cr
ea
te
d 
de
fe
ct
s +
 8
 w
ee
ks
 d
ay
s 
of
 h
ea
lin
g 
w
ith
 g
ut
ta
 p
er
ka
 in
 
de
fe
ct
s +
 in
te
rv
en
tio
n 
+ 
ha
rv
es
t 
at
 3
 m
on
th
s 
R
an
do
m
iz
ed
 to
: 
1.
 T
es
t: 
O
FD
+ 
G
TR
 
B
ov
in
e 
co
lla
ge
n 
 (n
 =
 8
) 
2.
 C
on
tro
l: 
O
FD
 (n
 =
 8
) 
 
St
at
is
tic
al
 u
ni
t =
te
et
h 
n 
 =
14
 te
et
h 
(2
 e
xc
lu
de
d)
 
C
on
tro
l =
6,
 T
es
t =
8 
Si
gn
ifi
ca
nt
ly
 le
ss
 e
pi
th
el
ia
l d
ow
n 
gr
ot
h 
an
d 
m
or
e 
ce
m
en
tu
m
 in
 G
TR
 g
ro
up
 b
ut
 n
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 
os
se
ou
s r
eg
en
er
at
io
n 
Le
ko
vi
c 
et
 a
l. 
(1
99
8)
 
7 
m
on
gr
el
 d
og
s. 
N
at
ur
al
ly
 
oc
cu
rr
in
g 
pe
rio
do
nt
iti
s. 
1 
m
on
th
 
hy
gi
en
e 
ph
as
e+
 in
te
rv
en
tio
n+
 
ha
rv
es
t a
t 6
 m
on
th
s. 
  
R
an
do
m
iz
ed
 to
: 
1.
 G
TR
: P
ol
yc
ar
bo
na
te
 
fil
te
r (
M
ill
ip
or
e)
 
2.
 G
TR
: S
ili
co
ne
 ru
bb
er
 
3.
 G
TR
: E
xp
an
de
d 
po
ly
te
tra
flu
or
et
hy
le
ne
 
(e
PT
FE
 , 
G
or
e-
Te
x)
 
4.
 G
TR
: P
ol
yc
ap
ro
la
ct
on
e 
5.
 S
ha
m
 
St
at
is
tic
al
 u
ni
t =
te
et
h 
n 
=5
 te
et
h 
in
 e
ac
h 
do
g,
 7
 
do
gs
 n
 =
35
 i.
e.
, n
 =
7 
+ 
7 
+ 
 
7 
+ 
7 
+ 
7 
 
 
1)
 S
ig
ni
fic
an
tly
 m
or
e 
ce
m
en
tu
m
 a
nd
 o
ss
eo
us
 
re
ge
ne
ra
tio
n 
in
 a
ll 
te
st
 g
ro
up
s a
s c
om
pa
re
d 
w
ith
 sh
am
.  
2)
 S
ig
ni
fic
an
tly
 m
or
e 
in
fla
m
m
at
io
n 
in
 P
ol
yc
ar
bo
na
te
 
fil
te
r a
nd
 p
ol
yc
ap
ro
la
ct
on
e 
gr
ou
ps
. 
M
oh
am
m
ed
 e
t 
al
. (
19
98
) 
24
 S
he
ep
 S
ur
gi
ca
lly
 c
re
at
ed
 
de
fe
ct
s b
ut
 w
ith
 2
 w
ee
ks
 o
f 
lig
at
ur
e 
pr
io
r t
o 
in
te
rv
en
tio
n-
 
in
te
rv
en
tio
n-
 H
ar
ve
st
 a
fte
r 2
 o
r 6
 
w
ee
ks
 
R
an
do
m
iz
ed
 to
: 
1.
O
FD
+ 
ca
rr
ie
r e
l (
25
%
 
pl
ur
on
ic
 F
12
7)
 o
nl
y 
 
2.
 O
FD
+T
G
F-
β 
in
 c
ar
rie
r 
ge
l+
 G
TR
 (e
PT
FE
, 
G
or
eT
ex
) 
3.
 O
FD
+ 
TG
F-
β 
in
 c
ar
rie
r 
ge
l  
al
on
e 
24
 sh
ee
p 
48
 d
ef
ec
ts
 
St
at
is
tic
al
 u
ni
t =
te
et
h 
24
 te
et
h 
ea
ch
 ti
m
e 
po
in
t 
 
Si
gn
ifi
ca
nt
ly
 m
or
e 
bo
ne
 in
 T
G
F-
β 
si
te
s a
nd
 T
G
F-
β+
 
G
TR
 si
te
s v
s c
on
tro
l a
nd
 si
gn
ifi
ca
nt
ly
 m
or
e 
bo
ne
 in
 
G
TR
+ 
TG
F-
β 
vs
 T
G
F-
β 
al
on
e.
  
N
o 
di
ffe
re
nc
es
 in
 c
em
en
tu
m
 fo
rm
at
io
n.
 
M
ur
ak
am
i e
t 
al
. (
19
99
) 
6 
B
ea
gl
e 
do
gs
 a
nd
 4
 M
ac
ac
a 
fa
sc
ic
ul
ar
is
 m
on
ke
ys
 S
ur
gi
ca
lly
 
cr
ea
te
d 
de
fe
ct
s +
 o
ne
 m
on
th
 
w
ith
 im
pr
es
si
on
 m
at
er
ia
l i
n 
de
fe
ct
s t
he
re
af
te
r s
ur
gi
ca
l 
in
te
rv
en
tio
ns
 
D
og
s s
ac
rif
ic
ed
 a
t 6
 w
ee
ks
 a
nd
 
m
on
ke
ys
 a
fte
r 8
 w
ee
ks
 
       
D
es
ig
na
te
d 
to
: 
1.
O
FD
 +
 g
el
at
in
ou
s c
ar
rie
r 
al
on
e 
2.
 O
FD
 +
 g
el
at
in
ou
s c
ar
rie
r 
w
ith
 re
co
m
bi
na
nt
 b
as
ic
 
fib
ro
bl
as
t g
ro
w
th
 fa
ct
or
 
(b
FG
F)
 
H
is
to
lo
gy
 
St
at
is
tic
al
 u
ni
t: 
te
et
h 
B
ea
gl
e 
do
gs
: 4
 c
on
tro
ls
 a
nd
 
7 
te
st
 
M
on
ke
ys
: 1
0 
co
nt
ro
ls
 a
nd
 6
 
te
st
 
bF
G
F 
w
as
 w
el
l t
ol
er
at
ed
 a
nd
 a
ct
ed
 a
s a
 b
io
co
m
pa
tib
le
 
“f
ill
er
”.
 R
eg
en
er
at
io
n 
of
 b
on
e 
w
as
 si
gn
ifi
ca
nt
ly
 b
et
te
r i
n 
co
nt
ro
l d
ef
ec
ts
. 
Te
st
: D
og
s:
 7
9.
6 
%
 n
ew
 b
on
e 
M
on
ke
ys
: 7
1.
3%
 
(a
re
a)
 
 
 6 
 
R
ip
am
on
ti 
et
 
al
., 
(2
00
1)
 
3 
ba
bo
on
s, 
M
od
el
 a
cc
or
di
ng
 to
 
R
ip
am
on
ti 
et
 a
l. 
19
94
 
bu
t o
nl
y 
60
 d
ay
s o
f h
ea
lin
g 
D
es
ig
na
te
d 
to
: 
1.
R
ec
om
bi
na
na
t h
um
an
 
os
te
og
en
ic
 p
ro
te
in
-1
,1
00
 
μg
  (
O
P-
1)
 in
 in
so
lu
bl
e 
co
lla
ge
no
us
 b
on
e 
m
at
rix
 
(I
C
B
M
) (
n 
= 
2)
 
2.
 O
P-
1 
10
0 
μg
  i
n 
IC
B
M
 +
 
B
M
P-
2 
10
0 
μg
  n
 =
 6
 
3.
 IC
B
M
+B
M
P-
2 
10
0 
μg
  
n=
4 
 
n 
=4
 d
ef
ec
ts
 p
er
 a
ni
m
al
 3
 
an
im
al
s 1
2 
de
fe
ct
s 
B
M
P-
2 
al
on
e 
si
gn
ifi
ca
nt
ly
 b
et
te
r b
on
e 
re
ge
ne
ra
tio
n 
th
an
 
O
P-
1/
B
M
P-
2 
co
m
bi
ne
d 
an
d 
O
P-
1 
al
on
e.
 
B
M
P-
2:
 4
8.
3%
 n
ew
 b
on
e 
(m
ea
n 
he
ig
ht
) 
O
P-
1:
 3
8.
6%
 n
ew
 b
on
e 
(m
ea
n 
he
ig
ht
). 
O
P-
1/
B
M
P-
2:
 4
0.
5%
 n
ew
 b
on
e 
(m
ea
n 
he
ig
ht
). 
 
Ta
ka
ya
m
a 
et
 
al
. (
20
01
) 
4 
M
ac
ac
a 
fa
sc
ic
ul
ar
is
 m
on
ke
ys
, 
Su
rg
ic
al
ly
 c
re
at
ed
 d
ef
ec
ts
 +
 o
ne
 
m
on
th
 w
ith
 im
pr
es
si
on
 m
at
er
ia
l 
in
 d
ef
ec
ts
 th
er
ea
fte
r s
ur
gi
ca
l 
in
te
rv
en
tio
ns
 
M
on
ke
ys
 sa
cr
ifi
ce
d 
af
te
r 8
 
w
ee
ks
 
D
es
ig
na
te
d 
to
: 
1.
O
FD
 +
 g
el
at
in
ou
s c
ar
rie
r 
al
on
e 
(n
 =
10
) 
2.
 O
FD
 +
 g
el
at
in
ou
s c
ar
rie
r 
w
ith
 re
co
m
bi
na
nt
 
0.
1%
ba
si
c 
fib
ro
bl
as
t 
gr
ow
th
 fa
ct
or
 (F
G
F-
2)
 (n
 =
 
8)
 
3.
 O
FD
+ 
ge
la
tin
ou
s c
ar
rie
r 
w
ith
 re
co
m
bi
na
nt
 0
.4
 %
 
FG
F 
-2
 (n
 =
6)
 
4.
 N
o 
tre
at
m
en
t (
n 
=8
) 
St
at
is
tic
al
 u
ni
t: 
te
et
h 
n 
=8
 te
et
h 
ea
ch
 m
on
ke
y 
i.e
., 
32
 te
et
h 
 
Si
gn
ifi
ca
nt
ly
 m
or
e 
ne
w
 b
on
e 
an
d 
ce
m
en
tu
m
 in
 F
G
F-
2 
0.
4 
%
 v
s. 
co
nt
ro
l. 
Si
gn
ifi
ca
nt
ly
 m
or
e 
ne
w
 c
em
en
tu
m
 b
ut
 n
ot
 b
on
e 
in
 F
G
F-
2 
0.
1 
%
 v
s. 
co
nt
ro
l. 
 FG
F-
2 
0.
4%
: 7
1.
3%
 n
ew
 b
on
e 
FG
F-
2 
0.
1 
%
: 5
8.
0%
 n
ew
 b
on
e 
 
D
og
an
 e
t a
l. 
20
02
. 
O
ne
 d
og
, S
ur
gi
ca
lly
 c
re
at
ed
 
fu
rc
at
io
ns
 c
el
l s
ee
de
d 
w
ith
 
bi
op
sy
 b
on
e 
ha
rv
es
te
d 
fr
om
 tw
o 
eP
TF
E 
tre
at
ed
 su
rg
ic
al
ly
 c
re
at
ed
 
fu
rc
at
io
n 
in
 th
e 
sa
m
e 
do
g.
 
H
ar
ve
st
 a
t 4
2 
da
ys
 
1.
 C
el
l s
ee
de
d 
fu
rc
at
io
ns
 
2.
 C
on
tro
ls
 le
ft 
un
tre
at
ed
 
(s
ha
m
) 
n 
=4
 m
an
di
bu
la
r f
ur
ca
tio
ns
 
(2
 te
st
  a
nd
 2
 c
on
tro
l) 
N
o 
st
at
is
tic
al
 a
na
ly
si
s 
pe
rf
or
m
ed
 
M
or
e 
ne
w
 b
on
e,
 c
em
en
tu
m
 a
nd
 c
on
ne
ct
iv
e 
tis
su
e 
at
ta
ch
m
en
t i
n 
ce
ll 
se
ed
in
g 
gr
ou
p.
 
M
ea
n 
ne
w
 b
on
e 
in
 c
el
l s
ee
di
ng
 g
ro
up
: 5
1.
2%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
in
 c
on
tro
l: 
32
.9
%
 (a
re
a)
. 
C
et
in
er
 e
t a
l.,
 
20
04
 
4 
m
on
gr
el
 d
og
s. 
Su
rg
ic
al
ly
 
cr
ea
te
d 
de
fe
ct
s +
 im
m
ed
ia
te
 
in
te
rv
en
tio
n 
+ 
ha
rv
es
t a
t 7
 
m
on
th
s 
R
an
do
m
ly
 a
ss
ig
ne
d 
to
: 
1.
 G
TR
 P
LA
: L
iq
ui
d 
po
ly
m
er
 m
em
br
an
es
 (L
PM
, 
A
tri
so
rb
®
) 
2.
 G
TR
 P
LA
: R
es
or
ba
bl
e 
pe
rio
do
nt
al
 m
es
h 
(R
PM
, 
R
es
ol
ut
®
) 
 
n 
=1
0+
10
 d
ef
ec
ts
 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 n
ew
 a
tta
ch
m
en
t a
nd
 n
ew
 
bo
ne
 b
et
w
ee
n 
gr
ou
ps
. 
 
 7 
 
R
eg
az
zi
ni
 e
t 
al
. 2
00
4 
4 
m
on
gr
el
 d
og
s. 
H
yg
ie
ne
 p
ha
se
 
2 
w
ee
ks
 p
rio
r t
o 
ex
pe
rim
en
t- 
Su
rg
ic
al
ly
 c
re
at
ed
 d
ef
ec
ts
 +
 
gu
tta
 p
er
ch
a 
fo
r 3
 w
ee
ks
- 
in
te
rv
en
tio
n 
+ 
G
TR
 re
m
ov
ed
 a
t 
4 
w
ee
ks
 +
 h
ar
ve
st
 a
t 8
 w
ee
ks
 
1.
 O
FD
 +
 E
D
TA
 g
el
 
2.
 O
FD
 +
 E
D
TA
 g
el
 +
 
EM
D
 
O
FD
+ 
ED
TA
 g
el
 +
 E
M
D
+ 
G
TR
 (G
or
eT
ex
) 
n 
 =
7 
(c
on
tro
l) 
+ 
8 
+ 
8.
  
Si
gn
ifi
ca
nt
ly
 m
or
e 
bo
ne
 in
 E
M
D
 a
lo
ne
 g
ro
up
 a
s 
co
m
pa
re
d 
w
ith
 th
e 
EM
D
 +
 G
TR
 a
nd
 sh
am
. 
M
ea
n 
ne
w
 b
on
e 
in
 sh
am
: 2
1.
7%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
EM
D
: 2
8.
5%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
EM
D
+ 
G
TR
: 6
7.
4%
 (a
re
a)
 
N
o 
di
ffe
re
nc
e 
in
 c
em
en
tu
m
 fo
rm
at
io
n 
be
tw
ee
n 
gr
ou
ps
. 
  
N
ag
ai
 e
t a
l. 
(2
00
5)
 
8 
be
ag
le
 d
og
s, 
Su
rg
ic
al
ly
 c
re
at
ed
 
de
fe
ct
s +
 4
 w
ee
ks
 w
ith
 
im
pr
es
si
on
 m
at
er
ia
l i
n 
de
fe
ct
s 
th
er
ea
fte
r r
em
ov
al
 o
f s
po
ng
e 
+ 
or
al
 h
yg
ie
ne
 fo
r 2
 w
ee
ks
 th
en
 
su
rg
ic
al
 in
te
rv
en
tio
ns
 
D
og
s s
ac
rif
ic
ed
 a
fte
r 4
 o
r 1
2 
w
ee
ks
 
1.
 P
la
te
le
t-d
er
iv
ed
 fa
ct
or
 
re
le
as
at
e 
(P
R
) o
n 
co
lla
ge
n 
sp
on
ge
 
2.
 C
ol
la
ge
n 
sp
on
ge
 a
lo
ne
 
3.
 C
on
tro
l (
lin
gu
al
 a
sp
ec
t 
of
 e
ac
h 
de
fe
ct
) 
n 
 =
3 
+ 
3 
m
an
di
bu
la
r 
de
fe
ct
s e
ac
h 
do
g,
 8
 d
og
s, 
48
 d
ef
ec
ts
 
Si
gn
ifi
ca
nt
ly
 m
or
e 
ce
m
en
tu
m
 a
nd
 b
on
e 
in
 P
R
 d
ef
ec
ts
 v
s. 
co
nt
ro
l o
r c
ol
la
ge
n 
sp
on
ge
 a
lo
ne
. M
or
e 
ne
w
 b
on
e 
in
 b
ot
h 
sp
on
ge
 a
lo
ne
 a
nd
 P
R
 si
te
s t
ha
n 
co
nt
ro
l. 
M
ea
n 
ne
w
 b
on
e 
in
 P
R
: 3
8.
6%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
co
lla
ge
n 
sp
on
ge
: 2
7.
4%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
co
nt
ro
l 3
.7
%
 (a
re
a)
 
  
M
ira
nd
a 
et
 a
l. 
(2
00
6)
 
3 
be
ag
le
 d
og
s, 
su
rg
ic
al
ly
 c
re
at
ed
 
de
fe
ct
+ 
im
pr
es
si
on
 m
at
er
ia
l i
n 
de
fe
ct
s f
or
 2
1 
da
ys
+ 
21
 d
ay
s 
he
al
in
g 
+ 
ex
pe
rim
en
ta
l s
ur
ge
ry
-
G
TR
 re
m
ov
ed
 a
t d
ay
 3
0-
 h
ar
ve
st
 
at
 4
 m
on
th
s 
1.
G
TR
 o
f m
od
ifi
ed
 g
la
s 
io
no
m
er
 c
em
en
t (
G
IC
) 
2.
G
TR
 P
ol
yl
ac
tic
 a
ci
d 
(G
U
I)
 
3.
C
on
tro
l 
n 
=9
 (3
 +
 3
 +
 3
) t
ee
th
 
N
o 
st
at
is
tic
al
 a
na
ly
si
s 
pe
rf
or
m
ed
 (t
oo
 sm
al
l n
) 
M
ed
ia
n 
ne
w
 b
on
e 
in
 G
IC
: 2
0.
6%
 (a
re
a)
. 
M
ed
ia
n 
ne
w
 b
on
e 
G
U
I: 
54
.3
%
 (a
re
a)
. 
M
ed
ia
n 
ne
w
 b
on
e 
co
nt
ro
l: 
24
.6
%
 (a
re
a)
 
A
N
! M
ed
ia
n 
va
lu
es
 
 
M
ac
ed
o 
et
 a
l. 
(2
00
6)
 
6 
m
on
gr
el
 d
og
s. 
su
rg
ic
al
ly
 
cr
ea
te
d 
de
fe
ct
s+
 im
pr
es
si
on
 
m
at
er
ia
l i
n 
de
fe
ct
s f
or
 2
1 
da
ys
 
th
er
ea
fte
r S
R
P 
+ 
2 
w
ee
ks
 o
f 
he
al
in
+ 
Ex
pe
rim
en
ta
l s
ur
ge
ry
+ 
ha
rv
es
t a
t 1
2 
w
ee
ks
. 
R
an
do
m
iz
ed
 to
: 
1.
 G
TR
 e
PT
FE
 (G
or
eT
ex
) 
w
ith
 m
em
br
an
e 
re
m
ov
al
 a
t  
2 
w
ee
ks
. 
2.
 G
TR
 e
PT
FE
 (G
or
eT
ex
) 
w
ith
 m
em
br
an
e 
re
m
ov
al
 a
t  
4 
w
ee
ks
 
2 
+ 
2 
te
et
h 
ea
ch
 d
og
 
A
na
ly
si
s a
t a
ni
m
al
 le
ve
l 
n 
 =
6 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 n
ew
 b
on
e,
 n
ew
 c
em
en
tu
m
 o
r 
ne
w
 c
on
ne
ct
iv
e 
tis
su
e 
be
tw
ee
n 
gr
ou
ps
. 
M
ea
n 
ne
w
 b
on
e 
in
 2
 w
ee
ks
 G
TR
 re
m
ov
al
: 6
6.
7%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
in
 4
 w
ee
ks
 G
TR
 re
m
ov
al
: 7
0.
5%
 (a
re
a)
. 
  
D
el
ib
er
ad
or
 e
t 
al
. (
20
06
) 
6 
m
on
gr
el
 d
og
s, 
Pr
of
yl
ax
is
 o
ne
 
w
ee
k 
pr
io
r t
o 
Su
rg
ic
al
ly
 c
re
at
ed
 
de
fe
ct
s. 
Im
m
ed
ia
te
ly
 tr
ea
te
d-
ha
rv
es
t a
t 9
0 
da
ys
. 
R
an
do
m
iz
ed
 to
: 
1.
Sh
am
 (b
lo
od
 c
lo
t a
lo
ne
) 
2.
 A
ut
og
en
ou
s b
on
e 
(A
B
) 
3.
 A
B
+ 
G
TR
: C
al
ci
um
 
su
lp
ha
te
 (C
S)
 
 
6 
te
et
h/
 d
og
 
n 
 =
12
 +
 1
2 
+ 
12
 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
gr
ou
ps
, i
.e
., 
sh
am
 a
s 
go
od
 a
s a
ut
og
en
ou
s +
 G
TR
 o
r a
ut
og
en
ou
s a
lo
ne
. 
M
ea
n 
ne
w
 b
on
e 
in
 sh
am
: 6
1.
9%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
in
 a
ut
og
en
ou
s b
on
e 
al
on
e:
 6
5.
0%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
in
 a
ut
og
en
ou
s b
on
e 
+ 
G
TR
: 5
9.
9%
 
(a
re
a)
. 
  
 8 
 
C
hr
is
tg
au
 e
t a
l. 
(2
00
7)
 
21
 b
ea
gl
e 
do
gs
. N
at
ur
al
ly
 
oc
cu
rr
in
g 
pe
rio
do
nt
iti
s b
ut
 
su
rg
ic
al
ly
 st
an
da
rd
iz
ed
 d
ef
ec
ts
+ 
O
FD
 +
 im
m
ed
ia
te
ly
 tr
ea
te
d+
 
H
ar
ve
st
 a
t 2
, 4
 a
nd
 8
 w
ee
ks
 (4
 
do
gs
 e
ac
h)
  +
 3
, 6
 a
nd
 1
2 
m
on
th
s 
(3
 d
og
s e
ac
h)
 
R
an
do
m
iz
ed
 to
: 
1.
G
TR
 P
ol
yd
ia
xo
no
n 
(M
em
po
l) 
2.
 G
TR
 P
ol
yl
ac
tic
 a
ci
d 
(G
ui
do
r)
 
3.
 G
TR
 C
ol
la
ge
n 
(B
io
gi
de
) 
4.
 G
TR
 (e
PT
FE
, G
or
eT
ex
) 
5.
 N
on
 ra
nd
om
iz
ed
 c
on
tro
l 
(to
ot
h 
P3
) 
 
To
ta
l 1
26
 te
et
h,
 6
 ti
m
e 
po
in
ts
 2
, 4
, 8
 w
ee
ks
: 
4 
te
et
h 
pe
r g
ro
up
 p
er
 ti
m
e 
po
in
t a
nd
 c
on
tro
l 8
 te
et
h 
pe
r t
im
e 
po
in
t. 
3,
 6
 a
nd
 9
 m
on
th
s:
 3
 te
et
h 
pe
r g
ro
up
 p
er
 ti
m
e 
po
in
t 
an
d 
co
nt
ro
l 6
 te
et
h 
pe
r t
im
e 
po
in
t. 
  
Im
m
un
o 
hi
st
oc
he
m
ic
al
 a
nd
 h
is
to
lo
gi
ca
l s
tu
dy
 o
n 
pe
rio
do
nt
al
 w
ou
nd
 h
ea
lin
g 
dy
na
m
ic
s a
fte
r G
TR
 
tre
at
m
en
t o
f f
ur
ca
tio
ns
. 
de
A
nd
ra
de
 e
t 
al
. (
20
07
)  
6 
m
on
gr
el
 d
og
s. 
2 
w
ee
ks
 
pr
of
yl
ax
is
 fo
llo
w
ed
 b
y 
su
rg
ic
al
ly
 c
re
at
ed
 d
ef
ec
ts
+ 
im
pr
es
si
on
 m
at
er
ia
l i
n 
de
fe
ct
s 
fo
r 2
 w
ee
ks
 a
nd
  t
he
re
af
te
r S
R
P 
+ 
2 
w
ee
ks
 o
f h
ea
lin
g 
+ 
Ex
pe
rim
en
ta
l s
ur
ge
ry
 +
 h
ar
ve
st
 
at
 1
2 
w
ee
ks
. 
R
an
do
m
iz
ed
 to
: 
1.
C
on
tro
l: 
O
FD
+G
TR
 
Po
ly
gl
yc
ol
ic
 a
ci
d:
 
tri
m
et
hy
le
ne
 c
ar
bo
na
te
 
(P
G
A
:T
M
C
) 
2.
 T
es
t: 
O
FD
+G
TR
 
A
ce
llu
la
r d
er
m
al
 m
at
rix
 
(A
D
M
) 
 
2 
+ 
2 
te
et
h 
ea
ch
 d
og
, 
A
na
ly
si
s a
t a
ni
m
al
 le
ve
l 
n 
=6
 
A
D
M
 re
su
lte
d 
in
 g
re
at
er
 in
cr
ea
se
 in
 k
er
at
in
iz
ed
 g
in
gi
va
l 
ot
he
rw
is
e 
no
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
s b
et
w
ee
n 
gr
ou
ps
 
M
ea
n 
ne
w
 b
on
e 
in
 A
D
M
: 7
0.
3%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
in
 4
 w
ee
ks
 P
G
A
:T
M
C
: 5
5.
1%
 (a
re
a)
. 
 
Te
ar
e 
et
 a
l. 
(2
00
8)
 
4 
C
ha
cm
a 
ba
bo
on
s, 
he
te
ro
pt
op
ic
al
ly
 in
du
ce
d 
bo
ne
 
fo
rm
at
io
n 
in
 re
ct
us
 a
bd
om
in
us
 
m
us
cl
e 
+ 
su
rg
ic
al
ly
 c
re
at
ed
 
de
fe
ct
s -
he
al
ed
 4
0 
da
ys
-
tre
at
m
en
t- 
H
ar
ve
st
 a
t 6
0 
da
ys
 
1.
M
at
rig
el
®
 a
lo
ne
 (c
on
tro
l) 
2.
 T
G
F-
β3
+M
at
rig
el
®
 
3.
 T
G
F-
β3
+ 
M
at
rig
el
®
 
in
du
ce
d 
bo
ne
 (I
B
) 
4.
 M
at
rig
el
®
 IB
 
5.
 T
G
F-
β3
+o
st
eo
ge
ni
c 
pr
ot
ei
n-
1 
IB
+ 
IC
B
M
  
n 
 =
16
 
TG
F-
β3
 IB
 +
 M
at
rig
el
®
 IB
 si
gn
ifi
ca
nt
ly
 m
or
e 
bo
ne
 th
an
 
co
nt
ro
l. 
M
ea
n 
ne
w
 b
on
e 
TG
F-
β3
+M
at
rig
el
®
 IB
: 5
8.
9%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
M
at
rig
el
®
 IB
: 6
4.
9%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
co
nt
ro
l: 
31
.3
%
 (a
re
a)
 
  
M
or
ris
  e
t a
l. 
20
08
 
Se
ve
n 
be
ag
le
 d
og
s, 
fu
rc
at
io
ns
 
su
rg
ic
al
ly
 c
re
at
ed
+T
w
is
te
d 
w
ire
 
w
ith
 g
au
se
-1
2 
w
ee
ks
-d
ef
ec
ts
 re
-
cu
t i
f r
em
od
el
ed
 +
 tr
ea
tm
en
t +
 
In
je
ct
io
ns
 re
pe
at
ed
 w
ee
kl
y 
fo
r 3
 
w
ee
ks
 –
 h
ar
ve
st
 a
fte
r 1
2 
w
ee
ks
 
R
an
do
m
iz
ed
 to
: 
1.
O
FD
+M
et
hy
lc
el
lo
lo
se
 
ge
l (
co
nt
ro
l) 
(n
=7
) 
2.
 O
FD
+M
et
hy
lc
el
lo
lo
se
 
ge
l+
 0
.5
 m
g 
Si
m
va
st
at
in
 
(te
st
 1
, n
=3
) 
3.
 O
FD
+M
et
hy
lc
el
lo
lo
se
 
ge
l+
 2
.0
 m
g 
Si
m
va
st
at
in
 
(te
st
 2
, n
=4
) 
  
2 
te
et
h 
ea
ch
 d
og
  
N
o 
di
ffe
re
nc
e 
in
 in
fla
m
m
at
io
n.
 
G
re
at
er
 re
m
ai
ni
ng
 b
on
e 
lo
ss
 in
 0
.5
 m
g 
Si
m
va
st
at
in
 g
ro
up
 
th
an
 c
on
tro
l. 
 
N
o 
di
ffe
re
nc
e 
in
 re
m
ai
ni
ng
 b
on
e 
lo
ss
 b
et
w
ee
n 
2 
m
g 
Si
m
va
st
at
in
 a
nd
 c
on
tro
l. 
     
 9 
 
K
el
es
 e
t a
l. 
20
09
 
4 
m
on
gr
el
 d
og
s, 
or
al
 h
yg
ie
ne
 
ph
as
e-
 S
ur
gi
ca
lly
 c
re
at
ed
 d
ef
ec
ts
 
(5
m
m
 in
 h
ei
gh
t a
nd
 2
 m
m
 in
 
de
pt
h)
 +
 3
 w
ee
ks
 w
ith
 
im
pr
es
si
on
 m
at
er
ia
l i
n 
de
fe
ct
s 
th
er
ea
fte
r r
em
ov
al
 o
f s
po
ng
e 
+ 
or
al
 h
yg
ie
ne
 fo
r 2
 w
ee
ks
 th
en
 
su
rg
ic
al
 in
te
rv
en
tio
ns
- h
ar
ve
st
 a
t 
12
 w
ee
ks
 
1.
O
FD
 +
 p
la
te
le
t r
ic
h 
pl
as
m
a 
pe
lle
t (
PP
) +
 G
TR
  
A
tri
so
rb
. 
2.
 O
FD
 +
 P
P 
3.
 O
FD
 a
lo
ne
 
 
n 
 =
24
 (8
 +
 8
 +
 8
) 
M
or
e 
ce
m
en
tu
m
 in
 g
ro
up
 P
R
P 
+ 
G
TR
 a
nd
 P
R
P 
al
on
e 
vs
 
co
nt
ro
l g
ro
up
 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 n
ew
 b
on
e 
be
tw
ee
n 
gr
ou
ps
 
1a
nd
 2
 b
ut
 b
ot
h 
te
st
 g
ro
up
s w
er
e 
be
tte
r t
ha
n 
th
e 
ne
ga
tiv
e 
co
nt
ro
l. 
M
ea
n 
ne
w
 b
on
e 
in
 P
R
+ 
G
TR
:6
1.
1%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
PP
 a
lo
ne
: 6
2.
6%
 (a
re
a)
. 
M
ea
n 
ne
w
 b
on
e 
co
nt
ro
l: 
42
.4
%
 (a
re
a)
 
 
Si
m
se
k 
et
 a
l. 
(2
01
0)
 
3 
m
on
gr
el
 d
og
s +
 su
rg
ic
al
ly
 
cr
ea
te
d 
de
fe
ct
s +
 im
pr
es
si
on
 
m
at
er
ia
l f
or
 3
 w
ee
ks
 +
 S
R
P+
 
af
te
r 2
 w
ee
ks
 o
f p
la
qu
e 
co
nt
ro
l: 
su
rg
ic
al
 in
te
rv
en
tio
n 
+ 
ha
rv
es
t a
t 
8 
w
ee
ks
 
1.
 O
FD
 
2.
 O
FD
 +
 P
R
P 
3.
 O
FD
+ 
au
to
ge
no
us
 b
on
e 
(A
C
B
)  
4.
 O
FD
+ 
A
C
B
 +
 P
R
P 
5.
 O
FD
+ 
m
es
en
ch
ym
al
 
st
em
 c
el
l (
M
SC
s)
 +
 P
R
P 
C
om
pa
ris
on
s a
t d
ef
ec
t l
ev
el
 
(n
 =
6 
pe
r g
ro
up
) 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
 in
 a
lv
eo
la
r b
on
e 
fil
l b
et
w
ee
n 
gr
ou
ps
 b
ut
 si
gn
ifi
ca
nt
ly
 m
or
e 
ce
m
en
tu
m
 fo
rm
at
io
n 
in
  
gr
ou
p 
3,
 4
, 5
 a
s c
om
pa
re
d 
to
 g
ro
up
 1
. 
Su
ai
d 
et
 a
l. 
(2
01
1)
 
Su
rg
ic
al
ly
 c
re
at
ed
 d
ef
ec
ts
, s
pl
it 
m
ou
th
 im
m
ed
ia
te
ly
 tr
ea
te
d 
an
d 
ha
rv
es
t a
fte
r 3
 m
on
th
s 
C
ol
la
ge
n 
sp
on
ge
 +
/- 
se
ed
in
g 
w
ith
 a
ut
ol
og
ou
s 
PD
L 
ce
lls
 w
ith
 C
ol
la
ge
n 
G
TR
 (R
es
ol
ut
) o
ve
r a
ll 
de
fe
ct
s 
7 
do
gs
, 1
4 
de
fe
ct
s 
H
is
to
lo
gy
 
Si
gn
ifi
ca
nt
ly
 m
or
e 
ne
w
 c
em
en
tu
m
, n
ew
 b
on
e 
an
d 
ne
w
 
PD
L 
an
d 
si
gn
ifi
ca
nt
ly
 le
ss
 d
ow
n-
gr
ow
th
 o
f e
pi
th
el
iu
m
 in
 
G
TR
 +
 P
D
L 
se
ed
ed
 d
ef
ec
ts
 a
s c
om
pa
re
d 
to
 G
TR
 a
lo
ne
 
 Ap
pe
nd
ix
 I.
 A
ni
m
al
 e
xp
er
im
en
ta
l s
tu
di
es
 o
n 
re
co
ns
tru
ct
iv
e 
tre
at
m
en
t o
f d
eg
re
e 
II
 fu
rc
at
io
n 
de
fe
ct
s. 
Pu
bm
ed
 d
at
ab
as
e 
w
er
e 
se
ar
ch
ed
 w
ith
 th
e 
fo
llo
w
in
g 
te
rm
s a
nd
 k
ey
 w
or
ds
 
an
d 
lim
ite
d 
to
 a
ni
m
al
s:
 fu
rc
at
io
n 
(to
ta
l h
its
 2
50
). 
Fu
rth
er
m
or
e 
th
e 
re
fe
re
nc
e 
lis
ts
 in
 th
e 
pu
bl
ic
at
io
ns
 li
st
ed
 w
er
e 
m
an
ua
lly
 se
ar
ch
ed
 fo
r a
dd
iti
on
al
 re
fe
re
nc
es
.  
Se
ar
ch
es
 w
er
e 
lim
ite
d 
to
 a
ni
m
al
s. 
 
  R
ef
er
en
ce
s 
B
og
le
, G
., 
G
ar
re
tt,
 S
., 
St
ol
le
r, 
N
. H
., 
Sw
an
bo
m
, D
. D
., 
Fu
lfs
, J
. C
., 
R
od
ge
rs
, P
. W
., 
W
hi
tm
an
, S
., 
D
un
n,
 R
. L
., 
So
ut
ha
rd
, G
. L
. &
 P
ol
so
n,
 A
. M
. 
(1
99
7)
 P
er
io
do
nt
al
 re
ge
ne
ra
tio
n 
in
 n
at
ur
al
ly
 o
cc
ur
rin
g 
cl
as
s i
i f
ur
ca
tio
n 
de
fe
ct
s i
n 
be
ag
le
 d
og
s a
fte
r g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
w
ith
 
bi
oa
bs
or
ba
bl
e 
ba
rr
ie
rs
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
68
: 5
36
-5
44
. 
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 B
ut
le
r, 
J. 
R
., 
R
aj
na
y,
 Z
. W
., 
V
er
ni
no
, A
. R
. &
 P
ar
ke
r, 
D
. (
19
98
) V
ol
um
et
ric
 c
ha
ng
es
 fo
llo
w
in
g 
ba
rr
ie
r r
eg
en
er
at
io
n 
pr
oc
ed
ur
es
 fo
r t
he
 su
rg
ic
al
 
m
an
ag
em
en
t o
f g
ra
de
 ii
 m
ol
ar
 fu
rc
at
io
n 
de
fe
ct
s i
n 
ba
bo
on
s:
 Ii
. B
on
e,
 c
em
en
tu
m
, e
pi
th
el
iu
m
, a
nd
 c
on
ne
ct
iv
e 
tis
su
e.
 In
te
rn
at
io
na
l J
ou
rn
al
 o
f 
Pe
ri
od
on
tic
s a
nd
 R
es
to
ra
tiv
e 
D
en
tis
tr
y 
18
: 5
8-
69
. 
C
af
fe
ss
e,
 R
. G
., 
N
as
jle
ti,
 C
. E
., 
M
or
ris
on
, E
. C
. &
 S
an
ch
ez
, R
. (
19
94
) G
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n:
 C
om
pa
ris
on
 o
f b
io
ab
so
rb
ab
le
 a
nd
 n
on
-
bi
oa
bs
or
ba
bl
e 
m
em
br
an
es
. H
is
to
lo
gi
c 
an
d 
hi
st
om
et
ric
 st
ud
y 
in
 d
og
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
65
: 5
83
-5
91
. 
C
af
fe
ss
e,
 R
. G
., 
N
as
jle
ti,
 C
. E
., 
Pl
ot
zk
e,
 A
. E
., 
A
nd
er
so
n,
 G
. B
. &
 M
or
ris
on
, E
. C
. (
19
93
) G
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
an
d 
bo
ne
 g
ra
fts
 in
 th
e 
tre
at
m
en
t o
f f
ur
ca
tio
n 
de
fe
ct
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
64
: 1
14
5-
11
53
. 
C
at
on
, J
. G
. &
 Z
an
de
r, 
H
. A
. (
19
75
) P
rim
at
e 
m
od
el
 fo
r t
es
tin
g 
pe
rio
do
nt
al
 tr
ea
tm
en
t p
ro
ce
du
re
s:
 I.
 H
is
to
lo
gi
c 
in
ve
st
ig
at
io
n 
of
 lo
ca
liz
ed
 
pe
rio
do
nt
al
 p
oc
ke
ts
 p
ro
du
ce
d 
by
 o
rth
od
on
tic
 e
la
st
ic
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
46
: 7
1-
77
. 
C
hr
is
tg
au
, M
., 
C
af
fe
ss
e,
 R
. G
., 
Sc
hm
al
z,
 G
. &
 D
'S
ou
za
, R
. N
. (
20
07
) E
xt
ra
ce
llu
la
r m
at
rix
 e
xp
re
ss
io
n 
an
d 
pe
rio
do
nt
al
 w
ou
nd
-h
ea
lin
g 
dy
na
m
ic
s 
fo
llo
w
in
g 
gu
id
ed
 ti
ss
ue
 re
ge
ne
ra
tio
n 
th
er
ap
y 
in
 c
an
in
e 
fu
rc
at
io
n 
de
fe
ct
s. 
Jo
ur
na
l o
f C
lin
ic
al
 P
er
io
do
nt
ol
og
y 
34
: 6
91
-7
08
. 
C
ire
lli
, J
. A
., 
M
ar
ca
nt
on
io
, E
., 
Jr
., 
A
dr
ia
na
, R
., 
M
ar
ca
nt
on
io
, C
., 
Li
a,
 R
. C
., 
G
oi
ss
is
, G
. &
 R
os
sa
, C
., 
Jr
. (
19
97
) E
va
lu
at
io
n 
of
 a
ni
on
ic
 c
ol
la
ge
n 
m
em
br
an
es
 in
 th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
le
si
on
s:
 A
n 
hi
st
om
et
ric
 a
na
ly
si
s i
n 
do
gs
. B
io
m
at
er
ia
ls
 1
8:
 1
22
7-
12
34
. 
D
an
es
h-
M
ey
er
, M
. J
., 
Pa
ck
, A
. R
. &
 M
cM
ill
an
, M
. D
. (
19
97
) A
 c
om
pa
ris
on
 o
f 2
 p
ol
yt
et
ra
flu
or
oe
th
yl
en
e 
m
em
br
an
es
 in
 g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 sh
ee
p.
 J
ou
rn
al
 o
f P
er
io
do
nt
al
 R
es
ea
rc
h 
32
: 2
0-
30
. 
de
 A
nd
ra
de
, P
. F
., 
de
 S
ou
za
, S
. L
., 
de
 O
liv
ei
ra
 M
ac
ed
o,
 G
., 
N
ov
ae
s, 
A
. B
., 
Jr
., 
de
 M
or
ae
s G
ris
i, 
M
. F
., 
Ta
ba
, M
., 
Jr
. &
 P
al
io
to
, D
. B
. (
20
07
) 
A
ce
llu
la
r d
er
m
al
 m
at
rix
 a
s a
 m
em
br
an
e 
fo
r g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
le
si
on
s:
 A
 h
is
to
m
et
ric
 a
nd
 c
lin
ic
al
 
st
ud
y 
in
 d
og
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
78
: 1
28
8-
12
99
. 
D
el
ib
er
ad
or
, T
. M
., 
N
ag
at
a,
 M
. J
., 
Fu
rla
ne
to
, F
. A
., 
M
el
o,
 L
. G
., 
O
ka
m
ot
o,
 T
., 
Su
nd
ef
el
d,
 M
. L
. &
 F
uc
in
i, 
S.
 E
. (
20
06
) A
ut
og
en
ou
s b
on
e 
gr
af
t 
w
ith
 o
r w
ith
ou
t a
 c
al
ci
um
 su
lfa
te
 b
ar
rie
r i
n 
th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s:
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C
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. D
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ra
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 re
pa
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ra
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at
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at
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t t
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at
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at
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ra
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ra
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se
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, r
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ad
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at
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 re
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 m
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 b
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 re
en
try
: T
es
t 1:
 0
.4
 m
m
, T
es
t 2:
 -0
.4
 m
m
 T
es
t 3:
 0
.1
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N
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l b
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 m
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, C
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, C
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 b
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, C
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, c
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 b
on
e 
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 re
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t: 
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m
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H
or
iz
on
ta
l b
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 re
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, C
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: C
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X
), 
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lfa
te
 +
 D
FD
B
A
 
(C
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 re
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m
 b
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D
X
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, C
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 m
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 C
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 C
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 b
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 m
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 m
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, C
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 m
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 b
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 re
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, C
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l b
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 re
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, C
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 m
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ra
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 c
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, C
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 m
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 p
at
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 re
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 m
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 m
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 c
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 m
ou
th
, 
cl
in
ic
al
 st
ud
y,
 2
6 
pa
tie
nt
s 
w
ith
 5
2 
de
fe
ct
s, 
6 
m
on
th
s 
O
FD
 +
/- 
(B
H
A
 (B
io
O
ss
)+
 
PR
P 
+ 
G
TR
 (B
io
G
id
e)
 
PD
 c
ha
ng
e:
 T
es
t: 
(B
H
A
+P
R
P+
G
TR
): 
4.
07
 m
m
, C
on
tro
l: 
2.
49
 m
m
 (N
.S
.) 
C
A
L 
ga
in
: T
es
t: 
3.
29
 m
m
, C
on
tro
l: 
1.
68
 m
m
 (N
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 b
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, C
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l b
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, C
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 p
at
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 m
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 m
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 b
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) 
PD
 re
du
ct
io
n:
 T
es
t: 
(B
H
A
 +
 P
-1
5)
: 0
.8
 m
m
, C
on
tro
l (
O
FD
 a
lo
ne
): 
1.
6 
m
m
 (N
.S
.) 
C
A
L 
ga
in
 v
er
tic
al
: T
es
t: 
1.
7 
m
m
, C
on
tro
l: 
2.
1 
m
m
 (N
.S
.) 
C
A
L 
ga
in
 h
or
iz
on
ta
l: 
Te
st
: 2
.4
 m
m
, C
on
tro
l: 
1.
5 
m
m
 (N
.S
.) 
R
ad
io
gr
ap
hi
c 
bo
ne
 g
ai
n:
 T
es
t: 
0.
9 
m
m
, C
on
tro
l: 
0.
6 
m
m
 (N
.S
.) 
   
A
im
et
ti 
et
 a
l.(
20
07
) 
C
as
e 
se
rie
s, 
11
 p
at
ie
nt
s, 
24
 
m
on
th
s 
EM
D
 +
 a
ut
ol
og
ou
s b
on
e 
PD
 re
du
ct
io
n:
 1
.6
7 
m
m
 
C
A
L 
ga
in
 v
er
tic
al
: 2
.2
3 
m
m
 
B
on
e 
so
un
di
ng
 re
du
ct
io
n 
ho
riz
on
ta
l: 
3.
39
 
B
on
e 
so
un
di
ng
 re
du
ct
io
n 
ve
rti
ca
l: 
3.
64
 m
m
 
 
 8 
 
Ly
on
s e
t a
l. 
(2
00
8)
 
Pr
os
pe
ct
iv
e 
ra
nd
om
iz
ed
 
ca
se
-c
on
tro
l c
lin
ic
al
 st
ud
y,
 
29
 p
at
ie
nt
s, 
9 
m
on
th
s 
O
FD
 +
 D
FD
B
A
 +
 P
ol
yl
ac
tic
 
ac
id
 (P
LA
) G
TR
 +
/-
D
ox
yc
yc
lin
e 
(P
D
ox
) o
r 
D
FD
B
A
 a
lo
ne
 
PD
 re
du
ct
io
n:
 T
es
t 1 
(D
FD
B
A
 +
 P
LA
 +
 P
D
ox
): 
1.
55
 m
m
, T
es
t 2 
(D
FD
B
A
 +
 P
LA
 - 
PD
ox
): 
1.
9 
m
m
 C
on
tro
l (
D
FD
B
A
 a
lo
ne
): 
1.
27
 m
m
 (N
.S
.) 
C
A
L 
ga
in
: T
es
t 1:
 0
.2
2 
m
m
, T
es
t 2:
 1
.3
 m
m
, C
on
tro
l: 
1.
9 
m
m
 (N
.S
.) 
PD
 h
or
iz
on
ta
l r
ed
uc
tio
n:
 T
es
t 1:
 1
.2
2 
m
m
, T
es
t 2:
 1
.3
 m
m
, C
on
tro
l: 
0.
6 
m
m
  (
N
.S
.) 
V
er
tic
al
 b
on
e 
ga
in
 re
en
try
: T
es
t 1:
 1
.4
 m
m
, T
es
t 2:
 1
.1
1 
m
m
 C
on
tro
l: 
2.
0 
m
m
 (N
.S
.) 
H
or
iz
on
ta
l b
on
e 
ga
in
 re
en
try
: T
es
t 1:
 2
.3
3 
m
m
, T
es
t 2:
 2
.1
1 
m
m
, C
on
tro
l: 
m
m
 (N
.S
.) 
K
ot
hi
w
al
e 
et
 a
l. 
(2
00
9)
 
Pr
os
pe
ct
iv
e 
ra
nd
om
iz
ed
 
sp
lit
 m
ou
th
 c
lin
ic
al
 st
ud
y,
 
10
 p
at
ie
nt
s, 
9 
m
on
th
s 
O
FD
 a
nd
 (B
H
A
) B
io
-O
ss
 +
 
A
m
ni
on
ic
 (A
M
) G
TR
 o
r 
D
FD
B
A
 +
 A
m
ni
on
ic
 G
TR
 
PD
 re
du
ct
io
n:
 T
es
t (
D
FD
B
A
 +
A
M
): 
4.
7 
m
m
, C
on
tro
l (
B
H
A
 +
A
M
): 
4.
4 
m
m
 (N
.S
.) 
C
A
L 
ga
in
: T
es
t: 
4.
8 
m
m
, C
on
tro
l: 
5.
1 
m
m
 (N
.S
.) 
 R
ad
io
gr
ap
hi
c 
bo
ne
 g
ai
n:
 T
es
t: 
0.
57
 m
m
, C
on
tro
l: 
0.
77
 m
m
 (P
<0
.0
5)
 
Pr
ad
ee
p 
et
 a
l. 
(2
00
9)
  
Pr
os
pe
ct
iv
e 
ra
nd
om
iz
ed
 
sp
lit
 m
ou
th
 c
lin
ic
al
 st
ud
y,
 
20
 p
at
ie
nt
s, 
6 
m
on
th
s 
O
FD
 +
/- 
PR
P 
PD
 re
du
ct
io
n:
 T
es
t: 
(P
R
P)
: 2
.3
 m
m
, C
on
tro
l: 
0.
8 
m
m
  (
P 
<0
.0
5)
 
C
A
L 
ga
in
: T
es
t: 
2.
5 
m
m
, C
on
tro
l: 
0.
1 
m
m
  (
P 
<0
.0
1)
 
C
A
L 
ho
riz
on
ta
l g
ai
n:
 T
es
t: 
2.
5 
m
m
, C
on
tro
l: 
0.
8 
m
m
 (P
 <
0.
00
1)
 
C
T:
 
V
er
tic
al
: T
es
t: 
1.
23
 m
m
, C
on
tro
l: 
0.
64
 m
m
  (
P 
<0
.0
5)
 
H
or
iz
on
ta
l: 
Te
st
: 1
.3
3 
m
m
, C
on
tro
l: 
0.
09
 m
m
  (
P 
<0
.0
1)
 
Ta
he
ri 
et
 a
l. 
(2
00
9)
 
Pr
os
pe
ct
iv
e 
ra
nd
om
iz
ed
 
ca
se
 c
on
tro
l c
lin
ic
al
 st
ud
y,
 
14
 p
at
ie
nt
s, 
18
 fu
rc
at
io
ns
 
O
FD
 +
B
H
A
 (B
io
-O
ss
) +
/-
C
ol
la
ge
n 
G
TR
 (B
io
G
id
e)
 
PD
 re
du
ct
io
n:
 T
es
t: 
(B
H
A
+ 
G
TR
): 
2.
4 
m
m
, C
on
tro
l: 
2.
4 
m
m
  (
N
.S
.) 
C
A
L 
ga
in
: T
es
t: 
2.
1 
m
m
, C
on
tro
l: 
1.
9 
m
m
  (
N
.S
.) 
C
A
L 
ho
riz
on
ta
l: 
Te
st
: 1
.2
 m
m
, C
on
tro
l: 
1.
6 
m
m
 ( 
N
.S
.) 
V
er
tic
al
 b
on
e 
ga
in
 re
en
try
: T
es
t: 
2.
1 
m
m
, C
on
tro
l: 
1.
9 
m
m
  (
N
.S
.) 
H
or
iz
on
ta
l b
on
e 
ch
an
ge
 re
en
try
: T
es
t: 
2.
4 
m
m
, C
on
tro
l: 
2.
1 
m
m
  (
N
.S
.) 
Sa
nt
an
a 
at
 a
l. 
(2
00
9)
 
Pr
os
pe
ct
iv
e 
ca
se
 c
on
tro
l 
cl
in
ic
al
 st
ud
y,
 6
0 
pa
tie
nt
s, 
12
 m
on
th
s 
O
FD
 +
/- 
m
ic
ro
gr
an
ul
ar
 H
A
 
m
ix
ed
 w
ith
 te
tra
cy
cl
in
e 
PD
 re
du
ct
io
n:
 T
es
t: 
(H
A
+T
et
ra
cy
cl
in
e)
: 3
.6
5 
m
m
, C
on
tro
l: 
0.
60
 m
m
 (P
 <
0.
05
) 
C
A
L 
ve
rti
ca
l g
ai
n:
 T
es
t: 
3.
05
 m
m
, C
on
tro
l: 
0.
65
 m
m
  (
P 
<0
.0
5)
 
C
A
L 
ho
riz
on
ta
l g
ai
n:
 T
es
t: 
3.
45
 m
m
, C
on
tro
l: 
0.
55
 m
m
  (
P 
<0
.0
5)
 
Pr
ad
ee
p 
et
 a
l. 
(2
01
1)
 
Pr
os
pe
ct
iv
e 
ra
nd
om
iz
ed
 
sp
lit
 m
ou
th
 c
lin
ic
al
 st
ud
y,
 
18
 p
at
ie
nt
s, 
9 
m
on
th
s 
O
FD
 +
/- 
PR
F 
cl
ot
 a
nd
 P
R
F 
m
em
br
an
e 
PD
 re
du
ct
io
n:
 T
es
t: 
(P
R
F)
: 4
.0
6m
m
, C
on
tro
l: 
2.
89
 m
m
  (
P 
<0
.0
1)
 
C
A
L 
ve
rti
ca
l g
ai
n:
 T
es
t: 
2.
33
 m
m
, C
on
tro
l: 
1.
28
 m
m
  (
P 
<0
.0
1)
 
C
A
L 
ho
riz
on
ta
l g
ai
n:
 T
es
t: 
2.
67
 m
m
, C
on
tro
l: 
1.
89
 m
m
  (
P 
<0
.0
1)
 
 
 Ap
pe
nd
ix
 II
I. 
C
lin
ic
al
 tr
ia
ls
 o
n 
re
ge
ne
ra
tiv
e 
tre
at
m
en
t o
f m
an
di
bu
la
r m
ol
ar
 b
uc
ca
l d
eg
re
e 
II
 fu
rc
at
io
n 
de
fe
ct
s. 
Pu
bm
ed
 d
at
ab
as
e 
w
er
e 
se
ar
ch
ed
 w
ith
 th
e 
fo
llo
w
in
g 
te
rm
s a
nd
 
ke
y 
w
or
ds
 a
nd
 li
m
ite
d 
to
 c
lin
ic
al
 tr
ia
ls
: f
ur
ca
tio
n 
an
d 
tre
at
m
en
t (
to
ta
l h
its
 1
66
) u
nt
il 
th
e 
da
te
 0
6.
04
.2
01
1.
 F
ur
th
er
m
or
e 
th
e 
re
fe
re
nc
e 
lis
ts
 in
 th
e 
pu
bl
ic
at
io
ns
 li
st
ed
 w
er
e 
m
an
ua
lly
 se
ar
ch
ed
 fo
r a
dd
iti
on
al
 re
fe
re
nc
es
. S
tu
di
es
 m
ix
in
g 
m
an
di
bu
la
r a
nd
 m
ax
ill
ar
y 
de
gr
ee
 II
 fu
rc
at
io
n 
de
fe
ct
s e
xc
lu
de
d 
if 
no
t r
es
ul
ts
 fo
r t
he
 m
an
di
bu
la
r m
ol
ar
s w
er
e 
re
po
rte
d 
se
pa
ra
te
ly
. R
es
ul
ts
 re
po
rte
d 
as
 m
ea
n 
va
lu
es
.  
 N
.R
.=
 N
ot
 re
po
rte
d,
 N
.S
. N
on
 si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
gr
ou
ps
, R
C
T=
 R
an
do
m
iz
ed
 c
lin
ic
al
 tr
ia
l 
 
 9 
 R
ef
er
en
ce
s 
A
im
et
ti,
 M
., 
R
om
an
o,
 F
., 
Pi
ge
lla
, E
. &
 P
ie
m
on
te
se
, M
. (
20
07
) C
lin
ic
al
 e
va
lu
at
io
n 
of
 th
e 
ef
fe
ct
iv
en
es
s o
f e
na
m
el
 m
at
rix
 p
ro
te
in
s a
nd
 a
ut
ol
og
ou
s 
bo
ne
 g
ra
ft 
in
 th
e 
tre
at
m
en
t o
f m
an
di
bu
la
r c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s:
 A
 se
rie
s o
f 1
1 
pa
tie
nt
s. 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f P
er
io
do
nt
ic
s a
nd
 R
es
to
ra
tiv
e 
D
en
tis
tr
y 
27
: 4
41
-4
47
. 
A
kb
ay
, A
., 
B
ar
an
, C
., 
G
un
ha
n,
 O
., 
O
zm
er
ic
, N
. &
 B
al
os
, K
. (
20
05
) P
er
io
do
nt
al
 re
ge
ne
ra
tiv
e 
po
te
nt
ia
l o
f a
ut
og
en
ou
s p
er
io
do
nt
al
 li
ga
m
en
t g
ra
fts
 
in
 c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
76
: 5
95
-6
04
. 
A
nd
er
eg
g,
 C
. R
., 
M
ar
tin
, S
. J
., 
G
ra
y,
 J.
 L
., 
M
el
lo
ni
g,
 J.
 T
. &
 G
he
r, 
M
. E
. (
19
91
) C
lin
ic
al
 e
va
lu
at
io
n 
of
 th
e 
us
e 
of
 d
ec
al
ci
fie
d 
fr
ee
ze
-d
rie
d 
bo
ne
 
al
lo
gr
af
t w
ith
 g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 th
e 
tre
at
m
en
t o
f m
ol
ar
 fu
rc
at
io
n 
in
va
si
on
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
62
: 2
64
-2
68
. 
A
nd
er
ss
on
, B
., 
B
ra
tth
al
l, 
G
., 
K
ul
le
nd
or
ff
, B
., 
G
ro
nd
ah
l, 
K
., 
R
oh
lin
, M
. &
 A
tts
tro
m
, R
. (
19
94
) T
re
at
m
en
t o
f f
ur
ca
tio
n 
de
fe
ct
s. 
G
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
ve
rs
us
 c
or
on
al
ly
 p
os
iti
on
ed
 fl
ap
 in
 m
an
di
bu
la
r m
ol
ar
s;
 a
 p
ilo
t s
tu
dy
. J
ou
rn
al
 o
f C
lin
ic
al
 P
er
io
do
nt
ol
og
y 
21
: 2
11
-2
16
. 
B
ec
ke
r, 
W
., 
B
ec
ke
r, 
B.
 E
., 
B
er
g,
 L
., 
Pr
ic
ha
rd
, J
., 
C
af
fe
ss
e,
 R
. &
 R
os
en
be
rg
, E
. (
19
88
) N
ew
 a
tta
ch
m
en
t a
fte
r t
re
at
m
en
t w
ith
 ro
ot
 is
ol
at
io
n 
pr
oc
ed
ur
es
: R
ep
or
t f
or
 tr
ea
te
d 
cl
as
s i
ii 
an
d 
cl
as
s i
i f
ur
ca
tio
ns
 a
nd
 v
er
tic
al
 o
ss
eo
us
 d
ef
ec
ts
. I
nt
er
na
tio
na
l J
ou
rn
al
 o
f P
er
io
do
nt
ic
s a
nd
 R
es
to
ra
tiv
e 
D
en
tis
tr
y 
8:
 8
-2
3.
 
B
ec
ke
r, 
W
., 
B
ec
ke
r, 
B.
 E
., 
M
el
lo
ni
g,
 J.
, C
af
fe
ss
e,
 R
. G
., 
W
ar
re
r, 
K
., 
C
at
on
, J
. G
. &
 R
ei
d,
 T
. (
19
96
) A
 p
ro
sp
ec
tiv
e 
m
ul
ti-
ce
nt
er
 st
ud
y 
ev
al
ua
tin
g 
pe
rio
do
nt
al
 re
ge
ne
ra
tio
n 
fo
r c
la
ss
 ii
 fu
rc
at
io
n 
in
va
si
on
s a
nd
 in
tra
bo
ny
 d
ef
ec
ts
 a
fte
r t
re
at
m
en
t w
ith
 a
 b
io
ab
so
rb
ab
le
 b
ar
rie
r m
em
br
an
e:
 1
-y
ea
r 
re
su
lts
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
67
: 6
41
-6
49
. 
B
el
al
, M
. H
., 
A
l-N
oa
m
an
y,
 F
. A
., 
El
-T
on
sy
, M
. M
., 
El
-G
ui
nd
y,
 H
. M
. &
 Is
hi
ka
w
a,
 I.
 (2
00
5)
 T
re
at
m
en
t o
f h
um
an
 c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s u
si
ng
 
co
nn
ec
tiv
e 
tis
su
e 
gr
af
ts
, b
io
ab
so
rb
ab
le
 m
em
br
an
e,
 a
nd
 re
so
rb
ab
le
 h
yd
ro
xy
la
pa
tit
e:
 A
 c
om
pa
ra
tiv
e 
st
ud
y.
 J
 In
t A
ca
d 
Pe
ri
od
on
to
l 7
: 1
14
-1
28
. 
B
ou
ch
ar
d,
 P
., 
G
io
va
nn
ol
i, 
J. 
L.
, M
at
to
ut
, C
., 
D
av
ar
pa
na
h,
 M
. &
 E
tie
nn
e,
 D
. (
19
97
) C
lin
ic
al
 e
va
lu
at
io
n 
of
 a
 b
io
ab
so
rb
ab
le
 re
ge
ne
ra
tiv
e 
m
at
er
ia
l 
in
 m
an
di
bu
la
r c
la
ss
 ii
 fu
rc
at
io
n 
th
er
ap
y.
 J
ou
rn
al
 o
f C
lin
ic
al
 P
er
io
do
nt
ol
og
y 
24
: 5
11
-5
18
. 
B
ou
ch
ar
d,
 P
., 
O
uh
ay
ou
n,
 J.
 P
. &
 N
ilv
eu
s, 
R
. E
. (
19
93
) E
xp
an
de
d 
po
ly
te
tra
flu
or
oe
th
yl
en
e 
m
em
br
an
es
 a
nd
 c
on
ne
ct
iv
e 
tis
su
e 
gr
af
ts
 su
pp
or
t b
on
e 
re
ge
ne
ra
tio
n 
fo
r c
lo
si
ng
 m
an
di
bu
la
r c
la
ss
 ii
 fu
rc
at
io
ns
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
64
: 1
19
3-
11
98
. 
B
re
m
m
, L
. L
., 
Sa
llu
m
, A
. W
., 
C
as
at
i, 
M
. Z
., 
N
oc
iti
, F
. H
. &
 S
al
lu
m
, E
. A
. (
20
04
) G
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s u
si
ng
 a
 
re
so
rb
ab
le
 p
ol
yl
ac
tic
 a
ci
d 
ba
rr
ie
r. 
Am
er
ic
an
 J
ou
rn
al
 o
f D
en
tis
tr
y 
17
: 4
43
-4
46
. 
C
al
on
gn
e,
 K
. B
., 
A
ic
he
lm
an
n-
R
ei
dy
, M
. E
., 
Y
uk
na
, R
. A
. &
 M
ay
er
, E
. T
. (
20
01
) C
lin
ic
al
 c
om
pa
ris
on
 o
f m
ic
ro
po
ro
us
 b
io
co
m
pa
tib
le
 c
om
po
si
te
 
of
 p
m
m
a,
 p
he
m
a 
an
d 
ca
lc
iu
m
 h
yd
ro
xi
de
 g
ra
fts
 a
nd
 e
xp
an
de
d 
po
ly
te
tra
flu
or
oe
th
yl
en
e 
ba
rr
ie
r m
em
br
an
es
 in
 h
um
an
 m
an
di
bu
la
r m
ol
ar
 c
la
ss
 ii
 
fu
rc
at
io
ns
. A
 c
as
e 
se
rie
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
72
: 1
45
1-
14
59
. 
C
am
ar
go
, P
. M
., 
W
ol
in
sk
y,
 L
. E
., 
B
ur
ge
ss
, A
. V
., 
W
ag
ne
r, 
W
. R
., 
Pa
lu
k,
 S
. F
. &
 K
en
ne
y,
 E
. B
. (
20
02
) B
ov
in
e-
de
riv
ed
 b
on
e 
pr
ot
ei
n 
ex
tra
ct
 in
 
th
e 
tre
at
m
en
t o
f m
an
di
bu
la
r c
la
ss
 ii
 fu
rc
at
io
ns
. C
om
pe
nd
iu
m
 o
f C
on
tin
ui
ng
 E
du
ca
tio
n 
in
 D
en
tis
tr
y 
23
: 1
02
3-
10
28
, 1
03
0,
 1
03
2 
pa
ss
im
; q
ui
z 
10
42
. 
 10
 
 C
am
el
o,
 M
., 
N
ev
in
s, 
M
. L
., 
Sc
he
nk
, R
. K
., 
Ly
nc
h,
 S
. E
. &
 N
ev
in
s, 
M
. (
20
03
) P
er
io
do
nt
al
 re
ge
ne
ra
tio
n 
in
 h
um
an
 c
la
ss
 ii
 fu
rc
at
io
ns
 u
si
ng
 p
ur
ifi
ed
 
re
co
m
bi
na
nt
 h
um
an
 p
la
te
le
t-d
er
iv
ed
 g
ro
w
th
 fa
ct
or
-b
b 
(r
hp
dg
f-
bb
) w
ith
 b
on
e 
al
lo
gr
af
t. 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f P
er
io
do
nt
ic
s a
nd
 R
es
to
ra
tiv
e 
D
en
tis
tr
y 
23
: 2
13
-2
25
. 
C
at
on
, J
., 
G
re
en
st
ei
n,
 G
. &
 Z
ap
pa
, U
. (
19
94
) S
yn
th
et
ic
 b
io
ab
so
rb
ab
le
 b
ar
rie
r f
or
 re
ge
ne
ra
tio
n 
in
 h
um
an
 p
er
io
do
nt
al
 d
ef
ec
ts
. J
ou
rn
al
 o
f 
Pe
ri
od
on
to
lo
gy
 6
5:
 1
03
7-
10
45
. 
C
hi
ts
az
i, 
M
. T
., 
M
os
to
fi 
Za
de
h 
Fa
ra
ha
ni
, R
., 
Po
ur
ab
ba
s, 
M
. &
 B
ah
ae
dd
in
, N
. (
20
07
) E
ff
ic
ac
y 
of
 o
pe
n 
fla
p 
de
br
id
em
en
t w
ith
 a
nd
 w
ith
ou
t e
na
m
el
 
m
at
rix
 d
er
iv
at
iv
es
 in
 th
e 
tre
at
m
en
t o
f m
an
di
bu
la
r d
eg
re
e 
ii 
fu
rc
at
io
n 
in
vo
lv
em
en
t. 
C
lin
ic
al
 O
ra
l I
nv
es
tig
at
io
ns
 1
1:
 3
85
-3
89
. 
C
ur
y,
 P
. R
., 
Je
ff
co
at
, M
. K
., 
Sa
llu
m
, A
. W
., 
C
af
es
se
, R
., 
N
oc
iti
 Ju
ni
or
, F
. H
. &
 S
al
lu
m
, E
. A
. (
20
03
) C
lin
ic
al
 a
nd
 ra
di
og
ra
ph
ic
 e
va
lu
at
io
n 
of
 
gu
id
ed
 ti
ss
ue
 re
ge
ne
ra
tio
n 
in
 th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s. 
A
 ra
nd
om
iz
ed
 c
lin
ic
al
 tr
ia
l. 
Am
er
ic
an
 J
ou
rn
al
 o
f D
en
tis
tr
y 
16
 S
pe
c 
N
o:
 
13
A
-1
6A
. 
C
ur
y,
 P
. R
., 
Sa
llu
m
, E
. A
., 
N
oc
iti
, F
. H
., 
Jr
., 
Sa
llu
m
, A
. W
. &
 Je
ff
co
at
t, 
M
. K
. (
20
03
) L
on
g-
te
rm
 re
su
lts
 o
f g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
th
er
ap
y 
in
 
th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s:
 A
 ra
nd
om
iz
ed
 c
lin
ic
al
 tr
ia
l. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
74
: 3
-9
. 
D
e 
Le
on
ar
di
s, 
D
., 
G
ar
g,
 A
. K
., 
Pe
dr
az
zo
li,
 V
. &
 P
ec
or
a,
 G
. E
. (
19
99
) C
lin
ic
al
 e
va
lu
at
io
n 
of
 th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
in
vo
lv
em
en
ts
 w
ith
 
bi
oa
bs
or
ba
bl
e 
ba
rr
ie
rs
 a
lo
ne
 o
r a
ss
oc
ia
te
d 
w
ith
 d
em
in
er
al
iz
ed
 fr
ee
ze
-d
rie
d 
bo
ne
 a
llo
gr
af
ts
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
70
: 8
-1
2.
 
D
on
os
, N
., 
G
la
vi
nd
, L
., 
K
ar
rin
g,
 T
. &
 S
cu
le
an
, A
. (
20
03
) C
lin
ic
al
 e
va
lu
at
io
n 
of
 a
n 
en
am
el
 m
at
rix
 d
er
iv
at
iv
e 
in
 th
e 
tre
at
m
en
t o
f m
an
di
bu
la
r 
de
gr
ee
 ii
 fu
rc
at
io
n 
in
vo
lv
em
en
t: 
A
 3
6-
m
on
th
 c
as
e 
se
rie
s. 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f P
er
io
do
nt
ic
s a
nd
 R
es
to
ra
tiv
e 
D
en
tis
tr
y 
23
: 5
07
-5
12
. 
do
s A
nj
os
, B
., 
N
ov
ae
s, 
A
. B
., 
Jr
., 
M
ef
fe
rt,
 R
. &
 B
ar
bo
za
, E
. P
. (
19
98
) C
lin
ic
al
 c
om
pa
ris
on
 o
f c
el
lu
lo
se
 a
nd
 e
xp
an
de
d 
po
ly
te
tra
flu
or
oe
th
yl
en
e 
m
em
br
an
es
 in
 th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
ns
 in
 m
an
di
bu
la
r m
ol
ar
s w
ith
 6
-m
on
th
 re
-e
nt
ry
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
69
: 4
54
-4
59
. 
Et
o,
 A
. L
., 
Jo
ly
, J
. C
., 
Je
ff
co
at
, M
., 
de
 A
ra
uj
o,
 N
. S
., 
de
 A
ra
uj
o,
 V
. C
. &
 C
ur
y,
 P
. R
. (
20
07
) U
se
 o
f a
no
rg
an
ic
 b
ov
in
e-
de
riv
ed
 h
yd
ro
xy
ap
at
ite
 
m
at
rix
/c
el
l-b
in
di
ng
 p
ep
tid
e 
(p
-1
5)
 in
 th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s:
 A
 c
lin
ic
al
 a
nd
 ra
di
og
ra
ph
ic
 st
ud
y 
in
 h
um
an
s. 
Jo
ur
na
l o
f 
Pe
ri
od
on
to
lo
gy
 7
8:
 2
27
7-
22
83
. 
Fl
an
ar
y,
 D
. B
., 
Tw
oh
ey
, S
. M
., 
G
ra
y,
 J.
 L
., 
M
el
lo
ni
g,
 J.
 T
. &
 G
he
r, 
M
. E
. (
19
91
) T
he
 u
se
 o
f a
 s
yn
th
et
ic
 sk
in
 su
bs
tit
ut
e 
as
 a
 p
hy
si
ca
l b
ar
rie
r t
o 
en
ha
nc
e 
he
al
in
g 
in
 h
um
an
 p
er
io
do
nt
al
 fu
rc
at
io
n 
de
fe
ct
s:
 A
 fo
llo
w
-u
p 
re
po
rt.
 J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
62
: 6
84
-6
89
. 
G
ar
re
tt,
 S
., 
M
ar
tin
, M
. &
 E
ge
lb
er
g,
 J.
 (1
99
0)
 T
re
at
m
en
t o
f p
er
io
do
nt
al
 fu
rc
at
io
n 
de
fe
ct
s. 
C
or
on
al
ly
 p
os
iti
on
ed
 fl
ap
s v
er
su
s d
ur
a 
m
at
er
 
m
em
br
an
es
 in
 c
la
ss
 ii
 d
ef
ec
ts
. J
ou
rn
al
 o
f C
lin
ic
al
 P
er
io
do
nt
ol
og
y 
17
: 1
79
-1
85
. 
G
ar
re
tt,
 S
., 
Po
ls
on
, A
. M
. , 
St
ol
le
r, 
N
. H
., 
D
ris
ko
, C
. L
., 
C
at
on
, J
. G
., 
H
ar
ro
ld
, C
. Q
., 
B
og
le
, G
., 
G
re
en
w
el
l, 
H
., 
Lo
w
en
gu
th
, R
. A
., 
D
uk
e,
 S
. P
. &
 
D
eR
ou
en
, T
. A
. (
19
97
) C
om
pa
ris
on
 o
f a
 b
io
ab
so
rb
ab
le
 g
tr 
ba
rr
ie
r t
o 
a 
no
n-
ab
so
rb
ab
le
 b
ar
rie
r i
n 
tre
at
in
g 
hu
m
an
 c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s. 
A
 
m
ul
ti-
ce
nt
er
 p
ar
al
le
l d
es
ig
n 
ra
nd
om
iz
ed
 si
ng
le
-b
lin
d 
tri
al
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
68
: 6
67
-6
75
. 
H
ug
os
on
, A
., 
R
av
al
d,
 N
., 
Fo
rn
el
l, 
J.,
 Jo
ha
rd
, G
., 
Te
iw
ik
, A
. &
 G
ot
tlo
w
, J
. (
19
95
) T
re
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
in
vo
lv
em
en
ts
 in
 h
um
an
s w
ith
 
bi
or
es
or
ba
bl
e 
an
d 
no
nr
es
or
ba
bl
e 
gu
id
ed
 ti
ss
ue
 re
ge
ne
ra
tio
n 
ba
rr
ie
rs
. A
 ra
nd
om
iz
ed
 m
ul
ti-
ce
nt
er
 st
ud
y.
 J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
66
: 6
24
-6
34
. 
 11
 
 Je
ps
en
, S
., 
H
ei
nz
, B
., 
Je
ps
en
, K
., 
A
rjo
m
an
d,
 M
., 
H
of
fm
an
n,
 T
., 
R
ic
ht
er
, S
., 
R
ei
ch
, E
., 
Sc
ul
ea
n,
 A
., 
G
on
za
le
s, 
J. 
R
., 
B
od
ek
er
, R
. H
. &
 M
ey
le
, J
. 
(2
00
4)
 A
 ra
nd
om
iz
ed
 c
lin
ic
al
 tr
ia
l c
om
pa
rin
g 
en
am
el
 m
at
rix
 d
er
iv
at
iv
e 
an
d 
m
em
br
an
e 
tre
at
m
en
t o
f b
uc
ca
l c
la
ss
 ii
 fu
rc
at
io
n 
in
vo
lv
em
en
t i
n 
m
an
di
bu
la
r m
ol
ar
s. 
Pa
rt 
i: 
St
ud
y 
de
si
gn
 a
nd
 re
su
lts
 fo
r p
rim
ar
y 
ou
tc
om
es
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
75
: 1
15
0-
11
60
. 
K
ar
ap
at
ak
i, 
S.
, F
al
k,
 H
., 
H
ug
os
o,
 A
., 
O
ls
so
n,
 G
. &
 S
lo
tte
, C
. (
19
99
) T
re
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s u
si
ng
 re
so
rb
ab
le
 a
nd
 n
on
-r
es
or
ba
bl
e 
gt
r b
ar
rie
rs
. S
w
ed
is
h 
D
en
ta
l J
ou
rn
al
 2
3:
 1
73
-1
83
. 
K
en
ne
y,
 E
. B
., 
Le
ko
vi
c,
 V
., 
El
ba
z,
 J.
 J.
, K
ov
ac
vi
c,
 K
., 
C
ar
ra
nz
a,
 F
. A
., 
Jr
. &
 T
ak
ei
, H
. H
. (
19
88
) T
he
 u
se
 o
f a
 p
or
ou
s h
yd
ro
xy
la
pa
tit
e 
im
pl
an
t i
n 
pe
rio
do
nt
al
 d
ef
ec
ts
. I
i. 
Tr
ea
tm
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
le
si
on
s i
n 
lo
w
er
 m
ol
ar
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
59
: 6
7-
72
. 
K
ot
hi
w
al
e,
 S
. V
., 
A
nu
ro
op
a,
 P
. &
 G
aj
iw
al
a,
 A
. L
. (
20
09
) A
 c
lin
ic
al
 a
nd
 ra
di
ol
og
ic
al
 e
va
lu
at
io
n 
of
 d
fd
ba
 w
ith
 a
m
ni
ot
ic
 m
em
br
an
e 
ve
rs
us
 b
ov
in
e 
de
riv
ed
 x
en
og
ra
ft 
w
ith
 a
m
ni
ot
ic
 m
em
br
an
e 
in
 h
um
an
 p
er
io
do
nt
al
 g
ra
de
 ii
 fu
rc
at
io
n 
de
fe
ct
s. 
C
el
l T
is
su
e 
Ba
nk
 1
0:
 3
17
-3
26
. 
Le
ko
vi
c,
 V
., 
C
am
ar
go
, P
. M
., 
W
ei
nl
ae
nd
er
, M
., 
V
as
ili
c,
 N
., 
A
le
ks
ic
, Z
. &
 K
en
ne
y,
 E
. B
. (
20
03
) E
ff
ec
tiv
en
es
s o
f a
 c
om
bi
na
tio
n 
of
 p
la
te
le
t-r
ic
h 
pl
as
m
a,
 b
ov
in
e 
po
ro
us
 b
on
e 
m
in
er
al
 a
nd
 g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 th
e 
tre
at
m
en
t o
f m
an
di
bu
la
r g
ra
de
 ii
 m
ol
ar
 fu
rc
at
io
ns
 in
 h
um
an
s. 
Jo
ur
na
l 
of
 C
lin
ic
al
 P
er
io
do
nt
ol
og
y 
30
: 7
46
-7
51
. 
Le
ko
vi
c,
 V
., 
K
en
ne
y,
 E
. B
., 
C
ar
ra
nz
a,
 F
. A
. &
 M
ar
tig
no
ni
, M
. (
19
91
) T
he
 u
se
 o
f a
ut
og
en
ou
s p
er
io
st
ea
l g
ra
fts
 a
s b
ar
rie
rs
 fo
r t
he
 tr
ea
tm
en
t o
f 
cl
as
s i
i f
ur
ca
tio
n 
in
vo
lv
em
en
ts
 in
 lo
w
er
 m
ol
ar
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
62
: 7
75
-7
80
. 
Le
ko
vi
c,
 V
., 
K
en
ne
y,
 E
. B
., 
K
ov
ac
ev
ic
, K
. &
 C
ar
ra
nz
a,
 F
. A
., 
Jr
. (
19
89
) E
va
lu
at
io
n 
of
 g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s. 
A
 
cl
in
ic
al
 re
-e
nt
ry
 st
ud
y.
 J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
60
: 6
94
-6
98
. 
Le
ko
vi
c,
 V
., 
K
lo
kk
ev
ol
d,
 P
. R
., 
C
am
ar
go
, P
. M
., 
K
en
ne
y,
 E
. B
., 
N
ed
ic
, M
. &
 W
ei
nl
ae
nd
er
, M
. (
19
98
) E
va
lu
at
io
n 
of
 p
er
io
st
ea
l m
em
br
an
es
 a
nd
 
co
ro
na
lly
 p
os
iti
on
ed
 fl
ap
s i
n 
th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s:
 A
 c
om
pa
ra
tiv
e 
cl
in
ic
al
 st
ud
y 
in
 h
um
an
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
69
: 
10
50
-1
05
5.
 
Ly
on
s, 
L.
 C
., 
W
el
tm
an
, R
. L
., 
M
or
et
ti,
 A
. J
. &
 T
re
jo
, P
. M
. (
20
08
) R
eg
en
er
at
io
n 
of
 d
eg
re
e 
ii 
fu
rc
at
io
n 
de
fe
ct
s w
ith
 a
 4
%
 d
ox
yc
yc
lin
e 
hy
cl
at
e 
bi
oa
bs
or
ba
bl
e 
ba
rr
ie
r. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
79
: 7
2-
79
. 
M
ac
ht
ei
, E
. E
., 
G
ro
ss
i, 
S.
 G
., 
D
un
fo
rd
, R
., 
Za
m
bo
n,
 J.
 J.
 &
 G
en
co
, R
. J
. (
19
96
) L
on
g-
te
rm
 st
ab
ili
ty
 o
f c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s t
re
at
ed
 w
ith
 
ba
rr
ie
r m
em
br
an
es
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
67
: 5
23
-5
27
. 
M
ar
ag
os
, P
., 
B
is
sa
da
, N
. F
., 
W
an
g,
 R
. &
 C
ol
e,
 B
. P
. (
20
02
) C
om
pa
ris
on
 o
f t
hr
ee
 m
et
ho
ds
 u
si
ng
 c
al
ci
um
 su
lfa
te
 a
s a
 g
ra
ft/
ba
rr
ie
r m
at
er
ia
l f
or
 th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 m
an
di
bu
la
r m
ol
ar
 fu
rc
at
io
n 
de
fe
ct
s. 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f P
er
io
do
nt
ic
s a
nd
 R
es
to
ra
tiv
e 
D
en
tis
tr
y 
22
: 4
93
-5
01
. 
M
ey
le
, J
., 
G
on
za
le
s, 
J. 
R
., 
B
od
ek
er
, R
. H
., 
H
of
fm
an
n,
 T
., 
R
ic
ht
er
, S
., 
H
ei
nz
, B
., 
A
rjo
m
an
d,
 M
., 
R
ei
ch
, E
., 
Sc
ul
ea
n,
 A
., 
Je
ps
en
, K
. &
 Je
ps
en
, S
. 
(2
00
4)
 A
 ra
nd
om
iz
ed
 c
lin
ic
al
 tr
ia
l c
om
pa
rin
g 
en
am
el
 m
at
rix
 d
er
iv
at
iv
e 
an
d 
m
em
br
an
e 
tre
at
m
en
t o
f b
uc
ca
l c
la
ss
 ii
 fu
rc
at
io
n 
in
vo
lv
em
en
t i
n 
m
an
di
bu
la
r m
ol
ar
s. 
Pa
rt 
ii:
 S
ec
on
da
ry
 o
ut
co
m
es
. J
ou
rn
al
 o
f P
er
io
do
nt
ol
og
y 
75
: 1
18
8-
11
95
. 
Pa
ra
sh
is
, A
. O
. &
 M
its
is
, F
. J
. (
19
93
) C
lin
ic
al
 e
va
lu
at
io
n 
of
 th
e 
ef
fe
ct
 o
f t
et
ra
cy
cl
in
e 
ro
ot
 p
re
pa
ra
tio
n 
on
 g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 th
e 
tre
at
m
en
t o
f c
la
ss
 ii
 fu
rc
at
io
n 
de
fe
ct
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
64
: 1
33
-1
36
. 
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 Pe
pe
la
ss
i, 
E.
 M
., 
B
is
sa
da
, N
. F
., 
G
re
en
w
el
l, 
H
. &
 F
ar
ah
, C
. F
. (
19
91
) D
ox
yc
yc
lin
e-
tri
ca
lc
iu
m
 p
ho
sp
ha
te
 c
om
po
si
te
 g
ra
ft 
fa
ci
lit
at
es
 o
ss
eo
us
 
he
al
in
g 
in
 a
dv
an
ce
d 
pe
rio
do
nt
al
 fu
rc
at
io
n 
de
fe
ct
s. 
Jo
ur
na
l o
f P
er
io
do
nt
ol
og
y 
62
: 1
06
-1
15
. 
Po
ls
on
, A
. M
., 
So
ut
ha
rd
, G
. L
., 
D
un
n,
 R
. L
., 
Po
ls
on
, A
. P
., 
B
ill
en
, J
. R
. &
 L
as
te
r, 
L.
 L
. (
19
95
) I
ni
tia
l s
tu
dy
 o
f g
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 c
la
ss
 
ii 
fu
rc
at
io
n 
de
fe
ct
s a
fte
r u
se
 o
f a
 b
io
de
gr
ad
ab
le
 b
ar
rie
r. 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f P
er
io
do
nt
ic
s a
nd
 R
es
to
ra
tiv
e 
D
en
tis
tr
y 
15
: 4
2-
55
. 
Po
nt
or
ie
ro
, R
., 
Li
nd
he
, J
., 
N
ym
an
, S
., 
K
ar
rin
g,
 T
., 
R
os
en
be
rg
, E
. &
 S
an
av
i, 
F.
 (1
98
8)
 G
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 d
eg
re
e 
ii 
fu
rc
at
io
n-
in
vo
lv
ed
 
m
an
di
bu
la
r m
ol
ar
s. 
A
 c
lin
ic
al
 st
ud
y.
 J
ou
rn
al
 o
f C
lin
ic
al
 P
er
io
do
nt
ol
og
y 
15
: 2
47
-2
54
. 
Po
nt
or
ie
ro
, R
., 
N
ym
an
, S
., 
Li
nd
he
, J
., 
R
os
en
be
rg
, E
. &
 S
an
av
i, 
F.
 (1
98
7)
 G
ui
de
d 
tis
su
e 
re
ge
ne
ra
tio
n 
in
 th
e 
tre
at
m
en
t o
f f
ur
ca
tio
n 
de
fe
ct
s i
n 
m
an
. 
Jo
ur
na
l o
f C
lin
ic
al
 P
er
io
do
nt
ol
og
y 
14
: 6
18
-6
20
. 
Pr
ad
ee
p,
 A
. R
., 
Pa
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Appendix IV

Appendix IV 
Description of markers analyzed in paper  I  
Wound fluid analyses 
To study the progress of cortical bone healing after 4 weeks of healing of sham PTG and heat 
oxidized PTG (WPTG) treated defects, lactate dehydrogenase (LDH) activity, bone alkaline 
phosphatase (ALP) activity and total protein in the wound fluid was evaluated. 
ALP is a membrane bound glycoprotein produced by osteoblasts and attached to the outer cell 
surface of osteoblasts. It  is required for osteoid formation and extracellular matrix 
mineralization.1 It is thus a good indicator of bone healing and primary mineralization. 
LDH release from cells is an index of tissue necrosis.2 LDH is a cytoplasmatic protein. At cell 
death the cellmembanes are opened and LDH will be released to the extracellular 
environment. 
Total protein is measured for achieving values to be used for adjusting other measured 
specific proteins or their total activity. Protein concentrations are usually determined and 
reported with reference to standards of a common protein e.g., bovine serum albumin (BSA), 
and are used to correct other measured specific proteins (by ELISA, for example) or their 
activity. Total protein in the sample can consequently be used to correct that all samples have 
equal quantity.3 
 
Markers analyzed by RT-PCR 
A number of phenotypic markers are characteristic of differentiated osteoblasts like 
osteocalcin (OCN) and runt-related transcription factor-2 (runx2) and osteoclasts like tartrate-
resistant acid phosphatase (TRAP) and H+ adenosine triphosphate (ATP)-ase. The detection 
of their gene expression levels gives an indication of osteoclast or osteoblast activity at the 
bone-implant interface 
OCN which is also called bone γ-carboxyglutamic acid (Gla protein or BGP) is an osteoblast-
specific protein and a major non-collagenous matrix protein of bone.4 It is synthesized by 
osteoblasts and constitues 1-2 % of the total protein in bone.5 
 
Collagen type I (Coll-I) accounts for 90 % of the total protein fraction in bone. It is abundant 
in peripheral tissues and it has been demonstrated that coll I signaling reduces receptor 
activator of nuclear factor κβ ligand (RANKL) expression from T-cells which to the least 
potentially may lead to a lower ability of these cells to induce osteoclast formation.6, 7 
 
Runx2 is a member of the runt homology domain family of transcription factors, which are 
essential for osteoblast differentiation and a key regulator of bone formation. Moreover 
Runx2 regulate some proteins (e.g., matrix metalloproteinase (MMP)-98) which again 
regulates vascular invasion in bone and cell migration.8-10  
 
TRAP is expressed by osteoclasts and thus a good marker for bone resorption.11 
 
Vacuolar H+-ATPase is involved in bone resorption and resides on the membrane of 
osteoclasts. Vacuolar H+-ATPase is pumping H+ from the cytoplasm and is thus mediating 
the acidification of the extracellular environment in the resorption lacuna.12 
 
The detection of the pro-inflammatory cytokines, TNF-α and IL-6 was used to evaluate 
macrophage activation. Tumor necrosis factor - (TNF-α) and interleukin (IL) -6 are 
promoters of osteoclast differentiation and cytokine secretion. 
  
IL-6 is a pro-inflammatory cytokine, which was evaluated in the study to determine 
macrophage activation. IL-6 is a pleiotropic (i.e., multifunctional) molecule which is secreted 
by monocytes, macrophages, T-helper cells and bone-marrow stromal cells and promote 
innate (i.e., non-specific immunity and the “first line of defense to pathogens”) immunity and 
elimination of pathogens. It promotes terminal differentiation of B-cells into plasma cells and 
stimulate antibody secretion.13 
 
TNF- is a pro-inflammatory cytokine, which was used to evaluate macrophage activation. 
TNF- is secreted by macrophages and mast cells and promotes innate immunity and 
elimination of pathogens.13 The effect of TNF-α on osteoblastogenesis is blockage of 
osteoblast differentiation by inhibition of two transcription factors indispensable for bone 
formation: Runx2 and Osterix (Osx).14 
 
IL-10 is secreted by T helper cells, targets macrophages and antigen presenting cells and 
suppresses cytokine production. IL-10 inhibit both inflammation and osteoclastogenesis.13  
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